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CHAPTER 1
GENERAL INTRODUCTION TO COMPLEX I DEFICIENCY (CID)
AND SCOPE OF THE THESIS
General introduction
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Mitochondria and the respiratory chain
Mitochondria are the power houses of the cell: cytoplasmic organelles devoted to energy
production. A typical eukaryotic cell can contain 100 to more than 1,000 mitochondria which
differ in size, shape and structure depending on the tissue and the physiological shape of the
cell. Mitochondria are characterized by the presence of two membranes, the outer and the inner
membrane, delineating two internal compartments, the intermembranous space and the
mitochondrial matrix. Substrate oxidation occurs in the mitochondrial matrix, and produces
electrons that are shuttled from NADH and FADH2 into the respiratory chain embedded in the
inner membrane. The respiratory chain consists of five multiprotein complexes, known as
complex I to V. Complex I to IV are involved in electron transfer to oxygen, the final electron
acceptor. Complex I, III, and IV translocate protons across the inner membrane, giving rise to
the electrochemical proton gradient (proton motive force), which drives the synthesis of ATP
from ADP and Pi by complex V.
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Figure 1. The mitochondrial respiratory chain and pathways of intermediary metabolism.
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Respiratory chain complexes
Complex I (NADH: Ubiquinone oxidoreductase) – The first complex of the respiratory
chain in mammals consists of at least 43 polypeptides (1,2). Complex I consists of proteins
containing flavin mononucleotide (FMN) and iron-sulphur clusters, and hydrofobic protein
fractions (3,4). Seven complex I subunits are mitochondrially encoded, while the remaining 35
or more are encoded by nuclear genes (2,5,6,7). From electron microscopy of the Neuros ora
crassa complex there is evidence that complex I is a boomerang shaped assembly, with one
arm facing into the mitochondrial matrix and the other arm being intricately associated with the
inner mitochondrial membrane. A possible arrangement of the major subunits can be predicted
from the homology to bacterial hydrogenase and dehydrogenase complexes (8-13). The
passage of electrons may go from the NADH binding site located on the 51 kD subunit,
through an FMN and 4Fe-4S center on the same protein, then through a 2Fe-2S center in the
24 kD protein, a 4Fe-4S center in the 75 kD protein and then probably through iron-sulphur
centers on the 20 kD and 23 kD subunits (13,14).
The final acceptor of electrons is ubiquinone although there is evidence for the presence of at
least two quinone reduction sites, with different sensitivity to quinone analogue inhibitors (15-
17). The mechanism whereby electron transport through the respiratory chain is coupled to
proton translocation across the mitochondrial inner membrane is not clear. The mtDNA-
encoded subunits are all part of the membrane arm of the complex and there is evidence that
some of them are involved in proton translocation. Important clues stem from patients affected
with mutations in these mtDNA-encoded subunits. It has been demonstrated that patients with
mutations in the ND1 gene have defective electron transport while patients with ND4 defects
have no such defect but are unable to carry out ATP synthesis from NADH linked substrates in
isolated mitochondria (18). This suggests that the coupling of electron transport and ATP
synthesis (mediated by the translocation of protons) is impaired in patients with ND4
mutations. Since ND2, ND4 and ND5 have a certain amount of structural  homology, it is
tempting to speculate that these three subunits are all involved in the process of proton
translocation in some way (19). The ND1 and ND6 subunits are probably involved in electron
transport since mutations in these subunits affect electron flow in complex I (18,19,20). In
addition, the ND1 subunit has been shown to be the binding site for both rotenone and for
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photoaffinity-labelled ubiquinone analogues, suggesting that this is the terminal acceptor for
quinone reduction within the membrane portion of complex I (17,21).
Of the nuclear DNA-encoded subunits, the 51 kD subunit carries the NADH binding site (22).
The same subunit also carries FMN and iron-sulphur centers, and therefore is likely to be
involved in electron transport. Iron-sulphur clusters are present in four more nuclear DNA-
encoded subunits. The function of most of the nuclear DNA-encoded subunits remains
obscure, however. Reversible phosphorylation of at least four of them has been described (23).
It is not clear what phosphorylation does to the activity of complex I. It seems that these
subunits can be phosphorylated in an atractyloside sensitive manner in whole mitochondria, but
to what purpose is not clear at this time (24,25).
Complex  II (Succinate: Ubiquinone oxidoreductase) – Complex II is localized on the inner
face of the mitochondrial inner membrane, and consists of four polypeptides. It is the only
complex of the respiratory chain entirely encoded by nuclear DNA (26). Complex II contains
FAD covalently bound to the 74 kD subunit, and iron-sulphur clusters. The conversion of
succinate to fumarate (by succinate dehydrogenase) in the TCA cycle with concomitant
production of FADH2, is coupled to transfer of electrons from FADH2 to ubiquinone.
Ubiquinone (coenzyme Q, coenzyme Q10 or CoQ) – is an extremely lipophilic electron
carrier loosely linked to the mitochondrial inner membrane (27). In mammals its structure
includes a benzoquinone with a tail of usually 10 isoprene units, which gives the molecule its
apolar properties and allows the coenzyme to freely move within the membrane (27).
These mobile properties are also suggested by the large amounts of CoQ in comparison with
other components of the respiratory chain (28). CoQ accepts electrons not only from NADH-
linked substrates, via complex I, but also through complex II from succinate and other
substrates linked directly to the respiratory chain through flavoprotein dehydrogenases (FAD
being the flavo moiety), including glycerol 3-phosphate and intermediates of fatty acid
metabolism (ETF and ETF:CoQ oxidoreductase).
Complex III (Ubiquinol: Ferrocytochrome c oxidoreductase or cytochrome bc1 c plex)
– The third complex of the respiratory chain consists of seven or eight polypeptides, and
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contains three cytochrome redoxcenters (cytochrome b562, b566, and c1) and a iron-sulphur
cluster. Only one of its subunits is encoded by mtDNA. The complex has a transmembrane
arrangement and is involved in the transfer of electrons between the two mobile electron
carriers, CoQ and cytochrome c (27). Complex III is the second site where electron transport
is coupled to ATP synthesis by proton translocation.
Cytochrome c – is a small protein loosely associated with the inner mitochondrial membrane,
with an aminoacid sequence highly conserved through evolution with 50% homology between
such diverse organisms as yeasts and humans, and is involved in electron transport between
complex III and IV (27).
Complex IV (Ferrocytochrome c: Oxygen oxidoreductase or cytochrome c oxidase)
– In mammals complex IV consists of 13 polypeptides, of which three are encoded by mtDNA
(26,29,30). It contains two cytochrome redoxcenters (cytochrome a and a3), and catalyzes the
ultimate step in electron transport, accepting electrons from cytochrome c and reducing
molecular oxygen to water. Complex IV is the third site for proton translocation.
Complex V (ATPase or ATP synthase) – Complex V is made up of 12-14 proteins, two of
them coded by mtDNA (26). It is composed of two segments, the F1 segment where the
process of ATP synthesis is located, and the F0 segment which spans the mitochondrial inner
membrane and contains a specific channel for passive movement of protons back into the
mitochondrial matrix (31,32).
Oxidative Phosporylation (OXPHOS). Adenosine triphosphate (ATP), the universal ‘energy
currency’ of the living cell, is produced in mitochondria as a result of OXPHOS. Several
theories have been put forward to explain the mechanism of OXPHOS. The chemiosmotic
theory of Mitchell is generally most accepted now (33). Mitchell postulated that transport of
electrons (generated by oxidation of substrates) through the respiratory chain is coupled to
translocation of protons from the matrix into the intermembranous space, presumably at the
level of complex I, III, and IV (26). All three complexes span the inner membrane
asymmetrically, being in contact with both the inner and outer faces of the mitochondrial
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membrane. As the inner membrane is thought to be  impermeable to ions in general and to
protons in particular, an electrochemical gradient of protons (Äp) is set across the membrane
(34). This gradient, which consists of a membrane potential (ÄØ, negative inside the matrix)
and a pH gradient (ÄpH, alkaline inside the matrix) (34,35), drives the synthesis of ATP from
ADP and Pi by complex V. Assuming 100% efficient coupling of respiration and
phosphorylation, oxidation of one mole of NADH will generate three moles of ATP. Because
one proton translocation site is bypassed in the oxidation of FADH2 (i.e. complex I), one mole
of FADH2 will generate only two moles of ATP instead of three. However, in vivo coupling of
respiration and phosphorylation is not entirely efficient, because the mitochondrial inner
membrane has a proton leak, so that a proportion of the protons translocated by the respiratory
chain return via this leak rather than driving ATP synthesis (34,36,37). In brown adipose
tissue, mitochondria have a specialized uncoupling protein mediating a sizeable proton leak
(34).
Control and regulation of OXPHOS. Mitochondrial respiratory activity may be measured by
polarographic methods, using a Clark type electrode for oxygen consumption measurements
during mitochondrial oxidation of certain substrates. The low rate of oxygen consumption in
the presence of a substrate but in the absence of ADP is denoted state 4 of respiration.
Subsequent addition of ADP stimulates oxygen consumption and state 3 is established. The
ratio between state 3 and 4 oxygen consumption rates is called respiratory control ratio (RCR),
and reflects the tightness of the coupling state of the mitochondria.
This coupling state relies on maintenance of the electrochemical gradient. This has been shown
by the use of so-called uncouplers, such as 2,4-dinitrophenol (DNP), trifluorocarbonyl cyanide
phenylhydrazone (FCCP) and carbamyl cyanide m-chlorophenylhydrazine (mCCCP). These
uncouplers dissipate the gradient by transporting protons back into the matrix, thus uncoupling
phosphorylation and respiration. This results in uncontrolled respiration without concomitant
ATP synthesis (27,28).
The overall rate of OXPHOS is regulated by the presence of adequate amounts of ATP, ADP,
Pi, oxygen, and oxidizable substrates that generate either NADH or FADH2 (34,38).
The classical model for the control of OXPHOS involves the feedback of ATP hydrolysis
products, ADP and Pi from cytosolic ATPases to mitochondrial OXPHOS. This model is
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based on data from isolated mitochondria in which the rate of OXPHOS is controlled by the
concentration of ADP and Pi (39). Although this simple feedback model may be accurate for
skeletal muscle mitochondria (38,40), data from intact tissues with high oxidative
phosphorylation capacities (i.e., heart, brain, and kidney) indicate that cytosolic concentrations
of ADP and Pi do not change significantly with work (41,42). The small changes in ADP and
Pi in heart, brain, and kidney may indicate that in these tissues ADP and Pi are involve  in the
fine feedback control of OXPHOS, while the system is relying on other regulators to cause the
larger changes. Delivery of the reducing equivalents NADH and FADH2 to the mitochondria
may be one of these other regulators, since it has been shown that alterations in NADH can
increase ATP synthesis without concomitant increases in ADP and Pi (43). Various stages of
NADH and FADH2 generation and delivery may be involved: the transport of pyruvate and
fatty acids into the mitochondria, and oxidation of these metabolites once inside the
mitochondria (in the TCA cycle or by â-oxidation). However, there is no consensus whether or
not delivery of reducing equivalents is actually driving OXPHOS or simply following the
removal of reducing equivalents by the cytochrome chain in the intact tissue. This may vary
from tissue to tissue: while data in liver and smooth muscle suggest delivery of reducing
equivalents is driving OXPHOS (44,45), very consistent data indicate that it is not the primary
regulator in skeletal muscle (46,47). Finally, oxygen delivery may be partially rate limiting for
OXPHOS (48), but to what extent this parameter is the primary regulator of OXPHOS in the
intact cell remains controversial too (38).
In summary, it is reasonable to assume that the products of ATP hydrolysis play an important
role in the control of OXPHOS, but cannot completely explain the interaction of OXPHOS and
work in all tissues. Probably control is distributed over several potential sites of regulation: the
metabolic control theory (49). The distribution of control may be different from tissue to tissue
and may change depending on the rate of ATP turnover (50).
Glycolysis and lactate production
The pyruvate that enters the mitochondria for oxidation has been formed from glucose or
glycogen in a series of intermediate steps catalyzed by cytosolic enzymes, called the glycolysis
pathway. Most of the control over the glycolysis pathway is distributed among three key
enzymes: hexokinase, phosphofructokinase, and pyruvate kinase. NADH formed
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concomitantly with pyruvate in the cytosol has to be transported into the mitochondria for
oxidation by the respiratory chain. Since NADH is incapable of crossing the inner
mitochondrial membrane, several processes exist to transfer reducing equivalents into the
matrix. These processes comprise substrate pairs, linked by suitable cytosolic and
mitochondrial isoenzymes, and specific transport systems. Two redox shuttles, the
dihydroxyacetone phosphate / glycerol-3-phosphate shuttle and the malate / aspartate shuttle,
are involved in the reduction of cytosolic substrates by NADH and translocation of the reduced
substrates into the matrix, where they are reoxidized and transported back to the cytosol to
initiate a new cycle (51,52). The dihydroxyacetone phosphate / glycerol-3-phosphate shuttle is
unique, since it exchanges cytosolic NADH for mitochondrial FADH2.
As an alternative to mitochondrial oxidation, NADH generated in the glycolysis pathway can
be oxidized in the cytosol coupled to reduction of pyruvate to lactate. Cytosolic oxidation of
NADH is not favorable for energy conservation, because only mitochondrial oxidation of
NADH is coupled to ATP synthesis. However, it may be important under certain conditions
when glycolysis is allowed to proceed.
Genetics of mitochondrial disorders
Mitochondrial disorders can theoretically give rise to any symptom, in any organ or tissue, at
any age with any mode of inheritance, due to the twofold genetic origin of most of the
mitochondrial components: mitochondrial DNA and nuclear DNA (53). The current
classification of mitochondrial disorders is based upon identification of mutations of
mitochondrial DNA. The linkage between a specific mutation in mitochondrial DNA and a
specific disease was first established in 1988 (54,55). In the past decade more diseases related
to mutations and rearrangements of mitochondrial and nuclear DNA were found.
Mitochondrial DNA (mtDNA)  and mtDNA mutations. The mammalian mitochondrial
genome is a small, double stranded (H-eavy and L-ight strand), circular DNA molecule of
16,569 bp (56). It has its own genetic code different from nuclear DNA (56,57), and
translation into proteins therefore requires a set of suitable transfer RNAs (tRNAs) and
ribosomal RNAs (rRNAs), which are encoded by genes contained in the mtDNA itself (56).
Mitochondrial DNA is transcribed as one long RNA devoid of intron sequences (58).
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Transcription of the H-strand starts at the only noncoding stretch of mtDNA, the displacement
loop (D-loop), a region of about 1 kb that contains the origin of replication of the H-strand
(OH), and the promotors for L- and H-strand transcription. A 30 nucleotide-long region,
positioned at 2/3 of the mtDNA length from OH, serves as the origin of replication of the L-
strand (OL). The genetics of mammalian mtDNA are characterized by the following unique
features: (i) Maternal inheritance. The mother transmits her oocyte mtDNA to her offspring,
while no contribution comes from the male gametes. (ii) High mutation rate. mtDNA lacks
protective proteins like histones, and is physically associated with the inner mitochondrial
membrane, where highly mutagenic oxygen radicals are generated as by-products of OXPHOS.
Despite its high mutation rate, mtDNA does seem to have a DNA repair system and is subject
to recombination (59) (iii) Polyploidy. Each human cell has hundreds of mitochondria, each
containing several mtDNA molecules. At cell division, mitochondria and their genomes are
randomly distributed to daughter cells. In normal conditions the mitochondrial genotype of an
individual is composed of a single mtDNA species, a condition known as homoplasmy.
However, the high mutation rate of mtDNA can occasionally produce a transitory condition
known as heteroplasmy, where the wild-type and the mutant genomes coexist intracellularly.
Because of mitochondrial polyploidy, during mitosis the two mtDNA species are stochastically
distributed to subsequent cell generations. A genetic drift known as mitotic (or replicative)
segregation determines the separation of the two mitochondrial genomes into two distinct cell
lineages, each containing only one mtDNA type. Pathological alterations of mtDNA fall into
three major classes: point mutations, deletion-insertions, and copy number mutations
(depletions).
Point mutations. Point mutations of mtDNA are usually maternally inherited and can occur in
mRNA, tRNA, or rRNA genes. Although more than 50 deleterious point mutations have been
identified to date (Table 1), four mutations are by far the most frequent. These are the 3243
AG ‘MELAS/PEO’, the 8344 AG ‘MERRF’, the 8993 TG ‘NARP’, and the 11778
AG ‘LHON’ mutations. Other mutations are more rarely found, while still others have been
described in only single individuals or families.
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Table 1. mtDNA mutations.
Phenotype Mutation Affected Gene Inheritance
KSS Single deletion Several genes S
PEO (± other signs) Single deletion Several genes S
3243 AG tRNALeu(UUR) M
3256 CT tRNALeu(UUR) M
5692 AG tRNAAsn M
5703 AG tRNALeu(CUN) M
Multiple deletions Several genes AD
PEO + MMC Multiple deletions Several genes AR
PEO/ sudden death 3251 AG tRNALeu(UUR) M
Single duplication Several genes S, M
Pearson syndrome Single deletion Several genes S
Single duplication Several genes S
MNGIE Multiple deletions Several genes S?
DIDMOAD Single deletion Several genes S
Multiple deletions Several genes S, AR?
Tissue-specific depletion Low mtDNA content All genes AR
MERFF 8344 AG tRNALys M
8356 TC tRNALeu(UUR) M
MERFF/MELAS 8356 TC tRNALeu(UUR) M
7512 TC tRNASer(UCN) M
HAM 7472 C(i) tRNA
Ser(UCN) M
MELAS 3243 AG tRNALeu(UUR) M
3252 AG tRNALeu(UUR) M
3271 TC tRNALeu(UUR) M
3291 TC tRNALeu(UUR) M
MMC 3260 AG tRNALeu(UUR) M
CM 3303 CT tRNALeu(UUR) M
4269 AG tRNAIle M
4300 AG tRNAIle M
4320 (-) T tRNAIle M
9997 TC tRNAGly M
15590 CT tRNAPro M
NARP/MILS 8993 TG ATPase 6 M
8993 TC ATPase 6 M
IBSN 9176 TC ATPase 6 M
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LHON 3460 GA ND1 M
11778 GA ND4 M
14484 TC ND6 M
LHON/dystonia 14459 GA ND6 M
11696 AG ND4 M
MM 3250 TC tRNALeu(UUR) M
3302 AG tRNALeu(UUR) M
15 bp microdeletion COIII M?
MND 5 bp microdeletion COI M?
DC 5549 tRNATyr M
DDM 3243 AG tRNALeu(UUR) M
14709 TC tRNAGlu M
SND 7445 TC tRNASer(UCN) M
AID 1555 AG 12S rRNA M
MEM 1 nt pair deletion tRNALeu(UUR) M
Abbreviations: AD = autosomal dominant; AR = autosomal recessive; AID = aminoglycoside-induced deafness;
CM = cardiomyopathy; DC = dementia-chorea; DDM = diabetes, deafness, and myopathy; DIDMOAD =
diabetes insipidus, diabetes mellitus, optic atrophy, and deafness; HAM = hearing loss, ataxia, and myoclonus;
IBSN = infantile bilateral striatal necrosis; KSS = Kearns-Sayre syndrome; LHON = Leber hereditary optic
neuropathy; M = maternal; MELAS = mitochondrial encephalomyopathy, lactic acidosis, and strokelike
episodes; MEM = mitochondrial encphalomyopathy; MERFF = myoclonus epilepsy with ragged-red fibers;
MILS = maternally inherited Leigh syndrome; MM = mitochondrial myopathy, MMC = mitochondrial
myopathy and cardiomyopathy; MND = motor neuron disease; MNGIE = mitochondrial neuro-gastro-intestinal
encephalomyopathy; NARP = neurogenic muscle weakness, ataxia, and retinitis pigmentosa; PEO =
progressive external ophthalmoplegia; S = sporadic; SND = sensoneural deafness.
From: Zeviani et al. Mitochondrial disorders. Medicine 77: 59-72, 1998.
Mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. Mitochondrial
encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS) is defined by the
presence of strokelike episodes due to focal brain lesions often localized in the parieto-occipital
lobes and lactic acidosis. Other signs of central nervous system involvement include dementia,
recurrent headache and vomiting, focal or generalized seizures, and deafness (60). The
pathogenesis of the strokelike episodes is uncertain but a mitochondrial dysfunction in blood
vessels is suggested by the observation of strong succinate dehydrogenase activity in the wall
of intramuscular arteries (61), due to marked proliferation of predominantly mutant
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mitochondria. MELAS was first associated with a heteroplasmic point mutation in the
tRNALeu(UUR), an  AG transition at position 3243 (62). Other MELAS-associated point
mutations were later reported (see Table 1), although the 3243 AG remains by far the most
frequent. The genotype-phenotype correlation of the 3243 AG mutation is rather loose since
the observed clinical manifestations are not limited to the full-blown MELAS syndrome.
For instance, the 3243 AG mutation has been detected in several patients (and families) with
maternally inherited PEO, isolated myopathy alone, cardiomyopathy, or in pedigrees with
maternally inherited diabetes mellitus and deafness (63,64,65).
Myoclonus epilepsy with ragged-red fibers. Myoclonus epilepsy with ragged-red fibers
(MERRF) is a maternally inherited neuromuscular disorder characterized by progressive
myoclonus, epilepsy, muscle weakness and wasting, cerebellar ataxia, deafness, and dementia
(66). Typical morphologic findings in skeletal muscle are so called ragged-red fibers, muscle
fibers characterized by the accumulation of abnormal mitochondria under the sarcolemmal
membrane. The most commonly observed mutation of mtDNA associated with MERRF is an
AG transition at position 8344 in the tRNALys gene (67). A second mutation has been
reported in the same gene, at position 8356 (68,69). Extensive clinical, biochemical, and
molecular investigation of large pedigrees showed a positive correlation between the severity
of the disease, age at onset, mtDNA heteroplasmy, and reduced activity of respiratory chain
complexes I and IV in skeletal muscle. However, even though the genotype-phenotype
correlation between MERRF syndrome and the 8344 AG mutation is tighter than that of
other mutations, the 8344 AG transition has also been reported in phenotypes as different as
Leigh syndrome, isolated myoclonus, familial lipomatosis, and isolated myopathy (70).
Neurogenic weakness, ataxia, and retinitis pigmentosa. Neurogenic weakness, ataxia, and
retinitis pigmentosa (NARP) is a maternally inherited, adult-onset syndrome associated with a
heteroplasmic TG transversion at position 8993 in the ATPase 6 subunit gene (71).
A transition at the same position (8993 TC) was later described in other NARP patients (72).
RRFs are absent in the muscle biopsy.The degree of heteroplasmy correlates with the severity
of the disease. For instance, when the percentage of mutant mtDNA is more than 95%,
patients show the clinical, neuroradiologic, and neuropathologic findings of Leigh syndrome
(hence called maternally inherited Leigh syndrome [MILS]) (73). The two phenotypes of
NARP and MILS may coexist in the same family. Impairment of ATP synthesis has been
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reported in cell cultures harboring the 8993 TG mutation, possibly because of defective
assembly of the enzyme complex (74).
Leber hereditary optic neuropathy. Leber hereditary optic neuropathy (LHON) is
characterized by bilateral, acute or subacute loss of central vision due to optic atrophy.
The visual defect can occasionally be associated with cardiac conduction abnormalities (pre-
excitation syndrome). Penetrance of LHON is much higher in males than in females, and onset
is usually in the second and third decade. A total of 17 mtDNA mutations is now reported to
be associated with LHON (75). However, mutations at only three nucleotide positions (np), np
11778 (subunit 4 of complex I, ND4) (55); np 3460 (subunit 1 of complex I, ND1) (76); and
np 14484 (subunit 6 of complex I, ND6) (77) encompass most LHON families in all human
populations, and are considered high-risk and primary LHON mutations (78,79).
The pathologic significance of the other LHON mutations is much less clear. Some mutations,
such as those at np 13730 (80), np 9438, and np 9804 (81), may well be primary mutations,
but they have been reported in only one or a few LHON families and their pathologic
significance requires confirmation. Other mutations are considered less severe LHON
mutations (secondary/ intermediate mutations). They are homoplasmic and associated with
each other and with primary mutations. Overall, it remains unclear whether they cause the
disease, contribute to the pathology, or are nonpathogenic mtDNA polymorphisms (82).
Of the three high-risk LHON mutations, the 14484 mutation seems to be associated with a
relatively mild course, compared with the 3460 or 11778 mutations, the latter being associated
with the worst visual outcome. Several other aspects of LHON remain unexplained, including
the basis of the extreme tissue specificity of the clinical lesion, the male/female skewing of
penetrance, and the biochemical consequence of each mutation. The influence of an X-linked
nuclear gene on the expression of the LHON mtDNA mutation has been postulated (83), but
not confirmed (84). Combination of LHON and dystonia has long been recognized as a distinct
entity (85). A pathogenic GA transition at nt 14459 in the ND6 gene (complex I) has been
reported in three independent LHON/dystonia pedigrees (20). A second AG transition at nt
11696 was later identified in a large LHON/dystonia family from the Netherlands (19).
Other mtDNA point mutations. Several other point mutations of mtDNA have been detected in
single patients or in pedigrees affected with different phenotypes (86). For instance, myopathy
and cardiomyopathy (MMC) is associated with a number of different tRNA gene mutations
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(86,87). Aminoglycoside-induced or spontaneous, non-syndromic progressive deafness has
been associated with a homoplasmic AG transition at np 1555 in the 12S rRNA gene. It has
been postulated that the 1555 AG mutation elongates the region where the tRNA binds to
the ribosome, thus facilitating the binding of aminoglycosides and, therefore, potentiating their
effects on the fidelity of the translation of the mRNA (88).
The cochlear cell death in these patients is thought to be due to misreading of mRNA during
mitochondrial protein synthesis in this highly energy-dependent structure.
Large-scale rearrangements of mtDNA: deletions and duplications. L rge- cale
rearrangements of mtDNA can be either single partial mtDNA deletions (mtDNAÄ) r more
rarely, partial duplications. Both types of mutation are heteroplasmic since they coexist with
variable amounts of wild-type mtDNA (mtDNAWT). Three main clinical phenotypes are
associated with these mutations: Kearns-Sayre syndrome, sporadic progressive external
ophthalmoplegia (PEO), and Pearson syndrome (89,90,91,92,93). Kearns-Sayre syndrome is a
sporadic, severe disorder characterized by the invariant triad of PEO, pigmentary retinopathy,
and onset before 20 years of age. Frequent additional symptoms are a progressive cerebellar
syndrome, heart block, and increased protein content in the cerbrospinal fluid. Sporadic PEO is
characterized by bilateral ptosis and ophthalmoplegia, frequently associated with variable
degrees of proximal muscle weakness and wasting, and exercise intolerance. Pearson bone
marrow-pancreas syndrome is a rare disorder of early infancy characterized by sideroblastic
anemia with pancytopenia and exocrine pancreatic insufficiency. It is noteworthy that infants
surviving into childhood may develop the clinical features of Kearns-Sayre syndrome (92,93).
Large-scale rearrangements have occasionally been described in young patients with different
phenotypes such as the diabetes insipidus, diabetes mellitus, optic atrophy, and deafness
(DIDMOAD) syndrome (94,95). The clinical syndromes associated with large-scale mtDNA
rearrangements are usually sporadic. Since deleted mtDNA species have been detected in
human oocytes (96), an unknown mechanism must prevent the vertical transmission or the
expansion of mtDNAÄ genomes. However, PEO has been reported to run in families.
The presence of these mtDNA abnormalities inherited as mendelian traits indicates the
existence of mutations in nuclear genes affecting the integrity of the mitochondrial genome
(97). Alternative hypotheses postulate that the responsible genes are involved in the nuclear
control of the biogenesis of the mitochondrial genome, or in the elimination of abnormal
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mtDNA species. Autosomal dominant (98,99) or recessive (100) progressive external
ophthalmoplegia (PEO) can be associated with the co-existence of wild-type mtDNA with
several deletion-containing mtDNA species. While autosomal dominant PEO (adPEO) is an
adult-onset, relative benign condition, the onset of autosomal recessive PEO is in childhood,
and the condition is often associated with severe cardiomyopathy, requiring cardiac
transplantation. Linkage analysis has revealed the existence of two distinct adPEO disease loci,
one on chromosome 10q (PEO1), found in one Finnish family (101), the other on chromosome
3p (PEO2), found in three Italian families (102). The existence of at least a third locus is
suggested by the presence of other adPEO families that fail to map to either locus.
Copy number mutations: mtDNA depletion. Depletion of mtDNA is a mendelian inherited
disorder whose clinical manifestations fall into three groups: (i) a fatal congenital myopathy
with or without a DeToni-Fanconi renal syndrome; (ii) a fatal infantile hepatopathy leading to
rapidly progressive liver failure; (iii) a late infantile or childhood myopathy, with onset after
one year of age, causing respiratory failure and death by three years (103,104). Southern blot
analysis is diagnostic, demonstrating the severe reduction of mtDNA in affected tissues (up to
98% in the most severe forms). The presence of affected sibs born from healthy parents
suggests an autosomal recessive mode of inheritance, possibly affecting a nuclear gene
involved in the control of the mtDNA copy number.
Nuclear Gene Defects – The observation of familial cases with mendelian inheritance and
severe isolated defects of the respiratory chain complexes not associated with mtDNA lesions
suggests the presence of mutations of nuclear genes as a source of respiratory chain
deficiencies. In recent years mutations have been found in nuclear encoded flavoprotein subunit
gene of succinate dehydrogenase, in two sibs affected by Leigh syndrome associated with
deficiency of complex II (105), as well as in the nuclear encoded NDUFV1 and 18-kD
(AQDQ) subunits of complex I, causing leukodystrophy and myoclonic epilepsy and a
nonspecific fatal progressive phenotype without increased lactate concentrations in body fluids,
respectively (106,107). The clinical presentation of respiratory chain defects of probable
nuclear origin is heterogenous, with onset ranging from neonatal to adult life.
The clinical features include fatal infantile multisystem syndromes, encephalomyopathies,
isolated myopathies, or myopathies and cardiomyopathies. In pediatric patients the most
frequent clinical features are severe psychomotor delay, generalized hypotonia, lactic acidosis,
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and signs of cardiorespiratory failure. Patients with later onset usually show signs of myopathy
associated with variable involvement of the central nervous system (ataxia, hearing loss,
seizures, polyneuropathy, pigmentary retinopathy, and, more rarely, movement disorders).
Other patients complain only of muscle weakness and/or wasting with exercise intolerance.
Leigh syndrome. Leigh syndrome, or subacute necrotizing encephalomyelopathy, is the most
common mitochondrial disorder of infancy. Affected infants show severe psychomotor delay,
cerebellar and pyramidal signs, dystonia, seizures, respiratory abnormalities, incoordination of
ocular movements, and recurrent vomiting. Focal symmetric lesions are found by magnetic
resonance imaging (MRI) in the brainstem, thalamus, and posterior columns of the spinal cord,
corresponding to areas of necrosis, with gliosis and vascular proliferation. Ragged-red fibers
are absent. Leigh syndrome is clearly a genetically heterogeneous entity. A severe, generalized
defect of cytochrome c oxidase (COX) is the most frequent biochemical abnormality.
Deficiency of complex I, complex II, or pyruvate dehydrogenase (PDH), are less common.
From a genetic point of view, Leigh syndrome has been occasionally associated with mtDNA
mutations, but in most cases it appears as an autosomal recessive trait, more rarely as an X-
linked trait (mutations of the gene encoding the E1á subunit of PDH), and in still other cases as
an apparent sporadic clinical entity. In any event, all defects described to date in patients with
Leigh syndrome affect oxidative metabolism and are likely to impair energy production. The
typical neuropathologic findings are, therefore, the expression of the damage produced by
impaired oxidative metabolism in the developing brain, irrespective of the specific biochemical
or genetic causes (108). It seems well established that the molecular errors and the altered
kinetics (109) underlying the defect of COX that is most frequently found in Leigh syndrome
do not affect structural genes directly, because sequencing of the eight nuclear genes encoding
ubiquitous COX subunits in patients with Leigh syndrome failed to demonstrate mutations in
several cases. On the other hand, mutations have been found in the nuclear encoded SURF-1
gene, involved in the assembly of COX subunits (110,111), and in the nuclear encoded
NDUFS7 (PSST) and NDUFS8 (TYKY) subunits of complex I in patients with Leigh
syndrome (112,113).
Mitochondrial respiratory chain defects: Complex I Deficiency
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Clinical presentation. Defects of human complex I may be isolated, associated with defects of
other components of the respiratory chain, or associated with specific diseases due to defects
of mtDNA.
Isolated Complex I Deficiency. Isolated Complex I Deficiency (CID) appears to be an
autosomal, or possibly in a few cases, an X-linked disease in which patients can suffer from a
wide constellation of symptoms (114,115). It was first identified as a separate entity in 1984 in
a patient who died in infancy (116). Analysis of muscle mitochondria showed an iron-sulphur
protein of complex I to be reduced (117). A second case  also died in infancy and was
demonstrated to have deficient rotenone-sensitive NADH cytochrome c reductase  and NADH
duroquinone reductase in muscle mitochondria, liver mitochondria and skin fibroblasts (118).
At autopsy both patients showed evidence of mitochondrial proliferation, ventricular
cardiomyopathy and spongy degeneration of the brain. Two well documented patients with
Leigh disease were shown to have muscle CID (119). Both infants displayed damage to the
putamen, thalamus and substantia nigra on CT scan of the brain. Now CID is recognized to be
the most common mitochondrial respiratory chain defect (120). Pitkänen and Robinson
described a group of 60 patients with isolated CID, half of which had Leigh disease with
possible associated cardiomyopathy (Table 2, ref. 120).
Table 2. The clinical presentation of isolated Complex I Deficiency in 60 patients.
Incidence Major features Patients
Most common Leigh’s disease ± cardiomyopathy or progressive deterioration35
Fairly common Fatal infantile lactic acidosis cystic changes in white matter 15
Uncommon Hepatopathy and tubulopathy     4
Cardiomyopathy and cataracts     2
Cataracts and developmental delay       2
Neonatal lactic acidemia     2
Mild symptoms
From: Robinson BH. Human Complex I deficiency: Clinical spectrum and involvement of oxygen free radicals
in the pathogenicity of the defect. Biochim. Biophys. Acta 1364: 271-286, 1998.
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Their findings are in agreement with those of Morris et al. and Rahman et al., in which isolated
CID was found to be a common cause of Leigh disease (108,121).
A second category frequently seen is fatal neonatal lactic acidosis, where the patient has such a
severe defect that the acidosis that results from the lactic acid production exceeds the buffering
capacity of the body (122,123). Severe cases of CID were found by Western blotting not to
assemble complex I (123). In patients with hepatopathy and tubulopathy there is an unusual
involvement of the liver and kidney sometimes accompanied by neurodegeneration (124). The
syndrome of cardiomyopathy and cataracts is characterized by bilateral congenital cataracts,
associated with hypertrophic ventricular cardiomyopathy (HC), exercise-induced
hyperlactatemia and mitochondrial myopathy. Three unrelated sibships produced seven
affected children out of 22 in which symptoms of varying severity were apparent
(125,126,127). There was no CNS involvement but many affected family members had chronic
progressive cardiomyopathy with early death as endpoint. Inheritance pattern in these families
is consistent with an autosomal recessive gene, and paternal transmission rules out any role of
mitochondrial DNA.
Complex I Deficiency  associated with defects of other components of the respiratory chain.
Combined complex I and IV deficiencies in muscle have been described in the literature as the
most frequent combination of respiratory chain defects in humans (128,129,130,131, 132,133).
These patients almost all suffered from a progressive encephalomyopathy and/or
ophthalmoplegia. Combined complex I and IV deficiencies associated with MELAS syndrome
were reported in Japanese patients (134). Both Mendelian and maternal patterns of inheritance
have been suggested, because both complexes consist of nuclearly and mitochondrially
encoded subunits (133). It was speculated that a decrease of mitochondrial biosynthesis might
lead to a combined complex I and IV deficiency in patients with Mendelian inheritance (132).
Indeed, a decrease in two nuclearly encoded subunits, subunit 1 of complex I and subunit 5 of
complex IV, were described in two brothers (129).
Complex I Deficiency associated with specific diseases due to defects of mtDNA. Thi group
of maternally inherited diseases has now been well characterized at the molecular level and
involves point mutations in mitochondrially-encoded tRNA species for leucine and isoleucine
in the case of MELAS, tRNA for lysine in the case of MERRF, and in the ND subunits of
complex I in the case of LHON (62,67,68,69,70,77). The mechanism related to the relative
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decrease in respiratory chain complexes depends very much on the species of tRNA affected
and the contribution of that tRNA to the synthesis of mtDNA encoded polypeptides of the
respiratory chain. Thus mutations in the tRNALeu(UUR) produce major complex I defects in the
muscle of affected patients because of the high titre of leucines encoded in the ND subunits of
complex I (135).
Diagnosis. The diagnosis CID relies on the results of screening tests, provocative tests,
enzyme assays, histopathological studies, and additional Magnetic Resonance Spectroscopy
(MRS) or Near Infrared Spectroscopy (NIRS)studies in muscle and brain of affected patients.
Screening tests. These include the determination of lactate, pyruvate, â-hydroxybutyrate,
acetoacetate, and their molar ratios in plasma (Table 3, ref. 53). The molar ratios of lactate and
pyruvate and â-hydroxybutyrate and acetoacetate reflect the redox state in cytosol and
mitochondria, respectively (136). The observation of a persistent hyperlactataemia (> 2.5 mM)
with elevated lactate-to-pyruvate and ketone body molar ratios in the fasted state is highly
suggestive of a respiratory chain deficiency (53). In addition, the finding of elevated total
ketone body levels in the fed state is also suggestive, since ketone bodies should normally
decrease after meals due to insulin release (paradoxical hyperketonemia).
Provocative tests. These should be carried out when basal screening tests are inconclusive:
1. Glucose loading test (2g/kg, orally), in order to unmask latent hyperlactatemia and/or
hyperketonemia.
2. Exercise test, in order to provoke elevations of plasma lactate as well as of lactate-to-
pyruvate and ketone body molar ratios.
3. Determination of redox state in the CSF, in order to detect elective increases of lactate and
lactate-to-pyruvate molar ratio in the liquor (only when no elevation of plasma lactate is
observed).
Enzyme assays. Enzyme assays are essential for the diagnosis of CID. These investigations
include two distinct procedures which provide independent clues to the diagnosis of respiratory
chain disorders: polarographic studies and spectrophotometric studies. Polarographic studies
consist of oxygen consumption measurements by mitochondria-enriched fractions (isolated
mitochondria) using a Clark type electrode upon addition of various oxidative substrates. The
substrates added can be NADH-related (pyruvate+malate, glutamate+malate,
palmitoylcarnitine), or FADH2-related (succinate).
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Table 3. Screening procedures.
Standard screening tests (at least 4 determinations daily in fasted and 1-hr fed state)
1. Plasma lactate
2. Lactate-to-pyruvate molar ratio (=redox state in cytosol)
3. Ketonemia (‘paradoxical’ elevation in fed state)
4. â-hydroxybutyrate-to-acetoacetate molar ratio (=redox state in mitochondria)
5. Blood glucose and free fatty acids
6. Urinary organic acids (lactate, ketone bodies, TCA cycle intermediates)
Provocative test (when standard tests are inconclusive)
1. Glucose test (2g/kg, orally) in fasted individuals with determination of blood glucose, lactate, pyruvate,
ketone bodies and their molar ratios at t = 15 min, 30 min, 45 min, 60 min, 90 min
2. Lactate-to-pyruvate molar ratios in the CSF (only when no elevation of plasma lactate is observed)
3. Redox state in plasma following exercise
Screening for multiple organ involvement
- Liver: hepatocellular dysfunction
- Kidney: proximal tubulopathy, distal tubulopathy, proteinuria, renal failure
- Heart: hypertrophic cardiomyopathy, heart block (ultrasound, ECG)
- Muscle: myopathic features (CK, ASAT, ALAT, histological abnormalities: RRF)
- Brain: leukodystrophy, poliodystrophy, hypodensity of the cerebrum, cerebellum, and brainstem,
multifocal areas of hyperintense signal (MELAS), bilateral symmetrical lesions of the basal ganglia
and brainstem (Leigh disease) (EEG, NMR, CT scan)
- Peripheral nerve: distal sensory loss, hypo- or areflexia, distal muscle wasting (usually subclinical),
reduced motor nerve conduction velocity and denervation features (nerve conduction velocity, EMG,
peripheral nerve biopsy showing axonal degeneration and myelinated fibre loss)
- Pancreas: exocrine pancreatic dysfunction
- Gut: villous atrophy
- Endocrine: hypoglycemia, hypocalcemia, hypoparathyroidism, growth hormone deficiency
(stimulation tests)
- Bone marrow: anemia, neutropenia, thrombopenia, pancytopenia, vacuolization of marrow precursors
- Eye: PEO, ptosis, optic atrophy, retinal degeneration (fundus, electroretinogram, visual evoked
potentials)
- Ear: sensorineural deafness (auditory evoked potentials, brainstem evoked potentials)
- Skin: trichothiodystrophy, mottled pigmentation of photo-exposed areas
Abbreviations: MELAS = mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes; PEO =
progressive external ophthalmoplegia. From: Munnich et al. Clinical presentations and laboratory
investigations in respiratory chain deficiency. Eur. J. Pediatr. 155: 262-274, 1996.
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In CID, polarographic studies will show impaired respiration upon addition of NADH-related
substrates, while respiration and phosphorylation are normal with FADH2-related succinate
(the opposite will be observed in case of complex II deficiency, whereas a block at the level of
complexes III and IV impairs oxidation of both NADH- and FADH2-related substrates).
Polarographic studies are feasible in mitochondria-enriched fractions from skeletal muscle
biopsies of only 100-200 mg of fresh muscle obtained under local anesthesia (137).
Polarographic studies on intact circulating lymphocytes or detergent-permeabilized cultured
cells (lymphoblastoid cell lines, skin fibroblasts) are also available (138,139).
Spectrophotometric studies consist of the measurement of respiratory enzyme activities
separately or in groups, using specific electron acceptors and donors. These studies do not
require isolation of mitochondrial fractions and can be carried out on tissue homogenates.
For this reason, the amount of material required for enzyme assays (1-20 mg) is very small and
can be easily obtained by needle biopsies of muscle, liver, kidney, and even by endomyocardial
biopsies (140). Since conclusive diagnostic evidence of respiratory chain deficiency is provided
by enzyme assays, it is particularly relevant what tissue is biopsied.
In principle, the relevant tissue is that which actually expresses the disease, e.g. skeletal muscle
in isolated myopathies, or the hematopoietic system in Pearson syndrome. When the disease is
mainly expressed in a barely accessible organ (brain, retina, endocrine, smooth muscle),
peripheral tissues should be extensively tested (including skeletal muscle, cultured skin
fibroblasts, circulating lymphocytes) (53).
Histopathological studies. The histological hallmark of mitochondrial myopathy is the ragged
red fibre (RRF) demonstrated with the modified Gomori trichrome stain, containing peripheral
and intermyofibrillar accumulations of abnormal mitochondria. Although the diagnostic
importance of histopathological studies is undisputed, the presence of RRF as the unique
criterion has been challenged by recent advances. It is now clear that absence of RRF does not
rule out the diagnosis of mitochondrial disorder, particularly in young patients (141).
Magnetic Resonance Spectroscopy (MRS) of muscle and brain. Phosphorus MRS allows for
study of muscle and brain energy metabolism in vivo. Phosphocreatine, inorganic phosphate,
AMP, ADP, ATP, and intracellular pH all can be measured. The phosphocreatine/ inorganic
phosphate ratio is the most useful parameter and may be measured at rest and during exercise
and recovery. A decreased ratio is found in most patients with respiratory chain deficiencies,
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and thus MRS is a useful noninvasive tool in the diagnosis of mitochondrial disease. It may
also be valuable in monitoring therapeutic trials. Yet, the observed anomalies are not specific
to respiratory enzyme deficiencies and no correlation can be made between MRS findings and
the site of respiratory enzyme defect (141).
Near Infrared Spectroscopy (NIRS) of muscle. NIRS is another technique that allows for in
vivo study of muscle energy metabolism, by noninvasive and direct quantitative measurement
of muscle oxygen consumption and blood flow. NIRS has been suggested a valuable tool in the
diagnostic workup of patients suspected to have a mitochondrial myopathy (142).
Treatment and prognosis. No satisfactory therapy is presently available for respiratory chain
deficiency. Treatment remains largely symptomatic and does not significantly alter the course
of the disease. It includes avoidance of drugs and procedures known to have a detrimental
effect (anaesthesia), supplementation with cofactors and substrates, symptomatic treatments,
prevention of oxygen radical damage to mitochondrial membranes and dietary
recommendations.
Avoidance of drugs (anaesthetics) . I  is advisable to avoid sodium valproate and barbiturates
which inhibit the respiratory chain and have occasionally been shown to precipitate hepatic
failure in respiratory enyme-deficient children (143). Tetracyclines and chloramphenicol should
be avoided as well, as they inhibit mitochondrial protein synthesis. Anaesthetical complications
include high sensitivity to muscle relaxants and to the induction agents etomidate and
thiopentone (144). Respiratory responses to hypoxemia and hypercapnia may be impaired
(145). Agents that disturb cardiac conduction should be avoided. If inhalation anaesthesia is
planned, isoflurane should be favored, since halothane may provoke rhythm disturbances (144).
Supplementation with cofactors and substrates. Treatment with riboflavin has been associated
with improvement in a few patients with CID (146,147,148). A 13 year old girl with complex I
deficient myopathy was succesfully treated with oral riboflavin 100 mg dialy, a
pharmacological dose without any overt side effects. Her exercise intolerance and pathological
variables in exercise tests (maximal work capacity, oxygen uptake and base excess) improved
markedly (146). In another 33 year old patient with CID, associated with MELAS syndrome,
administration of riboflavin in conjunction with nicotinamide was paralleled by cessation of
encephalomyopathic symptoms and by a spectroscopic and electrophysiologic response (147).
The evaluation of riboflavin treatment in six patients (148,149) with a mitochondrial myopathy
Chapter 1
____________________________________________________________________________
- 32 -
and CID, resulted in clear clinical improvement of the two patients suffering from clinically
pure myopathy, whereas the other patients with an encephalomyopathic form showed clinical
improvement in only one case. Disappointing results are observed in most cases however
(150,151). Carnitine is suggested in patients with secondary carnitine deficiency.
Succinate treatment in a single MELAS patient with CID was followed by the disappearance of
the strokelike episodes (152). Succinate funnels electrons into complex II, bypassing the
defective complex I.
Symptomatic treatments. Phy ical therapy is crucial in cases with hemiparesis and muscular
weakness and should aim to maintain or restore muscle coordination and joint mobility. Severe
acidosis can be corrected by infusion of sodium bicarbonate. Since the stroke-like episodes in
MELAS syndrome are generally believed to result from defective ATP production in the
affected brain area, rather than from vascular ischaemic insults (153), platelet inhibitors are
presumably without therapeutic benefit and their use has not been systematically investigated.
Cardiac abnormalities must be treated symptomatically. A pacemaker may restore adequate
cardiac conduction and cardiac failure can be treated with the usual drugs. Symptomatic
treatment may include pancreatic extract administration and repeated transfusions of blood and
platelets in Pearson syndrome.
Prevention of oxygen radical damage. The prevention of oxygen radical damage is the
rationale for administration of the antioxidants vitamin E and C. Vitamin E is considered to be
extremely important because of its association with cell membranes. Vitamin C also serves as
an important antioxidant and free radical scavenger, it is extremely labile, and it is highly
susceptible to a number of environmental factors, including temperature, smog and cigarette
smoke (154).
Dietary recommendations. Dietary recommendations are a high lipid-low carbohydrate diet in
patients with CID (53). Although it has been speculated that high glucose diets are a metabolic
challenge for these patients, the value of high lipid-low carbohydrate diets in these patients has
not been evaluated yet.
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Scope of the thesis
Complex I Deficiency (CID), a respiratory chain disorder characterized by impaired
mitochondrial oxidation of NADH, is being recognized in an increasing number of patients.
Elevated plasma lactate levels are a common laboratory finding in human CID, and are thought
to reflect increased oxidation of NADH (coupled to reduction of pyruvate) in the cytosol,
resulting from the impaired oxidation of NADH inside the mitochondria.
No satisfactory therapy is presently available for these patients. In recent years there has been a
resurgence of interest in the ketogenic (high fat) diet, used in the treatment of refractory
childhood epilepsy and metabolic disease (e.g. phosphofructokinase and pyruvate
dehydrogenase deficiency, ref. 155, 156). A high fat-low carbohydrate diet has been
recommended in the treatment of patients with CID, because it was recognized that high
glucose diets may impose a metabolic challenge in these patients (53). We propose the
following rationale for high fat diets in the treatment of human CID:
(I) In CID patients mitochondrial oxidation of NADH is thought to be diminished.
In these patients FADH2 may be an alternative to NADH because electrons from
FADH2 can enter the respiratory chain distal to complex I.
(II) The supply of FADH2 to the mitochondria can be increased (relative to NADH) by
increasing the amount of triglycerides/free fatty acids in the diet. From stochiometry of
substrate oxidation it follows that complete oxidation of free fatty acids yields a ratio of
FADH2 over NADH of 0.5, whereas glucose yields a much lower ratio of 0.2.
 Therefore we hypothesized that administration of fatty acids may improve mitochondrial
substrate oxidation in these patients, with possible lower dependency on (cytosolic) glycolytic
carbohydrate metabolism, i.e. lower plasma lactate concentrations and turnover rates as a
consequence. This hypothesis was tested in four CID patients who presented with myopathy
and exercise intolerance as main features of their clinical picture. This subgroup of patients
may benefit from fatty acid supplementation (by supplying FADH2 distal to complex I) at rest,
but particularly during exercise.
 In chapter 2 a hypothesis is presented with regard to how the respiratory chain deficit
translates in terms of whole-body oxygen consumption. It is suggested that the enhanced in
vivo oxygen consumption in these patients (measured with respiratory calorimetry), which is in
apparent contrast with the respiratory chain deficit demonstrated in vitro, can be explained by
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an increased rate of electron transport through the respiratory chain (distal to CoQ), driven by
a decreased phosphorylation potential (calculated from 31P-MRS measurements).
 In chapter 3 intravenous infusion (lipid versus glucose in isoenergetic amounts) experiments
that were carried out in patients and controls at rest and during exercise are described and
discussed. Mitochondrial substrate oxidation was studied using respiratory calorimetry.
 With respect to lactate metabolism, emphasis is put on lactate production into the circulation at
the whole body level (measured from dilution of [1-13C]lactate tracer).
 In chapter 4 emphasis is put on lactate disposal from the circulation, when we hypothesized an
additional rationale for high fat diets in patients with CID:
(III) Lactate conversion into blood glucose (gluconeogenesis) may be an important way of
lactate removal in CID patients, especially during exercise.
(IV) Increased free fatty acid availability (and oxidation) may stimulate lactate disposal via
gluconeogenesis in these patients.
Substrate regulation of gluconeogenesis during exercise was studied first in normal healthy
volunteers under the condition of hyperlactemia, caused by an intravenous infusion of sodium
lactate. Then our additional hypothesis regarding the effects of increased free fatty acid
availability on lactate disposal via gluconeogenesis was tested in three of the CID patients,
both at rest and during exercise. For this purpose intravenous infusions of lipids were used in
identical amounts to the experiments described in chapter 3. In both studies gluconeogenesis
was quantified using the deuterated water method, because it can discriminate between
gluconeogenesis from lactate/pyruvate and other gluconeogenic precursors (157).
The results of the studies in CID patients may also be of physiological rather than
pathophysiological importance, as they are informative on the effects of cellular redox state on
gluconeogenesis in man.
Finally, a general discussion and summary is presented in chapter 5. Results of diet intervention
(high fat versus high carbohydrate) studies in our patients are described here.
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Abstract
Patients with isolated Complex I Deficiency (CID) in skeletal muscle mitochondria often
present with exercise intolerance as their major clinical symptom. We studied in vivo
bioenergetics in three of these patients by measuring oxygen uptake at rest and during maximal
exercise, together with forearm ADP concentrations [ADP] at rest. Whole-body oxygen
consumption at rest (VO2rest) was measured with respiratory calorimetry. Maximal oxygen
uptake (VO2max) was measured during maximal exercise on a cycle ergometer.
Resting [ADP] was estimated from in vivo 31P Magnetic Resonance Spectroscopy
measurements of inorganic phosphate, phosphocreatine and ATP content of forearm muscle.
VO2rest was significantly increased in all three patients: 128 ± 14 % (SD) of values in healthy
controls. VO2max in patients was on average 2.8-fold their VO2rest, and was only 28% of
VO2max in controls. Resting [ADP] in forearm muscle was significantly increased, compared
with healthy controls (patients: 26 ± 2 (SD) µM, healthy controls: 9 ± 2 (SD) µM).
We conclude that the increased whole-body oxygen consumption rate at rest reflects increased
electron transport through the respiratory chain, driven by a decreased phosphorylation
potential. The increased electron transport rate may compensate for the decreased efficiency of
oxidative phosphorylation (phosphorylation potential) in these patients.
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Introduction
Defects of mitochondrial oxidative phosphorylation (OXPHOS), are known to be associated
with an increasing number of diseases, and can theoretically give rise to any symptom, in any
organ or tissue dependent upon mitochondrial energy supply (1). The OXPHOS system is
comprised of five enzyme complexes located in the mitochondrial inner membrane: the four
enzyme complexes of the respiratory chain (complex I,II,III, and IV), which constitute the
chain of electron transport to oxygen, and ATP synthase (F0F1-ATPase, complex V).
At three of these enzyme complexes electron transport is coupled to transmembrane proton
translocation: complex I, III, and IV. Translocation of protons at these coupling sites generates
an electrochemical gradient across the mitochondrial inner membrane, the protonmotive force,
which is used for ATP synthesis (2).
Patients with defects in components of the respiratory chain and consequently of OXPHOS are
generally thought to have an impaired flow of electrons through the respiratory chain.
Consequently, a loss of capacity for proton translocation is assumed, when any of the
complexes I,III, and IV of the respiratory chain are affected. Indeed, decreased maximal
oxidative rates under optimal assay conditions in isolated mitochondria are used as a diagnostic
tool, suggestive for impaired electron flow in mitochondria of these patients.
However, in apparent contrast to these findings in isolated mitochondria, in vivo increased
resting oxygen consumption rates at the whole-body level have been reported incidentally in
patients with defects in oxidative phosporylation (3,4,5,6).
In addition, separate studies in heterogeneous groups of patients with mitochondrial
myopathies, using in vivo 31P Magnetic Resonance Spectroscopy (31P-MRS), have shown
abnormalities in skeletal muscle high-energy phosphate metabolism including a decreased
phosphorylation potential and an elevated resting [ADP] in patients compared with controls
(5,7). Increased resting oxygen consumption rates were observed in some of these patients (5).
The present study elaborates on these paradoxical in vivo and in vitro findings in OXPHOS
patients. Whole-body oxygen consumption at rest and during maximal exercise was measured
in three patients with a documented isolated Complex I Deficiency (CID), presenting with
exercise intolerance as their major clinical symptom. Oxygen consumption measurements at
rest were combined with estimations of tissue [ADP] and phosphorylation potential from 31P-
MRS studies in forearm muscle.
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Patients and methods
Subjects
Three non related female CID patients, ages 20 to 25, were selected for the study (Table 1).
Their weights ranged from 52 to 61 kg. Fat free body mass ranged from  41 to 45 kg.
Table 1. Physical characteristics of CID patients and controls.
   CID patient   Controls
 ________________________ ______________________
   #1    #2    #3   mean (95% CI) n
_________________________________________________________________________________________
Age at study (yr)    25    20    22    22 ( 20 to 24 ) 8
Body weight (kg)    52    61    57    58 ( 56 to 60 ) 8
Fat free mass (kg)     41    45    44    44 ( 42 to 46 ) 8
Plasma lactate (mmol/L)   2.3   2.7   4.7   0.8 (0.6 to 1.0) 8
Blood pyruvate (µmol/L)  132  120  192    85 (75 to 95) 8
Lactate-to-pyruvate ratio 17.4 22.5 24.5   9.4 (7.4 to 11.4) 8
The patients had very similar clinical histories. They were all born from unrelated parents and
suffered from easily fatiguable mild muscle weakness dating back to early childhood.
Patient #1 experienced a single stroke-like episode at age 13, which resolved spontaneously
after a few hours. None of these patients showed signs of central nervous system involvement.
Muscle weakness and fatiguability have remained stable over time in all of them. Exercise
intolerance therefore dominated the clinical picture at the time of the study.
Patients #1 and #2 had been prescribed riboflavin and carnitine, but discontinued this therapy
because they recalled no benefit from this medication. At the time of the study, patient #3 was
on riboflavin and carnitine, even though she did not recall much benefit either. All patients
were engaged in social activities, with patient #1 a housewife, and patients #2 and #3 working
in service jobs. Mitochondrial DNA abnormalities (pointmutations, i.e. 3243 AG
MELAS/PEO, 8344 AG MERRF, 8993 TG NARP, 11778 AG LHON, deletions,
duplications, or mtDNA depletion) have not been demonstrated in any of these patients, nor
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could a maternal pattern of inheritance be shown. Therefore a mutation in a nuclear encoded
subunit of complex I was suspected. Lactate-to-pyruvate ratios in blood were increased and
ranged from 17.1 to 24.5 (Table 1). Eight healthy control subjects, matched for age, gender
and body weight/fat free mass, were recruited for the respiratory calorimetry studies. For the
31-Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) studies, control data from 20
healthy untrained volunteers were used as previously described (8). All subjects were studied
after an overnight fast without prior dietary preparation, i.e. on their own diet. The study was
approved by the Medical Ethics Committee of our hospital, and written informed consent was
obtained from all subjects.
Methods
Respiratory calorimetry. Open circuit indirect calorimetry was performed at rest under a
ventilated hood for 40 minutes. After assessment of height, body weight and fat free mass (four
skinfolds) subjects were acclimatized to room conditions (temperature: 21-25 °C) on a bed in
the supine position for 30 minutes before beginning the study. Stable values for oxygen
consumption (VO2) were reached within 5 min of recording. Computerized continuous gas
analysis and volume measurements (VO2 and VCO2) were performed (Oxycon Champion,
Jaeger, Breda, The Netherlands), as previously described (9). Gas and volume calibrations
were performed before each measurement. Standardization with alcohol burning was
performed regularly; the theoretical respiratory exchange ratio (0.67) was closely approached
in all standardizations (mean 0.66; coefficient of variation 1.6 percent, n=10). Within subject
coefficients of variation for VO2 measurements (two control subjects, one CID patient; each
subject studied three times) ranged from 4.1 to 5.1 percent.
Maximal exercise testing. All participants reported to the laboratory to perform an incremental
maximal exercise test on an electrically braked cycle ergometer (Lode Instruments, Groningen,
The Netherlands). Maximal oxygen uptake (VO2max) were assessed as previously decribed
(10).
31P-MRS experiments. Studies were conducted on the superficial mass of the flexor digitorum
profundus (FDP) muscle of the right forearm. 31P MRS spectra of the FDP were obtained at
1.5 Tesla on a Philips (Eindhoven, The Netherlands) S15 HP whole-body MRS spectrometer,
as decribed in detail elsewhere (11). Briefly, subjects were positioned prone and head-first on
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the patient bed with their right forearm extended forward, supported by cushions. Guided by
palpation of the ulnar bone directly adjacent to the muscle, the forearm was placed in a support
such that the FDP overlied a 25-mm-diameter two-turn surface coil tuned to the 31P frequency
(25.86 MHz) and was attached with Velcro strips. Correct positioning of the FDP over the  31P
surface coil was verified by 1H magnetic resonance imaging.
31P-MRS spectra of the superficial region of the FDP were obtained with a frequency-
modulated adiabatic 90° excitation pulse. 60 free induction decays (FIDs; 1,024 data points
with 333 µs dwell time) were collected with a repetition time of 3 seconds. The signals were
processed using the LAB ONE (New Methods Research) NMR1 spectroscopy processing
software, as described (11). Estmates of the relative peak areas of the various metabolites were
obtained by curve fitting of the spectrum to Lorentzian line shapes (Pi and PCr, both singlets;
g-, a-, b-ATP, two doublets and a triplet, respectively). Intracellular pH was determined from
the chemical shift of Pi relative to PCr, which was set at 0.00 ppm (12). Any regional variation
of pH within the sampled muscle mass was determined by examination of the Pi peak and
comparisons of its width with that of the PCr peak, as determined by the fitting routine.
Calculation of intracellular free ADP concentration and phosphorylation potential
The average free ADP concentration ([ADP]) in fibers within the sampled muscle mass was
calculated from the creatine kinase equilibrium relation according to the equation:
[ADP] = [ATP] ([TCr] - [PCr]) / (1.66x109) ( -pH) [PCr] [1]
where 1.66 x 109 M is the value of the equilibrium constant (13). It was assumed that the
concentrations of ATP and total creatine ([TCr]) in skeletal muscle of the patients were
unchanged from normal values (8.2 and 42.7 mM for [ATP] and [ TCr] respectively, ref. 14).
The phosphorylation potential was calculated according to the equation:
Phosphorylation potential = [ATP] / ([ADP] x [Pi]) [2]
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Results
In Table 2 the diagnostic findings are summarized with regard to microscopic and biochemical
investigations in freshly biopsied quadriceps (vastus lateralis) muscle of the patients. The
muscle biopsy showed ragged red fibers in each of the three patients.
All patients showed severely impaired oxidation of NADH-linked substrates and an enhanced
or normal oxidation of FADH2 and cytochrome c-linked substrates. Together these results
suggest an isolated defect located at the level of complex I of the respiratory chain. Indeed, the
activity of complex I in the muscle homogenate of all patients was severely diminished, while
the activities of the complexes III and IV were unimpaired or even increased.
Table 2. Microscopic and biochemical investigation of muscle biopsies in CID patients.
          CID patient   Controls
__________________________ ________________
    #1   #2     #3 mean ± SD n
_________________________________________________________________________________________
Light microscopy findings   RRF RRF RRF, L
Enzyme activity in fresh muscle homogenate [U(+) or mU (-) per g wet weight]:
- complex I (+)   0.18 0.76   0.33 3.19 ± 0.26 10
- complex II+III (+) 14.78 7.43 11.14 3.99 ± 0.43 21
- complex IV (-)    305  195    413    90 ± 7 16
Maximal oxygen uptake after substrate stimulation in isolated fresh muscle mitochondria
(nanoatoms oxygen min -1 per mg protein):
NADH-linked substrates
- pyruvate+malate+ADP       19    28       9    92 ± 5 22
- glutamate+malate+ADP         19    30     11    82 ± 7 22
- palmitoylcarnitine+malate+ADP     21    27     13    68 ± 5
22
Other substrates
- succinate+rotenone+ADP   166  268   115  104 ± 8 22
- ascorbate+TMPD+ADP   700  606   329  344 ± 13 22
Enzyme assays and polarographic studies have been performed according to Scholte et al (24). RRF: ragged red
fibers, L: lipidosis. TMPD=N,N,N',N'-tetramethyl-p-phenylenediamine.
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The results of the calorimetric and 31P-MRS studies as well as the maximal exercise tests are
shown in Table 3. Oxygen consumption at rest (VO2rest) in each of the three patients was
higher than the upper 95% confidence limit of VO2rest in controls, both when expressed per kg
of body weight (mean±SD: 128 ± 14 %, range: 112-137% of values in healthy controls) and
per kg of fat free mass (mean±SD: 127 ± 17%, range: 108-140% of values in healthy controls).
There were no differences in respiratory exchange ratio between patients and controls.
Table 3. Results of respiratory calorimetry and 31P MRS studies in CID patients and controls.
CID patient    Controls
 _____________________________ ______________________
  #1   #2   #3 mean±SD mean (95% CI)   n
__________________________________________________________________________________________
Respiratory calorimetry:
VO2 (ml/min/kg body weight)  3.81 4.61 4.67 4.36±0.48 3.40 (3.31 to 3.49)   8
VO2 (ml/min/kg ffm) 4.83 6.25 6.05 5.71±0.77 4.48 (4.36 to 4.60)
  8
VCO2 (ml/min/kg body weight) 3.11 3.71 4.08 3.63±0.49 2.92 (2.80 to 3.04)   8
VCO2 (ml/min/kg ffm) 3.94 5.03 5.29 4.75±0.72 3.85 (3.69 to 4.01)   8
Respiratory Exchange Ratio 0.81 0.81 0.87 0.83±0.03 0.86 (0.81 to 0.91)   8
31P-MRS:
[PCr]/[Pi] measured        6.1   5.3   5.3   5.6±0.5 11.1 (10.7 to 11.5) 20
[ADP] (µmol/L)        24    27    27    26±2    10 (9 to 11) 20
Phosphorylation Potential (mmol/L-1)    57    44    44    48±8  276 (274 to 278) 20
Maximal exercise testing:
VO2max (ml/min/kg bodyweight) 13.6 12.5 10.5 12.2±1.6 42.9 (41.2 to 44.6)
  8
Resting [ADP] and Phosphorylation Potential were calculated from 31P Magnetic Resonance Spectroscopy (31P-
MRS) measurements of [PCr]/[Pi], recorded from resting forearm muscle (60 free induction decays during four
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minutes) as previously described (11), assuming ATP and total creatine concentrations of 8.2 and 42.7 mM
respectively (14).
The measured PCr/Pi ratio in resting FDP muscle was below the lower 95% confidence limit of
controls in all three patients measured. Their calculated resting ADP concentrations in forearm
muscle were markedly higher than the upper 95% confidence limit of controls (mean±SD: 26 ±
2 µM, healthy controls 9 ± 2 µM). Calculated phosphorylation potentials were markedly lower
in patients than in controls.
Maximal oxygen uptake (VO2max) was 3.6-, 2.7-, and 2.2-fold increased, when compared
with resting VO2 in patient #1, 2, and 3, respectively. Because VO2 incr ased nearly 13-fold
from rest to maximal exercise in controls, VO2max in patients was on average only 28% of
VO2max in controls.
Discussion
The present study elaborates on previous incidental observations of increased resting metabolic
rates in patients with OXPHOS defects (3,4,5,6). An increased resting metabolic rate seems
paradoxical in view of the defective complex I. Three patients with an isolated CID were
selected to study this phenomenon in more detail. They were selected on the basis of a
relatively mild clinical picture, namely exercise intolerance as their major clinical symptom. We
postulated that in these patients the abnormalities in energy metabolism could be studied
without interference of more severe consequences of the defect, as seen for instance in patients
presenting in the newborn period with overwhelming lactic acidemia.
In our patients we observed that the deficiency of complex I at rest was associated with a
significantly elevated resting oxygen consumption rate, a decreased resting phosphorylation
potential, and an increased lactate-to-pyruvate ratio in blood. Oxygen consumption during
maximal exercise was severly limited. These in vivo findings were accompanied by an increase
in the in vitro activity, assayed under optimal conditions, of the distal part of the respiratory
chain (CoQ-O2), as well as by an increased amount of mitochondrial protein in their muscle
biopsies. These findings suggest that at rest mitochondrial substrate oxidation is stimulated
rather than impaired in these three CID patients.
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Consequences of the loss of one OXPHOS coupling site. The synthesis of ATP is coupled to
respiratory chain activity via the protonmotive force that is generated by proton translocation
across the mitochondrial inner membrane at three sites: complex I, III, and IV. In fully coupled
mitochondria oxidation of NADH-linked substrates is coupled to proton translocation at all
three sites, which results in three ATP synthesized for each oxygen atom reduced (theoretical
P/O ratio = 3). Oxidation of FADH2-linked substrates is coupled to only two sites (complex III
and IV, theoretical P/O ratio = 2). The P/O ratios that can be measured in ATP synthesizing
cells will be lower than these theoretical values following from stochiometry, and have been
predicted from non-equilibrium thermodynamics (15). Cairns et al. have actually measured P/O
ratios in isolated mitochondria. For the three tissues measured (i.e. brain, liver, and heart) they
found average P/O ratios with NADH-linked substrates of 2.32±0.25, whereas with FADH2-
linked substrates it was 1.76±0.11 (16). The loss of one OXPHOS coupling site in CID results
in a P/O ratio of ~ 1.75 for the oxidation of both NADH- and FADH2-li ked substrates (17)
and a loss of efficiency of ATP synthesis.
Compensation for the loss of one OXPHOS coupling site.  Central to the description of muscle
bioenergetics is the phosphorylation potential. In steady-state the phosphorylation potential in
the cytosol is the result of the balance between ATP hydrolysis, for maintenance of cellular
integrity, and ATP synthesis by mitochondrial OXPHOS. ATP hydrolysis is insensitive towards
the cellular phosphorylation potential in resting muscle (18).
By contrast, the rate of ATP synthesis and thereby cellular respiration strongly depends on the
phosphorylation potential in resting muscle: it increases sharply with decreasing
phosphorylation potential (18). A decrease in the efficiency of ATP synthesis at equal rates of
ATP hydrolysis, as in our CID patients, will result in a decrease in the steady-state
phosphorylation potential, as was indeed observed. Consequently cellular respiration will
increase until a new steady-state is reached, in which the rate of ATP synthesis again matches
the rate of ATP hydrolysis. This new steady-state should be reached at a lower
phosphorylation potential in order to maintain the increased cellular respiration rate. For our
patients it can be calculated that the rate of electron transport (and thus oxygen consumption)
should increase to 2.26/1.75 x 100% ~ 130% of controls in order to compensate for the loss of
efficiency of ATP synthesis. The observed mean increased resting oxygen consumption rates in
these three patients (128±14% of controls, Table 3) compared favourable to this theoretical
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value. In addition, the finding of increased activities of the complexes III and IV in muscle of
two of our patients and others (19,20) fits well to the concept of increased electron transport
through the respiratory chain distal of CoQ. An increased rate of electron transport driven by a
decreased phosporylation potential implies that the rate of electron transport through the
respiratory chain of these patients should be unrestricted at rest. This reasoning tacitly assumes
sufficient residual capacity of complex I to accommodate the increased resting metabolic
demand in these patients. We found that these patients can increase their oxygen consumption
rate (and thus electron transport) almost threefold on average during exercise (Table 3),
suggesting sufficient residual capacity must be present.
An interesting question remains to be elucidated with regard to the increased rate of electron
transport through the respiratory chain in the resting state: where do electrons enter the
respiratory chain in these patients? We would like to emphasize that a defect in complex I does
not necessarily imply a block in the flow of electrons through the complex, but could also
cause impairment of the associated proton translocation across the mitochondrial inner
membrane at this site. Majander et al. have shown that in CID patients respiration (electron
transport) may or may not be impaired depending on the type of mutation involved (21). In the
resting state mitochondrial oxidation of NADH does not seem to be impaired to a significant
extent in our three patients. The increased lactate-to-pyruvate ratios in blood of our patients
indicate that mitochondrial oxidation of NADH however is not completely unaffected.
The question arises why these patients have increased lactate-to-pyruvate ratios at rest,
indicative of an increased cytosolic redox potential (NADH/NAD+), when the rate of electron
flow through the respiratory chain is increased and enough residual capacity seems to be
present. We speculate that this apparent contradiction can be explained by an inverse
relationship between the (increased) redox potential and the (decreased) phosphorylation
potential. Cellular redox state and phosphorylation potential are inversely coupled at the level
of glycolysis by the simultaneous action of glyceraldehyde-3-phosphate dehydrogenase and
phosphoglycerate kinase, and at the level of transport of cytosolic reducing equivalents into the
mitochondria by the energy-dependent malate-aspartate shuttle (22,23).
We conclude that our finding of stimulated rather than impaired substrate oxidation in these
CID patients at rest, points to an increased electron transport rate that may compensate for the
decreased efficiency of oxidative phosphorylation (phosphorylation potential) in these patients.
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We speculate that this can result in an increased cytosolic redox potential, as reflected by an
increased lactate-to-pyruvate ratio in blood.
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Abstract
A high fat diet has been recommended for correction of biochemical abnormalities in patients
with Complex I Deficiency (CID). This study evaluated effects of intravenous infusion of
isoenergetic amounts of triacylglycerol or glucose on substrate oxidation and glycolytic
carbohydrate metabolism in four resting CID patients and 15 matched controls. Subjects were
infused with triacylglycerol (1.85 mg/kg/min) or glucose (5 mg/kg/min).
Respiratory calorimetry was used as a measure of mitochondrial substrate oxidation.
In addition, 31P Magnetic Resonance Spectroscopy (31P-MRS) measurements were done in
forearm muscle. Glycolytic carbohydrate metabolism was studied by plasma lactate
concentration and turnover (from dilution of [1-13C]lactate) measurements.
Whole-body oxygen consumption rates were higher in patients, compared with controls
(P<0.05). There were no differences in oxygen consumption and 31P-MRS measurements of
skeletal muscle energy state between triacylglycerol and glucose infusion in both groups.
Plasma lactate concentrations and turnover were higher in each of the four patients, compared
with controls (P<0.05). Lactate concentrations and turnover rates were lower during
triacylglycerol infusion, compared with glucose infusion (P<0.05), with comparable differences
in both patients and controls.
We conclude that triacylglycerol infusion, compared with glucose infusion, does not improve
oxidation of substrates or skeletal muscle energy state and does not lower plasma lactate
concentration and its rate of turnover to normal values in CID patients at rest.
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Introduction
Complex I Deficiency (CID), a respiratory chain disorder characterized by impaired
mitochondrial oxidation of NADH, is being recognized in an increasing number of patients (1).
Clinical manifestations range from pure myopathy restricted to the extraocular muscles (2)
and/or skeletal muscle (2,3), to multisystemic involvement in which various other tissues are
also affected (4,5). Elevated plasma lactate concentrations are a common laboratory finding in
human CID (2,3,4,5). The elevated lactate concentrations are thought to reflect increased
oxidation of NADH (coupled to reduction of pyruvate) in the cytosol, resulting from the
impaired oxidation of NADH inside the mitochondria of these patients.
A high fat-low carbohydrate diet has been recommended in the treatment of CID (6), because
it was recognized that high glucose diets may impose a metabolic challenge in these patients.
We propose the following rationale for high fat diets in the treatment of human CID:
(I) In CID patients mitochondrial oxidation of NADH is thought to be diminished.
In these patients FADH2 may be an alternative to NADH because electrons from
FADH2 can enter the respiratory chain distal to complex I.
(II) The supply of FADH2 to the mitochondria can be increased (relative to NADH) by
increasing the amount of triacylglycerols/free fatty acids in the diet. From stochiometry
of substrate oxidation it follows that oxidation of free fatty acids yields FADH2 and
NADH in a ratio of 0.5, whereas glucose yields a much lower ratio of 0.2.
Therefore we hypothesized that administration of fatty acids may improve mitochondrial
substrate oxidation, when compared with carbohydrate administration in CID patients.
The hypothesis is supported by in vitro studies of Doctor et al in renal cell cultures loaded with
glutamine (a NADH-linked substrate). Addition of rotenone, a known inhibitor of complex I,
in the presence of 2-deoxyglucose, a competitive inhibitor of glucose uptake, resulted in near
complete depletion of ATP and a significant drop in oxygen consumption. Subsequent addition
of heptanoate completely restored ATP concentrations and oxygen consumption (7). This
effect of heptanoate could only be shown in the absence of antimycin A (inhibits complex II),
suggesting that heptanoate oxidation can bypass complex I and that this is mediated by
complex II. Thus CID patients may benefit from fatty acid supplementation by supplying
FADH2 (distal to complex I). This may result in lower plasma lactate concentrations and
turnover rates. In the present study, effects of triacylglycerol or glucose administration on
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substrate oxidation and glycolytic carbohydrate metabolism were studied in four CID patients
and 15 healthy subjects. All patients had a documented Complex I Deficiency with exercise
intolerance as main feature of their clinical presentation. Glycolytic carbohydrate metabolism
was studied by plasma lactate concentration and turnover (from dilution of [1-13C] lactate)
measurements. Mitochondrial substrate oxidation was studied indirectly using respiratory
calorimetry. In addition, high energy phosphate metabolism was measured by 31P M gnetic
Resonance Spectroscopy done in forearm muscle (8,9).
Patients and methods
Subjects
Four non related female CID patients, ages 15 to 25 years, were studied (Table 1).
Their weights ranged from 45 to 61 kg. The patients had very similar clinical histories.
Table 1. Physical characteristics of CID patients and controls.
CID patient Controls
_______________________ _____________________
 #1  #2  #3  #4 mean (95% CI) n
__________________________________________________________________________________________
Age at study (yr)  25  20  22  15    21 (20 to 22) 15
Body weight (kg)  52  61  57  45 57.4 (54.7 to 60.1) 15
Fat free mass (kg)  41  45  44  35 44.5 (42.5 to 46.5) 15
Fasting plasma lactate (mmol/L)2.3 2.7 4.7 2.0   1.0 (0.8 to 1.2) 15
Wmax (W)  60  60  50  55  210 (192 to 228) 15
They were all born from unrelated parents and suffered from easily fatiguable mild muscle
weakness dating back to early childhood. Patient #1 experienced a single stroke-like episode at
age 13, which resolved spontaneously after a few hours. With the exception of patient #4, in
whom additional mild cerebellar atrophy and axonal neuropathy was diagnosed, these patients
showed no signs of central nervous system involvement. Muscle weakness and fatiguability
have remained stable over time in all of them. Exercise intolerance therefore dominated the
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clinical picture at the time of study. Maximal work performance (Wmax), assessed from an
incremental maximal exercise test on an electrically braked cycle ergometer (Lode Instruments,
Groningen, The Netherlands), as previously described (10) ranged from 50 to 60 W and was
on average only 25% of control values. Fasting 9 AM plasma lactate concentrations ranged
from 2.1 to 4.6 mmol/l (Table 1). Patients #1 and #2 had been prescribed riboflavin and
carnitine, but discontinued this therapy because they recalled no benefit from this medication.
At the time of the study, patients #3 and #4 were on riboflavin and carnitine, even though they
did not recall much benefit either. All patients were engaged in social activities, with patient #1
a housewife, patients #2 and #3 working in service jobs, and patient #4 attending school.
Patient #1 recently has given birth to a healthy son.
Table 2. Microscopic and biochemical investigation of muscle biopsies in patients #1, #2, and #3.
    CID patient Controls
__________________________ ___________________
    #1   #2     #3 mean ± SD  n
__________________________________________________________________________________________
Light microscopy findings   RRF RRF RRF, L
Enzyme activity in fresh muscle homogenate [U(+) or mU (-) per g wet weight]:
- complex I (+)   0.18 0.76   0.33 3.19 ± 0.26 10
- complex II+III (+) 14.78 7.43 11.14 3.99 ± 0.43 21
- complex IV (-)    305  195    413    90 ± 7 16
Maximal oxygen uptake after substrate stimulation in isolated fresh muscle mitochondria
(nanoatoms oxygen min -1 per mg protein):
NADH-linked substrates
- pyruvate+malate+ADP        19    28       9    92 ± 5 22
- glutamate+malate+ADP     19    30     11     82 ± 7 22
- palmitoylcarnitine+malate+ADP    21    27     13    68 ± 5 22
Other substrates
- succinate+rotenone+ADP   166  268   115  104 ± 8 22
- ascorbate+TMPD+ADP   700  606   329  344 ± 13 22
Enzyme assays and polarographic studies have been performed according to ref. 2. RRF: ragged red fibers, L:
lipidosis. TMPD=N,N,N',N'-tetramethyl-p-phenylenediamine.
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Complex I Deficiency was diagnosed with microscopic and biochemical investigations in
freshly biopsied quadriceps (vastus lateralis) muscle, showing markedly decreased activity of
Complex I (NADH-ubiquinone oxidoreductase, EC 1.6.99.3) in all patients. Mitochondrial
DNA abnormalities (pointmutations, i.e. 3243 AG MELAS/PEO, 8344 AG MERRF, 8993
TG NARP, 11778 AG LHON, deletions, duplications, or mtDNA depletion) have not been
demonstrated in any of these patients, nor could a maternal pattern of inheritance be shown. A
summary of the microscopic and biochemical investigations is given in Tables 2 and 3. Fifteen
healthy control subjects, matched for age, gender and body weight, were recruited for  the
(tracer) infusion and respiratory calorimetry studies. Another three subjects (two males, one
female, ages 18 to 28) volunteered for the 31Phosphorus Magnetic Resonance Spectroscopy
(31P-MRS) studies. None of these subjects had a family history of diabetes mellitus or took
medications. All subjects were studied after an overnight fast without prior dietary preparation,
i.e. on their own diet. Written informed consent was obtained in each subject. The
experimental protocol was approved by the Medical Ethics Committee of our hospital.
Table 3. Microscopic and biochemical investigation of muscle biopsies in CID patient #4.
CID patient #4 Control range   n
__________________________________________________________________________________________
Light microscopy findings RRF (-)
Enzyme activity in postnuclear supernatant [mU per mg protein]:
- complex I    13   24 - 87   9
- complex II+III 134   22 - 88 35
- complex IV 226   68 - 437 54
Oxidation of substrates by isolated fresh muscle mitochondria
(nanoatoms product hr -1 per mg protein):
NADH-linked substrates
- [1-14C]pyruvate+malate+ADP 152 273 - 705 20
- [U-14C]malate+pyruvate+malonate 154 320 - 996 20
- [U-14C]malate+acetylcarnitine+malonate 214 317 - 1155 20
Other substrates
- [1,4-14C]succinate+acetylcarnitine 153 206 - 546 19
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Enzyme assays and polarographic studies have been performed according to ref. 34. RRF: ragged red fibers.
Experimental protocol
Patients and controls reported at the laboratory at 8 AM on two occasions, separated by at
least seven days. The triacylglycerol and glucose infusions were assigned in random order.
All patients and controls participated in both the triacylglycerol and glucose infusion studies.
Two teflon catheters were inserted, one into a dorsal hand vein for infusion and the other into
a vein draining the dorsum of the contralateral hand for blood sampling. The hand was inserted
in a heated box to achieve arterialization of the venous blood (11). After drawing blood
sample, the catheter was flushed with heparinized saline (2.5 U/ml). Subjects were acclimatized
to room conditions (temperature: 21-25 °C) on a bed in the supine position for 30 minutes
before beginning the study. At time 0 an infusion of a lipid emulsion (Intralipid [20% w/v],
Fresenius Kabi, ’s-Hertogenbosch, The Netherlands) (1.85 mg/kg/min of triacylglycerols),
containing linoleic (50%), oleic (26%), palmitic (10%), linolenic (9%), and stearic (3.5%)
acids + heparin (7.5 U/kg/hr, prime 14 U/kg) or an infusion of glucose [10% w/v] (5
mg/kg/min) was initiated and maintained throughout the 100 minutes study period, during
which the subjects remained at rest in the supine position.
Isotope infusion. [6,6-2H2]glucose. Primed constant-rate infusions of [6,6-2H2]glucose (98%
enriched, Mass Trace, Woburn, USA) were administered in all four patients and in twelve of
the control subjects: prime 20.0 µmol/kg, continuous infusion rate 0.30 µmol/kg/min in
triacylglycerol infusion studies, and 0.50 µmol/kg/min in glucose infusion studies.
[1-13C]lactate. An unprimed constant-rate infusion of [1-13C]lactate (98% enriched, Mass
Trace, Woburn, USA) was started 30 minutes into the infusion of either triacylglycerol or
glucose, and continued throughout the remaining 70 minutes of the study period. The lactate
tracer infusion rates for the individual patients ranged between 1.00 and 1.50 µmol/kg/min.
Twelve control subjects received an unprimed constant-rate infusion of [1-13C]lactate at an
infusion rate of 0.45 µmol/kg/min for 70 minutes. The remaining three control subjects
received no lactate and glucose tracer at all, in order to examine effects of triacylglycerol and
glucose infusion on lactate and glucose background enrichments (no significant changes in
background enrichment could be detected upon administration of either substrate; data not
shown).
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Blood sampling and urine collection. Blo d samples were drawn at regular intervals, placed
on ice and transferred into sodiumfluoride tubes for plasma glucose, lactate, and triacylglycerol
measurements, lithium-heparinized tubes for free fatty acids, glycerol, cortisol, and insulin
determinations, and whole blood was deproteinized for measurement of blood pyruvate, b-
hydroxybutyrate, and acetoacetate. Samples for determination of  [6,6-2H2]glucose and [1-
13C]lactate enrichments were centrifuged at 4 °C and stored at -70 °C. Subjects voided at time
0 and 100 min, and urine was collected for determination of nitrogen excretion.
Respiratory calorimetry. Open circuit indirect calorimetry was performed at rest under a
ventilated hood for 40 minutes. The calorimetry was started after the subjects had been infused
with triacylglycerol or glucose for at least 45 minutes. Stable values for oxygen consumption
(VO2) were reached within 5 min of recording. Computerized continuous gas analysis and
volume measurements were performed (Oxycon Champion, Jaeger, Breda, The Netherlands),
as previously described (12). Gas and volume calibrations were performed before each
measurement. Standardization with alcohol burning was performed regularly; the theoretical
respiratory exchange ratio (0.67) was closely approached in all standardizations (mean 0.66;
coefficient of variation 1.6 percent, n=10).
31P-MRS studies. Patients and control subjects reported at the NMR facility at 8 AM for the
triacylglycerol and glucose infusions, on two separate days. A teflon catheter was inserted into
a dorsal hand vein for infusion of substrates. Subjects were infused with triacylglycerol (1.85
mg/kg/min) + heparin (7.5 U/kg/hr, prime 14 U/kg) or glucose [10% w/v] (5 mg/kg/min)
during a 100 minutes basal period, in which the subjects remained at rest. The infusions were
maintained at the same rate throughout the following 30 minutes study period. Three of the
CID patients (patient #1, #2 and #3) and three control subjects participated in the 31P-MRS
studies. Studies were conducted on the superficial mass of the flexor digitorum profundus
(FDP) muscle of the right forearm. The FDP muscle is affected in these patients, as evidenced
by the decreased maximal voluntary contraction output of the muscle, which is comparable to
the decrease in maximal exercise performance (Wmax) measured on the cycle ergometer
(unpublished observations). 31P-NMR spectra of the FDP were obtained at 1.5 T on a Philips
(Eindhoven, The Netherlands) S15 HP whole-body NMR spectrometer, as described in detail
elsewhere (13). Measurements were performed by one researcher (KdM). Briefly, subjects
were positioned prone and head first on the patient bed with their right arm extended forward,
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supported by cushions. Guided by palpation of the ulnar bone directly adjacent to the muscle,
the forearm was placed into a support such that the FDP overlied a two-turn 25-mm-diameter
surface coil tuned to the  31P frequency (25.86 Mhz) and was attached with Velcro strips.
Correct positioning of the FDP over the 31P surface coil was checked by 1H magnetic
resonance imaging. 31P-NMR spectra of the superficial region of the FDP were obtained with a
frequency-modulated adiabatic 90° excitation pulse. Sixty free induction decays (1,024 data
points with 333-µs dwell time) were collected with a repetition time of 3 seconds.
Sample analysis
Plasma glucose, lactate, and triacylglycerol concentrations were determined enzymatically
using autoanalyzers (Dimension AR and ACA SX, Dade, USA). The concentrations of [6,6-
2H2]glucose and [1-13C]lactate used for the tracer infusions and for the standard curves (see
below) were measured with the autoanalyzer using calibration curves from weighed, waterfree
glucose (Merck, Darmstadt, Germany) and zinc lactate (Sigma, St. Louis, USA), respectively.
Plasma insulin and cortisol concentrations were determined using a microparticle enzyme
immunoassay method (IMX analyzer, Abbott, USA) and a fluorescencepolarisation
immunoassay (TDX analyzer, Abbott, USA), respectively. Blood pyruvate, b-hyd oxybutyrate,
acetoacetate, plasma free fatty acids, and glycerol were measured using automated enzymatic
colorimetric methods (COBAS FARA II, Hoffmann-La Roche, UK). Urinary nitrogen was
assayed according to a micro Kjeldahl method (14).
The isotopic enrichments of glucose and lactate in plasma were measured using gas
chromatography-mass spectrometry GCMS, Hewlett Packard 5890, USA). Plasma [6,6-
2H2]glucose enrichment was measured in the penta-acetate derivative, using positive chemical
NH3  ionization, selectively monitoring ions at mass-to-charge ratio (m/z) 408 and 410 (15).
The peak ratios (408/410) were compared with those of a standard curve prepared by diluting
98% tracer [6,6-2H2]glucose (Mass Trace, Woburn, USA) with weighed tracee glucose
amounts, and reported as tracer to tracee mole ratios (TTR). The enrichment of [1-13C]lactate
in plasma was measured in the N-propylamide heptafluorobutyrate derivative, using electron
impact ionization, selectively monitoring ions at m/z 86 and 87 (16). The TTRs were likewise
derived from the peak ratios and compared with a standard curve prepared by diluting 98%
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tracer sodium[1-13C]lactate (Mass Trace, Woburn, USA) with weighed amounts of tracee zinc
lactate.
31P-MRS studies. Free induction dacays were processed using the LAB ONE (New Methods
Research) NMR1 spectroscopy processing software, as described in detail elsewhere (13).
Estimates of the relative peak areas of the various metabolites were obtained by curve fitting of
the spectrum to Lorentzian line shapes: anorganic phosphate (Pi) and phosphocreatine (PCr),
both singlets; g-, a-, and b-ATP, two doublets and a triplet, respectively.
Calculations
Whole-body turnover of glucose. In st ady-state experiments, the whole-body rate of
appearance of glucose was calculated as follows (17):
Glucose Ra (µmol/kg/min) = I / TTR [1]
where glucose Ra is the rate of appearance of glucose in the whole-body, I the infusion rate of
the [6,6-2H2]glucose tracer in mmol/kg/min, and TTR the tracer to tracee molar ratio in plasma.
Isotopic enrichments were considered to be in steady-state when the TTRs of the four
consecutive samples from time 70 to 100 min had a coefficient of variation < 10%, and a slope
not significantly different from zero. When the isotopic enrichments were not in steady-state,
turnover rate was calculated with Steele’s equations for non-steady-state conditions (18), as
follows:
I - Vd ((Gi+Gj)/2)*(DTTR/ DT)
 ________________________
Glucose Ra (µmol/kg/min) = [2]
(TTRi+TTRj)/2
where Vd is the volume of distribution of glucose in ml/kg (200 ml/kg), (Gi+Gj)/2 is the mean
plasma glucose concentration (in mmol/ml) measured at timepoints Ti and j, DTTR is the
change in TTR from Ti to Tj, DT is the time interval (Tj-Ti) in minutes, and (TTRi+TTRj)/2 is
the mean TTR measured at time points Ti and Tj. Steady-state in [6,6-2H2]glucose TTRs was
attained during triacylglycerol infusion in three out of four patients and eight out of 12
controls, respectively. During glucose infusion [6,6-2H2]glucose TTRs were in steady-state in
three out of four patients and five out of 12 controls, respectively.
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Whole-body turnover of lactate (+pyruvate). A single common pool approach for lactate and
pyruvate was used for the calculation of whole-body lactate (+pyruvate) turnover. Wolfe and
co-workers have reported that in anesthesized dogs plasma pyruvate enrichment was 92% of
plasma lactate enrichment at steady-state when [1-13C]lactate tracer was infused (19,20).
Results of Large et al. suggest that this approach could also be applicable to humans (21).
Therefore, we assumed that the turnover rates calculated from dilution of labeled lactate in
plasma represent not only lactate but also pyruvate turnover:
Ra lactate (+pyruvate) = I / TTR [3]
where Ra lactate (+pyruvate) is the whole-body lactate (+pyruvate) turnover in µmol/kg/min,
I the infusion rate of the [1-13C]lactate tracer in µmol/kg/min, and TTR the tracer to tracee
molar ratio of lactate. Steady-state conditions for lactate TTRs were defined as described for
glucose. When isotopic enrichments were not in steady-state, turnover rate was calculated with
Steele’s equations for non-steady-state conditions (27), as described for glucose above (Eq. 2).
The volume of distribution for lactate (+pyruvate) was assumed to be 500 ml/kg (22,23).
During triacylglycerol infusion, steady-state in lactate TTRs was attained in three out of four
patients and in seven out of 12 controls, respectively. Lactate TTRs during glucose infusion
were in steady-state in all four patients and in 10 out of 12 controls.
Respiratory calorimetry. Carbohydrate oxidation was calculated according to Ferrannini (24):
4.55*VCO2 - 3.21* VO2 - 2.87*N
___________________________
Carbohydrate oxidation (µmol/kg/min) = [4]
   (1000/180)*BW
where VO2 and VCO2 are expressed in ml/min, N is the urinary nitrogen excretion expressed in
mg/min, BW is body weight in kg, and 180 is the molecular weight of the typical carbohydrate
glucose. The calculated whole-body rate of substrate oxidation was assumed to reflect
mitochondrial oxidation, neglecting non-mitochondrial peroxisomal and microsomal oxygen
consumption. This non-mitochondrial oxygen consumption, insensitive to cyanide, has been
estimated in rat species and was shown to amount 10 to 20% of total oxygen consumption of
perfused rat skeletal muscle (25). Data regarding non-mitochondrial oxygen consumption in
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humans are not available. The relative contributions of non-mitochondrial oxygen consuming
processes to total oxygen consumption were assumed not to be different whether
triacylglycerol or glucose was being infused.
31P-MRS studies. Calculation of metabolite concentrations. The c centrations of Pi and PCr
were calculated from measured Pi/b-ATP and PCr/b-ATP peak ratios, as described elsewhere
(26).
Analysis of outcome parameters: comparison of values in individual patients with control
group values for whole-body oxygen consumption, plasma lactate concentrations, and lactate
(+pyruvate) turnover rates. Triacylglycerol or glucose administration can be expected to affect
outcome parameters differently not only in patients but also in control subjects.
Hypothesized effects in patients then should be additional to those in controls. Effects of
triacylglycerol infusion (compared with glucose infusion) on outcome parameters in individual
patients and controls can be described as follows:
ÄVO2 = VO2 TG - VO2 GL [5]
Ä plasma lactate concentration = plasma lactate TG - plasma lactate GL [6]
Ä Ra lactate (+pyruvate) = Ra lactate (+pyruvate) TG - Ra lactate (+pyruvate) GL [7]
Where the subscripts TG and GL refer to triacylglycerol infusion and glucose infusion,
respectively. Effects of triacylglycerol infusion (compared with glucose infusion) are
considered additional and according to our hypothesis when the values for ÄVO2, Ä plasma
lactate, and Ä Ra lactate (+pyruvate) in individual patients exceed the upper limit of the 95%
CI in controls for these parameters.
Statistical analysis
The results are presented as means ± SD. Because control data were normally distributed
whereas patient data were not, parametric and non-parametric statistical methods were used
for comparisons within both groups: Student’s t-tests and Wilcoxon ranked sum tests for
paired data in controls and subjects, respectively. Between group comparisons were made
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using non-parametric Mann-Whitney tests. Two-factor repeated measures ANOVA was used
for the comparison within and between groups at different time points. Values of the outcome
parameters VO2, plasma lactate, Ra lactate (+pyruvate) and leg exercise endurance time in
individual patients were compared to 95% confidence intervals (95% CI) of controls.
Statistical significance was set at p < 0.05.
Results
Comparison between patient and control groups.
Plasma concentrations (Table 4)
   Controls. Plasma glucose, insulin, lactate, and blood pyruvate concentrations were
significantly higher during glucose infusion, when compared with triacylglycerol infusion.
Lactate-to-pyruvate ratios were not different. Plasma free fatty acid, triacylglycerol, blood â-
hydroxybutyrate, acetoacetate, and plasma glycerol concentrations were significantly higher
during triacylglycerol infusion, when compared with glucose infusion. Plasma cortisol
concentrations were similar in both infusion conditions.
   Patients. Plasma glucose, insulin, and blood pyruvate concentrations were not different from
controls during infusion of either substrate. Plasma lactate concentrations were significantly
higher during both triacylglycerol (P<0.01) and glucose infusion (P<0.01), when compared
with controls. Lactate-to-pyruvate ratios were higher in patients than in controls during
infusion of either substrate (both P<0.05). Plasma free fatty acids during triacylglycerol
infusion were lower in patients than in controls (P<0.05), while during glucose infusion there
was no difference between the two groups. Plasma triacylglycerol, blood â-hydroxybutyrate,
and plasma glycerol concentrations were not different from control values. Blood acetoacetate
concentrations during triacylglycerol infusion were lower in patients; the blood â-
hydroxybutyrate-to-acetoacetate ratio was significantly higher in patients, when compared with
controls (P<0.01). Plasma cortisol concentrations were not different from control values.
Table 4. Plasma substrate concentrations.
  CID PATIENTS (n=4)   CONTROLS (n=15)
_____________________________________ __________________________________
  Fasting   Triacylglycerol  Glucose   Fasting   Triacylglycerol Glucose
      T=0  T=70-100 T=70-100           T=0 T=70-100 T=70-100
____________________________________________________________________________________________________________________
Plasma glucose (mmol/L)     5.4±0.7     5.4  ±0.5 §   8.1  ±1.2     5.0±0.3   5.1±0.3 *   8.7±1.2
Plasma lactate (mmol/L) 2.93±1.22 1.40† ±0.60 § 2.28† ±0.83 0.89±0.25 0.67±0.21 * 1.30±0.33
Blood pyruvate (µmol/L)   140±35    84  ±29  113  ±21    84±11       67±14 *  124±22
Lactate/pyruvate Ratio 20.4±3.7 16.6§ ±2.3 16.8§ ±1.0 10.8±0.7 10.6±3.5 11.0±2.7
Plasma triacylglycerols (mmol/L) 0.90±0.15 1.17  ±0.37§ 0.78  ±0.26 0.75±0.08 1.10±0.35  *0.60±0.24
Plasma free fatty acids (mmol/L) 0.48±0.11 0.73§ ±0.16 § 0.20  ±0.14 0.53±0.12 1.15±0.30  *0.13±0.07
Plasma glycerol (mmol/L) 0.08±0.06 0.15  ±0.08  ND 0.06±0.01 0.16±0.07 * 0.04±0.02
Blood â-hydroxybutyrate (mmol/L)0.16±0.20 0.43  ±0.18  ND 0.04±0.03 0.30±0.10      ND
Blood acetoacetate (mmol/L) 0.07±0.02 0.12† ±0.02  ND 0.08±0.03 0.19±0.04      ND
Plasma insulin (mU/l) 12.8±2.0   8.1  ±2.3 § 26.6  ±2.8   6.6±1.5   5.6±2.3 * 27.4±7.3
Plasma cortisol (mU/l) 1.14±0.36 0.89  ±0.43 0.83  ±0.35 0.92±0.29 0.64±0.34 0.65±0.30
Values are means ± SD in 4 patients and 15 controls. * P < 0.001, triacylglycerol versus glucose infusion in controls (2-factor ANOVA, followed
by paired t-test). § P < 0.05, triacylglycerol versus glucose infusion in patients (2-factor ANOVA, followed by paired Wilcoxon ranked sum test). *
P < 0.001, † P < 0.01, § P < 0.05 patients versus controls (2-factor ANOVA, followed by Mann-Whitney test). ND not detectable (<0.02 mM).
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Respiratory calorimetry (Table 5)
   Controls. Whole-body oxygen consumption rates during triacylglycerol infusion were
significantly higher than during glucose infusion, while respiratory exchange ratios were
significantly lower (both P<0.001). Total carbohydrate oxidation rates were lower during
triacylglycerol infusion, when compared with glucose infusion. The estimated rate of oxidation
of carbohydrate was ~ 50% of the rate of glucose turnover during infusion of either substrate
and less than the rate of appearance of lactate (+pyruvate).
   Patients. There was no significant difference in whole-body oxygen consumption between
triacylglycerol and glucose infusion experiments. Oxygen consumption rates were significantly
higher in the patient group, when compared with the control group, both during triacylglycerol
(4.41±0.38 versus 3.70±0.24 ml/kg/min, P<0.01) and during glucose (4.20±0.45 versus
3.51±0.23 ml/kg/min, P<0.05) infusion. Respiratory exchange ratios and total carbohydrate
oxidation rates were not different from control values during infusion of either substrate. There
were no differences in plasma glucose turnover between patients and controls, both during
triacylglycerol and glucose infusion.
Table 5. Respiratory calorimetry and whole-body glucose and lactate (+pyruvate) turnover.
   CID PATIENTS (n=4)   CONTROLS (n=15)
     ________________________ _________________________
   Triacylglycerol   Glucose  Triacylglycerol  Glucose
__________________________________________________________________________________________
VO2 (ml/kg/min) 4.41
† ±0.38 4.20§ ±0.45 3.70±0.24* 3.51±0.23
VCO2 (ml/kg/min) 3.36
§ ±0.28 3.70§ ±0.45 2.96±0.23† 3.08±0.21
RER 0.76  ±0.04‡ 0.88  ±0.06 0.80±0.02* 0.88±0.03
CHox (µmol/kg/min)     4.8  ±3.3 ‡ 16.4  ±6.2   7.3±1.8 * 14.1±2.8
Glucose Ra (µmol/kg/min) 14.5  ±1.9 31.1  ±2.7 13.9±2.6 * 28.8±0.9
Ra lac (+pyr) (µmol/kg/min) 31.1§ ±4.0 ‡ 43.8  ±15.2 22.3±4.9 † 30.7±5.9
Values are means ± SD in 4 patients and 15 controls (n=12 controls for Ra lac (+pyr) and glucose Ra). * P <
0.001, † P < 0.01, § P < 0.05 triacylglycerol versus glucose infusion in controls (2-factor ANOVA, followed
bypaired Student’s t-test). ‡ P = 0.0679 triacylglycerol versus glucose infusion in patients (paired Wilcoxon
ranked sum test) † P < 0.01, § P < 0.05 patients versus controls (Mann-Whitney test). RER: respiratory
exchange ratio. CHox: carbohydrate oxidation.
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Outcome parameters in individual patients in comparison with control values.
Whole-body oxygen consumption, plasma lactate concentrations, and lactate (+pyruvate)
turnover rates (Table 6, Figure 1). In Figure 1 the values for ÄVO2, Ä plasma lactate, and Ä
Ra lactate (+pyruvate) in individual patients are depicted together with the respective 95%
CI’s in controls. Additional effects of triacylglycerol infusion on whole-body oxygen
consumption rates and plasma lactate concentrations could only be demonstrated in two
patients. In one of them, also an additional effect on Ra lactate (+pyruvate) could be
demonstrated. In neither of the patients triacylglycerol infusion could lower plasma lactate
concentrations or lactate (+pyruvate) turnover rates to values that were within the 95% CI of
controls.
Table 6. Whole-body oxygen consumption, plasma lactate concentrations,and  lactate (+pyruvate) turnover
during triacylglycerol or glucose infusions in individual patients.
CID patient Controls
___________________________________ ______________________
   #1    #2    #3   #4 mean (95% CI)  n
__________________________________________________________________________________________
Whole-body VO2 (ml/kg/min)
Triacylglycerol  4.03  4.82  4.63  4.14  3.70 (3.57 to 3.83) 15
Glucose  3.95  4.40  4.73  3.72  3.51 (3.38 to 3.64) 15
Ä VO2 
1  0.08  0.42 -0.10  0.42  0.19 (0.08 to 0.30) 15
Plasma lactate (mmol/L)
Triacylglycerol  1.30  1.03  2.28  1.00  0.67 (0.54 to 0.80) 15
Glucose  1.73  1.75  3.50  2.15  1.30 (1.13 to 1.47) 15
Ä Plasma lactate 1 -0.43 -0.72 -1.22 -1.15 -0.63 (-0.93 to -0.33) 15
Whole-body Ra lactate (+pyruvate) (µmol/kg/min)
Triacylglycerol  27.6  29.7  36.8  30.1  22.3 (19.2 to 25.4) 12
Glucose  35.8  34.7  66.2  38.4  30.7 (27.0 to 34.5) 12
Ä Ra lactate (+pyruvate) 1   -8.2  -5.0 -29.4   -8.3   -8.4 (-13.0 to -3.8) 12
Values are individual observations in patients and means + 95% confidence interval of the mean in controls.
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1 Difference between triacylglycerol and glucose infusion studies.
ÄV O 2 [ml /kg/min]
#2, #4#1#3
    M ean
of controlsP 5 P95
0.190.08 0.30
Ä  P lasm a Lactate [m m o l/L]
-0.63 -0.93-0.33
#1 #2 #3#4
Ä  R a  Lactate  (+pyruvate)
          [µmol /kg/min] -8.4 -13.0-3.8
#2  #1,  #4 #3
   Accord ing
to hypothesis
    Contrary
to hypothesis
Figure 1. Differences between triacylglycerol and glucose infusion studies for VO2 (ÄVO2), plasma lactate
(Äplasma lactate), and Ra lactate (+pyruvate) (Ä Ra lactate (+pyruvate)) in individual patients. Grey area: 95%
confidence interval for differences in controls. P5: lower limit of 95% confidence interval for differences in
controls. P95: upper limit of 95% confidence interval for differences in controls. Values beyond P95 in
individual patients indicate an effect of triacylglycerol additiona to that in controls according to hypothesis:
ÄVO2 in patients > ÄVO2 in controls, and ÄPlasma Lactate and ÄRa  Lactate (+pyruvate) in patients <
ÄPlasma Lactate and ÄRa  Lactate (+pyruvate) in controls, respectively.
31P-MRS measurements in FDP muscle (Table 7)
PCr/Pi ratios in individual patients were lower during infusion of either substrate, when
compared with control values, reflecting decreased muscle energy state due to impaired
mitochondrial function. PCr/Pi ratios during triacylglycerol infusion were not different from
those during glucose infusion, both in patients and in controls.
 Table 7. 31P-NMR measurements in FDP muscle
CID patient    Controls
________________ _________________
#1 #2 #3 #1 #2 #3
__________________________________________________________________________________________
PCr/Pi ratio
Triacylglycerol 5.6 6.7 5.3 9.1 7.7 10.0
Glucose 6.1 5.6 7.4 8.4 8.1 12.7
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PCr: phosphocreatine. Pi: anorganic phosphate.
Discussion
In the present study no additional beneficial effects could be shown from triacylglycerol
infusion in resting CID patients, when compared with glucose infusion. Triacylglycerol infusion
failed to improve mitochondrial substrate oxidation, as evidenced both by whole-body oxygen
consumption and high energy phosphate measurements in resting muscle.
In these patients triacylglycerol infusion also failed to lower plasma lactate concentrations and
lactate (+pyruvate) turnover rates to values that were within the normal control range.
Analysis of outcome parameters: comparison of values in individual patients with control
group values. In controls triacylglycerol infusion can be expected to be associated with higher
whole-body oxygen consumption rates, lower plasma lactate concentrations and lower lactate
(+pyruvate) turnover rates, when compared with glucose infusion. The measured difference in
whole-body oxygen consumption rate between the two infusion conditions in the control group
was relatively small (~5 %) and according to stoichiometric expectations.
Plasma lactate concentrations and lactate (+pyruvate) turnover rates  were significantly lower
during triacylglycerol infusion, when compared with glucose infusion. Other studies in normal
subjects have also shown that administration of triacylglycerol is associated with lower plasma
lactate concentrations, compared with glucose administration (27,28,29,30).
In our patients it was assumed that  substrate oxidation would be impaired during infusion of
glucose, a NADH-linked substrate. Triacylglycerol administration then was aimed at improving
substrate oxidation, when compared with glucose administration. With respect to our whole-
body oxygen consumption measurements it was assumed that thus improved substrate
oxidation rates during triacylglycerol infusion would be reflected by increased oxygen
consumption rates, when compared with glucose infusion (see methods). The effect on whole-
body oxygen consumption could be ascribed to our specific hypothesis in CID patients only
when it significantly exceeded observed effects in controls (additional effect in patients). In
those patients that may have benefitted from ameliorated substrate oxidation, as evidenced by
increased whole-body oxygen consumption rates during triacylglycerol administration, we
expected plasma lactate concentrations and lactate (+pyruvate) turnover rates to be decreased,
when compared with glucose administration. Again, such additional effects could only be
ascribed to our hypothesis when they significantly exceeded effects in controls.
Triacylglycerol infusion in Complex I Deficiency
____________________________________________________________________________
- 81 -
Whole-body oxygen consumption. Triacylglycerol infusion was associated with substantially
increased oxygen consumption rates (compared with glucose) in only two patients: #2 and #4.
However, even in these two patients there was no additional effect of triacylglycerol infusion
on oxygen consumption outside the range of triacylglycerol infusion effects in controls (range
Ä VO2 controls = -0.20 to 0.43 ml/kg/min, data not shown). Our finding of significantly
increased whole-body oxygen consumption rates in all four patients (compared with controls)
during both triacylglycerol and glucose infusion, is in accordance with previously reported data
on whole-body oxygen consumption in fasting CID patients by our group (31) and others (4).
We explain the increased oxygen consumption rate in these patients as a compensatory
mechanism necessary to maintain their resting ATP synthetic rate when mitochondrial
oxidative phosphorylation is less efficient due to the defective respiratory chain complex
(unpublished observations).
Plasma lactate concentration and lactate (+pyruvate) turnover. A significant additional effect
of triacylglycerol infusion on plasma lactate concentrations could only be shown in two
patients: #3 and #4. In one of these (#4), the substantially lower plasma lactate concentration
during triacylglycerol infusion was associated with an increase in whole-body oxygen
consumption, according to our hypothesis. In the other patient (#3) this was just the opposite.
This patient also showed a significant additional effect of triacylglycerol infusion on lactate
(+pyruvate) turnover. However, in both patients triacylglycerol infusion failed to lower plasma
lactate concentrations and lactate (+pyruvate) turnover rates to values that were within the
normal control range.
31P-MRS measurements. During infusion of either substrate, PCr/Pi ratios in resting forearm
muscle were lower in each of the three patients that participated in the 31P-NMR studies, when
compared with controls. However, there were no important differences in PCr/Pi ratios
between triacylglycerol and glucose infusion in any of the three patients that participated in the
31P-NMR studies. In addition, triacylglycerol infusion failed to increase PCr/Pi ratios to control
values. This is the most direct in vivoevidence that triglyceride infusion does not change the
energy state in affected resting skeletal muscle of CID patients.
Relevance for the use of high fat diets in CID patients. The results of the present study
suggest that the biochemical abnormalities in these four CID patients at rest are not likely to
improve from prescription of a high fat diet. Some remarks need to be made regarding the
observed lack of effect. First, free fatty acid availability for oxidation may be lower in patients
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than in controls. However, our finding of lower RERs during triacylglycerol infusion in
patients compared with controls, suggests that free fatty acid oxidation is unimpaired or even
stimulated. The lower plasma free fatty acid concentrations during triacylglycerol infusion in
patients, compared with controls, may also be the consequence of their preferential oxidation
in CID patients. Second, the type of fatty acids administered may be of importance. In the
studies of Doctor et al. (7) heptanoate, a short chain odd-numbered fatty acid, was used to
bypass rotenone inhibited complex I in renal cell cultures. We have administered Intralipid,
containing only a small amount of esterified short chain odd-numbered fatty acids, however
(see methods). In order to address the issue, triacylglycerol infusions containing different fatty
acids should be studied in a larger group of CID patients. Limited numbers of available patients
make it difficult to increase the sample size however. Finally, the findings in these four CID
patients do not necessarily preclude prescription of a high fat diet in other CID patients. We
have selected four patients with a documented complex I deficiency with exercise intolerance
as main feature of their clinical presentation. At rest they only showed abnormalities of
biochemical nature. No clinical signs like muscle wasting were observed.
It may be that our hypothesis, aimed at improving mitochondrial substrate oxidation, is not
valid in the patients that we have selected, at least not in the resting condition. It is tempting to
speculate however, that in those patients that have clinical signs and symptoms at rest due to
impaired mitochondrial substrate oxidation, triacylglycerol may be of benefit. In addition,
triacylglycerol administration may be useful in CID patients when energy demands are
increased, e.g. during exercise.
In conclusion, contrary to our hypothesis, triacylglycerol infusion failed to improve
mitochondrial oxidation of substrates and failed to lower plasma lactate concentrations and
lactate (+pyruvate) turnover rates to normal values, in these four CID patients at rest.
The results suggest that the biochemical abnormalities in these four patients at rest are not
likely to improve from prescription of a high fat diet, but do not necessarily preclude use of the
diet in other CID patients.
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Abstract
A high fat diet has been recommended in the treatment of patients with mitochondrial
myopathy due to Complex I Deficiency (CID). This exercise study evaluated effects of
intravenous infusion of isoenergetic amounts of triacylglycerol or glucose on substrate
oxidation, glycolytic carbohydrate metabolism, and exercise endurance time in four CID
patients and 15 matched controls. Subjects were infused with triacylglycerol (3.7 mg/kg/min)
or glucose (10 mg/kg/min), during leg exercise endurance time testing at low intensity (15%
Wmax). Respiratory calorimetry was used as a measure of mitochondrial substrate oxidation.
Glycolytic carbohydrate metabolism was studied by plasma lactate concentration and turnover
(from dilution of [1-13C]lactate) measurements. In addition, 31P Magnetic Resonance
Spectroscopy (31P-MRS) measurements (of PCr/Pi ratios) were done in forearm muscle during
exercise, using increasing workloads in a ramp protocol. In three patients leg exercise
endurance time was better during triacylglycerol infusion, when compared with glucose
infusion. Whole-body oxygen consumption rates during exercise were higher in each of the
four patients with infusion of triacylglycerol. Plasma lactate concentrations and turnover rates
were lower during triacylglycerol infusion in three patients. There were no differences in
PCr/Pi ratios during exercise between triacylglycerol and glucose infusion in both the patient
and control group. We conclude that triacylglycerol infusion, compared with glucose infusion,
is associated with improved oxidation of substrates, lower plasma lactate concentrations and
turnover rates, and improved leg exercise endurance in myopathic CID patients. PCr/Pi ratios
during exercise however were not different, whether patients were infused with triacylglycerol
or glucose .
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Introduction
Recently we proposed a potential role for high fat-low carbohydrate diets in the treatment of
patients with mitochondrial myopathy due to Complex I Deficiency (CID, Ref. 1).
We hypothesized that administration of triacylglycerols in these patients may improve
mitochondrial substrate oxidation rates, in comparison with glucose administration, using the
following rationale:
(I) In CID patients mitochondrial oxidation of NADH is thought to be diminished.
In these patients FADH2 may be an alternative to NADH because electrons from
FADH2 can enter the respiratory chain distal to complex I.
(II) The supply of FADH2 to the mitochondria can be increased (relative to NADH) by
increasing the amount of triacylglycerols/free fatty acids in the diet. From stochiometry
of substrate oxidation it follows that complete oxidation of a free fatty acid yields a
ratio of FADH2 over NADH of 0.5, whereas glucose yields a much lower ratio of 0.2.
Thus substrate oxidation in CID patients may benefit from fatty acid supplementation by
supplying FADH2 (distal to complex I). Furthermore, it was hypothesized that these patients
then may be less dependent on glycolytic carbohydrate metabolism, i.e. have lower plasma
lactate concentrations and turnover rates during triacylglycerol administration. In our recent
study in myopathic CID patients at rest (1) substrate oxidation rates were shown to be
stimulated rather than impaired, both during glucose or triacylglycerol infusion. In addition,
triacylglycerol infusion did not lower plasma lactate concentration and its rate of turnover to
resting control values. These findings suggest that, as these patients did not show any clinical
signs or symptoms at rest, in vivo cellular energy balance was maintained, despite in vitro
mitochondrial impairment. During exercise, when energy requirements are elevated, in vivo
oxidation of NADH may become limiting. Triacylglycerol administration then may be of
benefit to these patients by increasing the relative supply of FADH2 and lowering plasma
lactate concentration and turnover. This may result in improved exercise tolerance.
In the present study, effects of triacylglycerol or glucose administration on substrate oxidation
and glycolytic metabolism were studied during low-intensity cycle exercise in four CID patients
and 15 healthy controls. Respiratory calorimetry was used as a measure of mitochondrial
substrate oxidation. Glycolytic carbohydrate metabolism was studied by plasma lactate
concentration and turnover (from dilution of [1-13C]lactate) measurements. In addition,
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31P Magnetic Resonance Spectroscopy (31P-MRS) measurements (of PCr/Pi ratios) were done
in forearm muscle during (sub)maximal exercise, using increasing workloads in a ramp
protocol.
Patients and methods
Subjects
Details of the four patients and of a total of eighteen healthy control subjects have been
covered in a previous paper (1). Briefly, all patients had very similar clinical histories of easily
fatiguable mild muscle weakness dating back to early childhood. Muscle weakness and
fatiguability have remained stable over time in all of them. Exercise intolerance therefore
dominated the clinical picture at the time of the study. Complex I Deficiency was diagnosed
with microscopic and biochemical investigations in freshly biopsied quadriceps (vastus
lateralis) muscle, showing markedly decreased activity of Complex I (NADH-ubiquinone
oxidoreductase, EC 1.6.99.3) in all patients (range 5.6 to 23.8% of normal). The fifteen
healthy control subjects for the (tracer) infusion and respiratory calorimetry studies were
matched for age, gender and body weight, while the three subjects for the 31P Magnetic
Resonance Spectroscopy (31P-MRS) studies were two males and one female, ages 18 to 28.
None of these subjects had a family history of diabetes mellitus or took medications.
All subjects were studied after an overnight fast without prior dietary preparation, i.e. on their
own diet. Written informed consent was obtained from each subject. The experimental
protocol was approved by the Medical Ethics Committee of our hospital.
Preexperiment testing. All participants reported to the laboratory at least three days before the
onset of experiments to perform an incremental maximal exercise test on an electrically braked
cycle ergometer (Lode Instruments, Groningen, The Netherlands). Maximal workload (Wmax)
and maximal oxygen uptake (VO2max) were assessed as previously described (2). Wmax in the
patients ranged from 50 to 60 W and was on average only 25% of control values (mean 210
W, Table 1). The results of this test were used to calculate a workload equal to 15% of each
subject’s Wmax. Calculated workloads in patients thus ranged from 7 to 9 W.
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Table 1. Physical characteristics of CID patients and controls.
 CID patient   Controls
_________________________ ______________________
   #1    #2    #3    #4  mean (95% CI)  n
__________________________________________________________________________________________
Age at study (yr)    25    20    22    15      21 (20 to 22) 15
Body weight (kg)    52    61    57    45   57.4 (54.7 to 60.1)15
Fat free mass (kg)    41    45    44    35   44.5 (42.5 to 46.5)15
Max exercise testing:
Wmax (W)    60    60    50    55   210 (192 to 228) 15
VO2max (ml/min)  721  750  596  797 2461 (2321 to 2601)15
VO2max (ml/min/kg) 13.6 12.5 10.5 17.6  42.9 (41.6 to 44.2) 15
Fasting plasma lactate (mmol/L)  2.3   2.7   4.7   2.0    1.0 (0.8 to 1.2)  15
From our own experience it is known that the workloads thus chosen in the patients could be
sustained for a relatively prolonged period of time (> 0.5 hour), in order to test exercise
endurance. Seven of the control subjects exercised at 15% of their respective Wmax (range: 24
to 37W, corresponding to about 30% VO2max). The remaining eight control subjects were
studied during stationary cycle exercise at an absolute workload similar to that in patients
(7W), in order to take into account possible confounding effects of the extreme low exercise
intensity on exercise mechanics. Both workloads can be easily sustained by healthy subjects for
hours.
Experimental protocol
Patients and controls reported at the laboratory at 8 AM on two occasions, separated by at
least seven days. The triacylglycerol and glucose infusions were assigned in random order.
All patients and controls participated in both the triacylglycerol and glucose infusion studies. In
order to ‘prime’ the metabolic pathways before the initiation of exercise, all subjects were
infused with either triacylglycerols (Intralipid [20% w/v], Fresenius Kabi, ’s-Hertogenbosch,
The Netherlands (1.85 mg/kg/min of triacylglycerols), containing linoleic (50%), oleic (26%),
palmitic (10%), linolenic (9%), and stearic (3.5%) acids + heparin (7.5 U/kg/hr, prime 14
U/kg) or glucose [10% w/v] (5 mg/kg/min) at rest for 120 minutes. Then they performed
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stationary cycle exercise at 15% Wmax (patients and seven controls) or at 7W (eight controls)
for a nominal period of 90 minutes in controls and/or until exhaustion in patients.
Triacylglycerol and glucose infusion rates were doubled to 3.70 and 10 mg/kg/min,
respectively.
Isotope infusion. [6,6-2H2]glucose. Primed constant-rate infusions of [6,6-2H2]glucose (98%
enriched, Mass Trace, Woburn, USA) were administered in all four patients and in nine of the
control subjects: prime 20.0 µmol/kg, continuous infusion rate 0.30 µmol/kg/min in
triacylglycerol infusion studies, and 1.00 µmol/kg/min in glucose infusion studies.
[1-13C]lactate. An unprimed constant-rate infusion of [1-13C]lactate (98% enriched, Mass
Trace, Woburn, USA) was administered throughout the nominal 90 minutes of exercise.
The lactate tracer infusion rates during exercise for the individual patients ranged between 2.50
and 5.34 µmol/kg/min. Nine control subjects received an unprimed constant-rate infusion of
[1-13C]lactate at an infusion rate of 0.56 µmol/kg/min during the 90 minutes exercise period.
The remaining six control subjects received no lactate tracer at all, in order to examine effects
of triacylglycerol and glucose infusion, as well as exercise on lactate background enrichments
(no significant changes in background enrichment could be detected upon administration of
either substrate or upon initiation of exercise; data not shown).
Blood sampling and urine collection. Blo d was sampled at regular intervals during exercise
and handled as described previously (1). Subjects voided before and after exercise and urine
was collected for determination of nitrogen excretion.
Respiratory calorimetry. Open circuit indirect calorimetry was performed continuously during
the 90 minutes exercise period, using a face mask. Stable values for oxygen consumption
(VO2) were reached within 5 min of recording. Computerized continuous gas analysis and
volume measurements were performed (Oxycon Champion, Jaeger, Breda, The Netherlands),
as previously described (3). Gas and volume calibrations were performed before each
measurement. Standardization with alcohol burning was performed regularly; the theoretical
respiratory exchange ratio (0.67) was closely approached in all standardizations (mean 0.66;
coefficient of variation 1.6 percent, n=10).
31P-MRS studies. Patients and control subjects reported at the NMR facility at 8 AM for the
triacylglycerol and glucose infusions, on two separate days. Subjects were infused with
triacylglycerol (Intralipid [20% w/v] (1.85 mg/kg/min of triacylglycerols) + heparin (7.5
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U/kg/hr, prime 14 U/kg) or glucose [10% w/v] (5 mg/kg/min) during a 100 minute basal
period, in which the subjects remained at rest. The infusions were maintained at the same rate
throughout the following 30 min study period. Measurements were done at rest and during
exercise at on average six normalized power output levels. The results obtained at rest have
been described previously (1). Exercise consisted of bulb-squeezing on an audio signal
(frequency, 0.33 Hz, duration, 300 ms) using only the fourth and fifth digits at progressively
increasing submaximal work loads in a ramp protocol with feedback of power output (details
described in Ref. 4). Power output was measured and recorded as ò P× dv (developed pressure
times displaced volume of air) and normalized to power output during maximal voluntary
contraction (MVC). The highest implemented workload in patients ranged from 30 to 45%
MVC, while it was 50% MVC in controls. Three of the CID patients (patient #1, #2 and #3)
and three control subjects participated in the 31P-MRS studies. All subjects were right handed.
Studies were conducted on the superficial mass of the flexor digitorum profundus (FDP)
muscle of the right forearm, as described in detail elsewhere (4). The FDP muscle is affected in
these patients, as evidenced by the decreased maximal voluntary contraction output of the
muscle, which is comparable to the decrease in maximal exercise performance (Wmax)
measured on the cycle ergometer (unpublished observations). Measurements were performed
by one researcher (KdM). Radio-frequency pulsing during exercise was gated to the audio
signal that synchronized bulb-squeezing using a homebuilt audio-triggering device.
To minimize motion artifacts and improve standardization of the measurements, the radio-
frequency pulse was set to occur 1,250 ms after contraction.
Sample analysis
Blood- and urinesamples as well as NMR spectra were analyzed as described previously (1).
Calculations
Whole-body turnover of glucose. In st ady-state experiments, the whole-body rate of
appearance of glucose was calculated as follows (5):
Glucose Ra (µmol/kg/min) = I / TTR [1]
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where glucose Ra is the rate of appearance of glucose in the whole-body, I the infusion rate of
the [6,6-2H2]glucose tracer in mmol/kg/min, and TTR the tracer to tracee molar ratio in plasma.
Isotopic enrichments were considered to be in steady-state when the TTRs of the final four
consecutive samples (time 175 to 205 min) had a coefficient of variation < 10%, and a slope
not significantly different from zero. When the isotopic enrichments were not in steady-state,
turnover rate was calculated with Steele’s equations for non-steady-state conditions (6), as
follows:
I - Vd ((Gi+Gj)/2)*(DTTR/ DT)
 ________________________
Glucose Ra (µmol/kg/min) = [2]
    (TTRi+TTRj)/2
where Vd is the volume of distribution of glucose in ml/kg (200 ml/kg), (Gi+Gj)/2 is the mean
plasma glucose concentration (in mmol/ml) measured at timepoints Ti and j, DTTR is the
change in TTR from Ti to Tj, DT is the time interval (Tj-Ti) in minutes, and (TTRi+TTRj)/2 is
the mean TTR measured at time points Ti and Tj. Steady-state in [6,6-2H2]glucose TTRs was
attained during triacylglycerol infusion in three out of four patients and in seven of the nine
infused controls, respectively. During glucose infusion [6,6-2H2]glucose TTRs were in steady-
state in three out of four patients and in six of the nine infused controls, respectively.
Whole-body turnover of lactate (+pyruvate). A single common pool approach for lactate and
pyruvate was used for the calculation of whole-body lactate (+pyruvate) turnover. Wolfe and
co-workers have reported that in anesthesized dogs plasma pyruvate enrichment was 92% of
plasma lactate enrichment at steady-state when [1-13C]lactate tracer was infused (7,8). Results
of Large et al. suggest that this approach could also be applicable to humans (9). Therefore,
we assumed that the turnover rates calculated from dilution of labeled lactate in plasma
represent not only lactate but also pyruvate turnover:
Ra lactate (+pyruvate) = I / TTR [3]
where Ra lactate (+pyruvate) is the whole-body lactate (+pyruvate) turnover in mmol/kg/min,
I the infusion rate of the [1-13C]lactate tracer in mmol/kg/min, and TTR the tracer to tracee
molar ratio. Steady-state conditions for lactate TTRs were defined as described for glucose.
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When isotopic enrichments were not in steady-state, turnover rate was calculated with Steele’s
equations for non-steady-state conditions (6), as described for glucose above (Eq. 2).
The volume of distribution for lactate (+pyruvate) was assumed to be 500 ml/kg (10,11).
During exercise, steady-state in lactate TTRs was attained in only one of the four patients,
both during triacylglycerol and during glucose infusion. In controls, steady-state in lactate
TTRs was attained in seven of the nine infused subjects during triglyceride infusion, while
during glucose infusion it was in six out of nine.
Respiratory calorimetry. Carbohydrate oxidation was calculated according to Ferrannini (12):
4.55*VCO2 - 3.21* VO2 - 2.87*N
___________________________
Carbohydrate oxidation (µmol/kg/min) = [4]
    (1000/180)*BW
where VO2 and VCO2 are expressed in ml/min, N is the urinary nitrogen excretion
expressed in mg/min, BW is body weight in kg, and 180 is the molecular weight of the typical
carbohydrate glucose. The calculated whole-body rate of substrate oxidation was assumed to
reflect mitochondrial oxidation, neglecting non-mitochondrial peroxisomal and microsomal
oxygen consumption. This non-mitochondrial oxygen consumption, insensitive to cyanide, has
been estimated in rat species and was shown to amount 10 to 20% of total oxygen
consumption of perfused rat skeletal muscle or incubated hepatocytes in the resting state and
during exercise (13,14). Data regarding non-mitochondrial oxygen consumption in humans are
not available. The relative contributions of non-mitochondrial oxygen consuming processes to
total oxygen consumption were assumed not be different whether triacylglycerol or glucose
was being infused.
31P-MRS studies. Calculation of metabolite concentrations. During exercise, the concen-
trations of Pi and PCr were calculated from measured Pi/b-ATP and PCr/b-ATP ratios,
respectively, as described elsewhere (15).
Analysis of outcome parameters: comparison of values in individual patients with control
group values for whole-body oxygen consumption, plasma lactate concentrations, lactate
(+pyruvate) turnover rates, and leg exercise endurance time. Triacylglycerol or glucose
administration can be expected to affect outcome parameters differently not only in patients
Triacylglycerol infusion in Complex I Deficiency
____________________________________________________________________________
- 95 -
but also in control subjects. Hypothesized effects in patients then should be additional to those
in controls. Effects of triacylglycerol infusion (compared with glucose infusion) on outcome
parameters in individual patients and controls can be described as follows:
Ä VO2 = VO2 TG - VO2 GL [5]
Ä plasma lactate concentration = plasma lactate TG - plasma lactate GL [6]
Ä Ra lactate (+pyruvate) = Ra lactate (+pyruvate) TG - Ra lactate (+pyruvate) GL [7]
Where the subscripts TG and GL refer to triacylglycerol infusion and glucose infusion,
respectively. Effects of triacylglycerol infusion (compared with glucose infusion) are
considered additional and according to our hypothesis when the values for ÄVO2, Ä plasma
lactate, and Ä Ra lactate (+pyruvate) in individual patients exceed the upper limit of the 95%
CI in controls for these parameters.
Statistical analysis
The results are presented as means ± SD. Because control data were normally distributed
whereas patient data were not, parametric and non-parametric statistical methods were used
for comparisons within both groups: Student’s t-tests and Wilcoxon ranked sum tests for
paired data in controls and subjects, respectively. Between group comparisons were made
using non-parametric Mann-Whitney tests. Two-factor repeated measures ANOVA was used
for the comparison within and between groups at different time points. Values of the outcome
parameters VO2, plasma lactate, Ra lactate (+pyruvate) and leg exercise endurance time in
individual patients were compared to 95% confidence intervals (95% CI) of controls.
Statistical significance was set at p < 0.05.
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Results
Comparison between patient and control groups.
Plasma concentrations (Table 2)
   Controls exercising at 7W. Plasma glucose, insulin, and blood pyruvate concentrations were
significantly higher during glucose infusion, when compared with triacylglycerol infusion.
Plasma lactate concentrations and lactate-to-pyruvate ratios were not different. Plasma free
fatty acid, triacylglycerol, blood â-hydroxybutyrate, acetoacetate, and plasma glycerol levels
were significantly higher during triacylglycerol infusion, when compared with glucose infusion
(all P < 0.001). Plasma cortisol levels were similar in both infusion conditions.
   Controls exercising at 15% Wmax. Plasma glucose, insuline, lactate, and lactate-to-pyruvate
ratios were lower during glucose infusion in controls exercising at this level, compared with
controls exercising at 7W (all P < 0.05). Plasma substrate concentrations during triacylglycerol
infusion were not different, whether controls were exercising at 7W or at 15% Wmax.
   Patients. Plasma glucose and insulin concentrations were not different from control values
during infusion of either substrate. Plasma lactate levels were significantly higher during both
triacylglycerol (P < 0.001) and glucose infusion (P < 0.01), when compared with controls.
Blood pyruvate concentrations and lactate-to-pyruvate ratios were significantly higher in the
patients during infusion of either substrate (both P < 0.05 and P < 0.01 for blood pyruvate and
lactate-to-pyruvate ratio, respectively). Plasma free fatty acids during triacylglycerol infusion
were lower in patients than in controls, while during glucose infusion there was no difference
between the two groups. Plasma triacylglycerol, blood â-hydroxybutyrate, and plasma glycerol
levels were not different from control values. Blood acetoacetate levels during triacylglycerol
infusion were lower in patients; the blood â-hydroxybutyrate-to-acetoacetate ratio was
significantly higher in patients, when compared with controls (P < 0.001).
Plasma cortisol levels were not different from control values.
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Table 2. Plasma substrate concentrations.
   CID PATIENTS (n=4)      CONTROLS at 7W (n=8)    CONTROLS at 15% Wmax(n=7)
  _________________________ _________________________ _________________________
  Triacylglycerol    Glucose  Triacylglycerol  Glucose  Triacylglycerol  Glucose
____________________________________________________________________________________________________________________
Plasma glucose (mmol/L)     5.4  ±0.6 §   9.4  ±1.8   5.0±0.3 *   9.4±1.1   5.2±0.3 *   8.0±1.3
Plasma lactate (mmol/L) 7.34* ±3.88     7.30† ±0.84 0.90±0.37   1.18±0.34 0.83±0.21 0.78±0.11
Blood pyruvate (µmol/L)  207§ ±96  177§ ±66    64±20 §    85±11    66±16 §    82±11
Ratio lactate/pyruvate 34.6† ±8.4 38.4† ±14.2 15.6±7.4 13.7±4.2 12.7±1.9 §   9.6±1.3
Plasma free fatty acids (mmol/L) 0.86§ ±0.18     * 0.10  ±0.06 1.44±0.42 * 0.08±0.06 1.90±0.69 * 0.12±0.05
Plasma triglycerides (mmol/L) 2.16  ±0.78§ 0.71  ±0.22 2.06±0.79 * 0.52±0.17 2.28±0.90 * 0.53±0.24
Blood â-hydroxybutyrate (mmol/L)0.48  ±0.38 0.09  ±0.10 0.40±0.17 ND 0.26±0.05 ND
Blood acetoacetate (mmol/L) 0.11  ±0.06 ND 0.19±0.08 ND 0.16±0.03 ND
Ratio ketone bodies   4.5  ±2.0 ----   2.1±0.3 ----   1.6±0.3 ----
Plasma glycerol (mmol/L) 0.26  ±0.06 ND 0.31±0.06 * 0.03±0.03 0.41±0.23 * 0.03±0.03
Plasma insulin (mU/l)   8.9  ±7.4 § 54.3  ±17.0   4.4±2.3 * 38.3±16.1   4.8±1.6 * 22.9±7.4
Plasma cortisol (mU/l) 0.84  ±0.36 0.58  ±0.24 0.70±0.23 0.72±0.45 0.37±0.21 0.52±0.32
Values are means ± SD in 4 patients and 15 controls (8 controls exercising at 7W, 7 controls exercising at 15% Wmax). * P < 0.001, † P < 0.01, §
P < 0.05 triacylglycerol versus glucose infusion (2-factor repeated measures ANOVA).* P < 0.001, † P < 0.01, § P < 0.05 patients versus controls
(2-factor repeated measures ANOVA). ND not detectable (<0.02 mM)
Table 3. Respiratory calorimetry and whole-body glucose turnover.
   CID PATIENTS (n=4)      CONTROLS at 7W  (n=8)    Controls at 15% Wmax (n=7)
  __________________________ __________________________   _________________________
  Triacylglycerol    Glucose Triacylglycerol  Glucose   Triacylglycerol    Glucose
_______________________________________________________________________________________________________________________
VO2 (ml/kg/min) 7.98  ±2.24 6.72   ±0.46 6.57±0.82 6.43±0.71 11.95±0.82 11.44±0.53
VCO2 (ml/kg/min) 6.61§ ±1.66 6.53   ±0.46 5.08±0.62 § 5.89±0.62        9.49±0.50§ 10.12±0.58
RER 0.83† ±0.04 § 0.97   ±0.06 0.77±0.03 * 0.92±0.03       0.80±0.03*   0.88±0.03
CHOx (µmol/kg/min) 24.2* ±7.0     41.7   ±22.4   9.9±3.1 * 32.7±5.9   25.1±4.2 *   51.0±10.1
Glucose Ra (µmol/kg/min) 17.9  ±2.8 * 54.1   ±2.0 13.8±2.5 § 53.3±7.9   14.9±2.1 *   55.0±1.3
Values are means ± SD in 4 patients and 15 controls (8 controls exercising at 7W, 7 controls exercising at 15% Wmax). P < 0.001, † P < 0.01, § P
< 0.05 triacylglycerol versus glucose  infusion (paired Wilcoxon ranked sum test in patients, paired Student’s t-test in controls). * P < 0.001, † P <
0.01, § P < 0.05 patients versus controls (Mann-Whitney test). RER: respiratory exchange ratio. CHOx: carbohydrate oxidation.
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Respiratory calorimetry and whole-body glucose turnover (Table 3)
   Controls. There was no difference in whole-body oxygen consumption between the glucose
and triacylglycerol infusion experiments at either exercise intensity. The respiratory exchange
ratio during triacylglycerol infusion was significantly lower than during glucose infusion, both
at 7W and at 15% Wmax: 0.77±0.03 versus 0.92±0.03, and 0.80±0.03 versus 0.88±0.03,
respectively (both P < 0.001). Total carbohydrate oxidation rates were lower during
triacylglycerol infusion, when compared with glucose infusion (P < 0.001).
Patients. In each of the four patients the whole-body oxygen consumption rate measured
during triacylglycerol infusion was higher than that during glucose infusion. Respiratory
exchange ratios during triacylglycerol infusion were significantly higher in patients than in
controls (P < 0.01); the total carbohydrate oxidation rate during triacylglycerol infusion in
patients was significantly higher than that in controls exercising at 7W. Plasma glucose
turnover rates were not different from control values during infusion of either substrate.
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#4,  #2# 3 # 1
    M ean
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-0 .28 -0.630 .07
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          [ µ m o l / k g / m i n ] -11.0 -16.5-5.5
# 2   # 1 # 3
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to hypothes i s
    Cont ra ry
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  # 4
Figure 1. Differences between triacylglycerol and glucose infusion studies for VO2 (ÄVO2), plasma lactate
(Ä plasma lactate), and Ra lactate (+pyruvate) (Ä Ra lactate (+pyruvate)) in individual patients. Grey area:
95% confidence interval for differences in controls. P5: lower limit of 95% confidence interval for differences
in controls. P95: upper limit of 95% confidence interval for differences in controls. Values beyond P95 in
individual patients indicate an effect of triglyceride additional to that in controls according to hypothesis:
ÄVO2 in patients > ÄVO2 in controls, and ÄPlasma Lactate and ÄRa  Lactate (+pyruvate) in patients <
ÄPlasma Lactate and ÄRa  Lactate (+pyruvate) in controls, respectively.
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Outcome parameters in individual patients in comparison with control values.
Whole-body oxygen consumption, plasma lactate concentrations, and lactate (+pyruvate)
turnover rates (Table 4, Figure 1). In Figure 1 the values for ÄVO2, Ä plasma lactate, and
Ä Ra lactate (+pyruvate) in individual patients are depicted together with the respective 95%
CI’s in controls. In all patients additional effects of triacylglycerol infusion could be
demonstrated on whole-body oxygen consumption. Additio al effects of triacylglycerol
infusion on plasma lactate concentration and Ra lactate (+pyruvate), according to our
hypothesis, could be demonstrated in two and three of them, respectively. In patient #2
triacylglycerol infusion had an additional effect on plasma lactate concentration and Ra lactate
(+pyruvate) contrary to our hypothesis.
Table 4. Whole-body oxygen consumption,plasma lactate concentrations, and lactate (+pyruvate) turnover
during triacylglycerol or glucose infusions in individual patients.
  CID patient Controls: at 7W (n=8)   at 15% Wmax (n=7)
_________________________ ________________ __________________
   #1   #2   #3    #4   mean (95% CI)      mean (95% CI)
__________________________________________________________________________________________
Whole-body VO2 (ml/kg/min)
Triacylglycerol  5.66 6.87 8.56 10.82  6.57 (5.88 to 7.26) 11.95 (11.19 to 12.71)
Glucose  4.86 4.99 7.87   9.16  6.43 (5.84 to 7.02) 11.44 (10.95 to 11.93)
Ä VO2 
1  0.80 1.88 0.69   1.66  0.14 (-0.21 to 0.49)  0.51 (-0.49 to 1.51)
Plasma lactate (mmol/L)
Triacylglycerol  6.93 7.27 12.3   2.85  0.90 (0.59 to 1.21)   0.83 (0.63 to 1.03)
Glucose  6.58 4.15 15.0   3.48  1.18 (0.90 to 1.46)   0.78 (0.68 to 0.88)
Ä Plasma lactate 1  0.35 3.12 - 2.7 -0.63 -0.28 (-0.63 to 0.07)  0.05 (-0.10 to 0.20)
Whole-body lactate (+pyruvate) turnover (µmol/kg/min)
Triacylglycerol     57    77  106     52  33.0 (28.6 to 37.4) 2
Glucose     87    55  162     72   44.0 (36.4 to 51.6) 2
Ä Ra lactate (+pyruvate) 1 - 30    22  - 56   - 20 - 11.0 (-16.5 to -5.5) 2
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Values are individual observations in patients and means + 95% confidence interval of the mean in controls.
1Difference between triacylglycerol and glucose infusion studies. 2 Pooled data for 9 controls.
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Figure 2. Exercise endurance time in CID patients. Solid bars: triacylglycerol infusion. Open bars: glucose
infusion.
Leg exercise endurance time (Figure 2)
The control subjects completed the leg exercise protocol irrespective of the substrate being
infused. Three patients had to stop exercise prematurely during glucose infusion (between 48
and 65 minutes), while the fourth patient completed the nominal 90 minutes. All patients
completed 90 minutes of cycle exercise when triacylglycerol was being infused.
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Figure 3A. PCr/Pi ratios at rest and during exercise in a typical patient triacylglycerol () and glucose ()
infusion study. MVC: maximal voluntary contraction.
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Figure 3B. PCr/Pi ratios at rest and during exercise in a typical control triacylglycerol () and glucose ()
infusion study. MVC: maximal voluntary contraction.
31P-MRS measurements during exercise in FDP muscle (Figure 3)
In Figure 3 results are depicted of a typical 31P-MRS exercise study in a patient and a control.
Relative performance levels in the arm exercise ramp protocol during triacylglycerol infusion
were not different from those during glucose infusion in both patients and controls. At rest
PCr/Pi ratios were lower in all patients during infusion of either substrate, when compared with
control values. During exercise PCr/Pi ratios during triacylglycerol infusion were not different
from those during glucose infusion, both in patients and in controls.
Discussion
Analysis of outcome parameters: comparison of values in individual patients with control
group values. Our hypotheses with regard to possible beneficial effects of triacylglycerol
infusion during exercise in myopathic CID patients, assumed that mitochondrial substrate
oxidation rates would be impaired during exercise and administration of glucose (NADH/
FADH2 = 0.2). Triacylglycerol administration then was aimed at improving mitochondrial
substrate oxidation, since oxidation of triacylglycerols delivers a higher amount of FADH2
relative to NADH to the mitochondrial respiratory chain (NADH/ FADH2 = 0.5).
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With respect to our whole-body oxygen consumption measurements it was assumed that
improved mitochondrial substrate oxidation rates during triacylglycerol infusion would be
reflected by increased oxygen consumption rates, when compared with glucose infusion (see
methods). The effect on whole-body oxygen consumption could be ascribed to our specific
hypothesis in CID patients only when it significantly exceeded observed effects in controls
(additional effect in patients). In those patients that may have benefitted from ameliorated
mitochondrial substrate oxidation, as evidenced by increased whole-body oxygen consumption
during triacylglycerol administration, we expected plasma lactate concentrations and lactate
(+pyruvate) turnover rates to be decreased, when compared with glucose administration.
Again, such additional effects could only be ascribed to our hypothesis when they significantly
exceeded effects in controls.
Whole-body oxygen consumption. Triacylglycerol infusion was associated with substantially
increased oxygen consumption rates (compared with glucose) in all four patients. In each of
the patients this effect of triacylglycerol infusion on oxygen consumption was additional to
that in the control group, both compared to controls exercising at 7W (Figure 1) and at 15%
Wmax (data not shown). In comparison with controls exercising at 7W, absolute rates of
whole-body oxygen uptake were lower (on average 14%) in two patients (# 1 and 2), while
they were higher (on average 40%) in the other two (#3 and 4). Thus the assumption of
impaired substrate oxidation rates during exercise seems to hold in only two of our patients.
In the other two patients oxygen consumption rates were relatively increased during exercise
with infusion of either substrate, just as they were at rest (1). In our recent paper dealing with
resting state we have suggested that the finding of increased whole-body oxygen uptake may
be explained as a compensatory mechanism necessary to maintain resting ATP synthetic rate
when mitochondrial oxidative phosphorylation is less efficient due to the respiratory chain
deficit (1). The increased oxygen consumption rates during exercise suggest that this putative
mechanism may also (partly) compensate during exercise in these two patients.
Plasma lactate concentration and lactate (+pyruvate) turnover rate. In three out of four
patients the results with respect to plasma lactate concentration and lactate (+pyruvate)
turnover were according to our expectations: a significant addit on l effect of triacylglycerol
infusion on both outcome parameters could be shown. In the remaining patient (patient #2)
however, findings were just the opposite: she showed higher plasma lactate concentrations and
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lactate (+pyruvate) turnover rates during triacylglycerol infusion, when compared with glucose
infusion. Because the Steele equation was used to calculate Ra lactate (+pyruvate) (see
methods), lactate concentration and turnover in this patient were not independently measured.
We have no explanation for the contrasting findings in this patient, that are even more
remarkable since leg exercise endurance time during triacylglycerol infusion was significantly
better, despite higher lactate concentration and turnover.
Exercise endurance. In three out of four patients endurance time was clearly limited during
glucose infusion, when compared with triacylglycerol infusion. The remaining patient
completed the 90 minute low-intensity exercise trial irrespective of the substrate being infused.
This patient also showed the lowest plasma lactate concentrations during both glucose and
triacylglycerol infusion, suggesting endurance time may be related to circulating plasma lactate
levels. On the other hand, endurance time in patient #2 was limited during glucose infusion,
despite lower plasma lactate levels, when compared with triacylglycerol infusion, suggesting
endurance time is not just a simple function of plasma lactate concentrations. Now the question
arises why three out of four patients had to terminate their low-intensity cycle exercise
prematurely during glucose infusion. Although our infusion experiments have not been carried
out in a doubleblind design, we feel that each of these patients had to stop because of total
exhaustion, and were unbiased towards outcome of the exercise trial. Therefore, we feel
confident that the observed difference in performance has a physiological rather than a
psychological basis.
Because lactate production in muscle usually is accompanied by release of [H+], diff rences in
[H+] release could possibly explain for differences in exercise endurance. However, none of the
patients became acidotic during infusion of either substrate and exercise at this low-intensity
level (data not shown), suggesting that these patients can effectively compensate for excess
[H+] release from their exercising muscle. Blood bicarbonate levels decreased only mildly and
to a comparable extent during exercise and infusion of either substrate (data not shown). These
findings do not rule out a relationship between exercise endurance and a decrease in
intramuscular pH. The MRS data obtained from a different (forearm) muscle during exercise
did not show any differences in chemical shift of inorganic phosphate resonance (reflecting
differences in intramuscular pH; data not shown) between glucose and triacylglycerol infusion,
however. Thus we can only speculate about the mechanism causing early termination of leg
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exercise during glucose infusion in these patients. We think early depletion of their muscle
glycogen stores is involved. In normal healthy subjects carbohydrate administration during
exercise did not spare muscle glycogen stores (16,17,18). In contrast, triacylglycerol infusion
was associated with significant sparing of muscle glycogen during exercise (19,20,21,22,23).
Most of these studies however involved exercise at moderate to intense exercise levels (~ 70%
VO2max, corresponding to ~ 60% Wmax in normals). Although we have aimed at low exercise
intensity levels (15% Wmax) that could be sustained for a prolonged period of time by our
myopathic patients, the relatively high oxygen consumption rates (on average 55% of
VO2max) and RER’s measured during exercise suggest that these exercise levels should be
considered relatively intense for our patients (in normals exercise intensity levels correlate with
carbohydrate oxidation rates, and thus RERs). If we then assume similar effects of
carbohydrate versus triacylglycerol administration on muscle glycogen stores during exercise in
our patients as observed in normal subjects at higher intensity levels (70% VO2max), this could
possibly explain early depletion of their muscle glycogen during leg exercise and glucose
infusion, when compared with triacylglycerol infusion.
31P-MRS measurements during exercise. There were no differences in PCr/Pi ratios during
exercise between triacylglycerol and glucose infusion studies in patients, despite improved
outcome parameters with triacylglycerol infusion (when compared with glucose infusion). This
apparent contrast may be explained by the different exercise protocols that have been used.
The (tracer) infusion and respiratory calorimetry studies involved steady-state cycle exercise at
a low intensity level that was aimed to be endurable for a prolonged period of time (> 0.5
hour). The 31P-MRS studies were done in forearm muscle during (sub)maximal exercise, using
a different protocol with increasing workloads in a ramp design, that will fatigue the muscle
relatively soon. As shown by the PCr/Pi ratios, triacylglycerol infusion was not associated with
improved skeletal muscle energy state during exercise in such a ramp design.
In conclusion, in the present study triacylglycerol infusion was shown to be associated with
improved mitochondrial substrate oxidation rates and lower plasma lactate concentrations and
lactate (+pyruvate) turnover rates in myopathic CID patients during exercise, when compared
with glucose infusion. These findings during leg exercise were associated with improved
exercise endurance during triacylglycerol infusion in a majority of patients. PCr/Pi r tios,
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measured in a forearm exercise ramp protocol, however were not different whether patients
were infused with triacylglycerol or glucose.
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Abstract
This study measured the disposal of a lactate load via gluconeogenesis during prolonged low-
intensity exercise in seven healthy subjects, using a relatively new stable isotope method.
All subjects served as their own control: on one occasion they received a sodium lactate
infusion during the final hour of four hours cycle exercise, in the control experiment they
received an isomolar sodium bicarbonate infusion. Lactate infusion increased gluconeogenesis
from lactate from 29.2±3.6% to 45.7±3.6% of glucose Ra, while during bicarbonate infusion it
increased only slightly. Total gluconeogenic rates also increased upon lactate infusion: from
45.3±6.1% to 63.6±0.2% of glucose Ra, while they were unchanged during bicarbonate
infusion. There were no differences in total glucose Ra between the lactate and bicarbonate
infusion studies at all times. Gluconeogenesis from lactate accounted for ~ 12% of the disposal
of the lactate load, while oxidation could have accounted for 37%. These findings suggest (1)
apparent autoregulation of glucose output in normal healthy subjects during low-intensity
exercise. (2) lactate infusion increases GNG from lactate, while GNG from non-lactate
precursors (glycerol) is unaffected.
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Introduction
Total output of glucose from liver and kidneys is the result of two processes, glycogenolysis and
gluconeogenesis (GNG). In healthy humans at rest there is ample evidence for autoregulation of
glucose output: infusions of gluconeogenic substrates (1,2,3,4) stimulate GNG but have no effect on
total glucose production. The mechanisms responsible for this autoregulatory process are
incompletely understood. Several putative explanations have been proposed, including glucose or
glycogen cycling (5), an increase in GNG from one precursor matched by a similar decrease in GNG
from other precursors (2,6), and a decrease in the rate of glycogenolysis (5). Although it has long
been known that glycogenolysis and not GNG is the primary source of glucose production during
exercise, the mechanisms involved in the interaction between the two sources of glucose production
during exercise are also not very well understood. Whether autoregulation of glucose output can
also be demonstrated during exercise remains to be established.
The purpose of the present study therefore was to examine if autoregulation of glucose output was
apparent during exercise and to provide insight into the mechanisms involved. The role of substrate
availability, the interaction between GNG from lactate and from other precursors, as well as the
interaction between GNG and glycogenolysis were all studied during prolonged low-intensity
exercise both with and without administration of an exogenous lactate load. A relatively new stable
isotope technique was used based upon the incorporation of deuterium from body water into
gluconeogenic precursors and quantification of the appearance of deuterium in blood glucose.
Patients and methods
   
Subjects
Seven healthy subjects (three male and four female), age range 21 to 28 years, volunteered for the
study. Their physical characteristics are listed in Table 1. None of the subjects had a family history of
diabetes mellitus or were taking any medications. Written informed consent was obtained in each
subject. The experimental protocol was approved by the Medical Ethics Committee of our hospital.
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Preexperiment testing (Table 1). All participants reported to the laboratory at least three days before
the experiments to perform an incremental maximal exercise test on an electrically braked cycle
ergometer (Lode Instruments, Groningen, The Netherlands). Maximal workload (Wmax) and
maximal oxygen uptake (VO2max) were assessed as previously described (7).
The results of this test were used to calculate a workload equal to 30% of each subject’s VO2m x
(corresponding to about 18% Wmax) which was used in both exercise studies.
From the literature it is known that this level of low-intensity exercise can be sustained for a
prolonged period of time (8).
Table 1. Physical characteristics of the study population.
Age BW FFM VO2max 
1 Wmax 1
Subject Sex (yr) (kg) (kg) (ml/min/kg) (W/kg)
____________________________________________________________________________
1. F 21 55.7 43.6 46.1 4.31
2. F 27 65.1 50.1 33.9 3.07
3. F 24 67.9 43.4 32.8 2.95
4. F 24 59.5 46.1 36.5 3.03
5. M 22 70.3 66.3 65.7 4.84
6. M 28 81.8 69.6 48.8 4.40
7. M 26 73.2 64.4 41.8 3.55
Mean 25 67.6 54.8 43.7 3.74
SE   1   3.3   4.3     4.3 0.29
1 VO2max and Wmax are expressed per kg BW. BW is body weight. FFM is fat free mass
Experimental protocol
Subjects reported at the laboratory at 7:30 AM on two occasions, separated by at least six weeks.
The lactate and control infusions were assigned in random order. All seven subjects participated in
both infusion studies. Four days before each study, subjects were placed on a diet containing at least
200 grams of carbohydrate daily. The subjects ate their last meals at 6:00 PM the evening before the
day of the study. For measurement of GNG, they were given oral [2H2]O (Is tec, Miamisburg,
Ohio), 5 g/kg body water divided into four doses (at 9:00, 10:00, 11:00 P.M., and 12:00 midnight).
Body water was assumed to be 73% of fat free mass, which was assessed by skinfold measurement.
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At  8:00 AM on the day of the study two indwelling catheters were inserted, one into a cubital vein
for infusion and the other into a dorsal hand vein of the contralateral arm for blood sampling. The
hand was kept warm in a heated box to achieve arterialization of the venous blood (9). After
drawing blood sample, the catheter was flushed with heparinized saline (2.5 U/ml). Subjects were
acclimatized to room conditions (temperature 21-25 °c) on a bed in the supine position for 30
minutes before beginning the study. After a basal blood sample was obtained at 8:30 AM (time -60
min), a primed constant-rate infusion of [6,6-2H2]glucose (98% enriched, Mass Trace, Woburn,
USA) was started and continued for five hours (prime: 15 µmol/kg, continuous infusion rate
0.15µmol/kg/min). Subjects then rested in the supine position for one hour (time -60 to 0 min).
After this basal period they stepped from the bed on the cycle ergometer after voiding for urine
collection. Then they performed stationary cycle exercise at 18% Wmax for four hours (0 to 240
min).
Lactate/ bicarbonate infusion. In order to examine the disposal of an exogenous load of lactate
during exercise, a primed constant-rate infusion of 1M sodium-L(+)-lactate (purity 93% L(+)
lactate, ICN Biomedicals, Zoetermeer, The Netherlands) was initiated after three hours of cycle
exercise and continued for 60 minutes (prime: 675µmol/kg over 5 min, subsequent continuous
infusion rate 60 µmol/kg/min). In control experiments 1M (8.4% w/v) sodium bicarbonate was
infused in isomolar amounts in order to mimic changes in osmolar and acid-base balance associated
with sodium lactate infusion (3).
Respiratory calorimetry. Open circuit indirect calorimetry was performed at rest using a ventilated
hood system for 40 minutes (time -40 to 0 min). Stable values for oxygen consumption (VO2) were
reached within 5 min of recording. During exercise, respiratory calorimetry measurements were
performed during two periods (period I: 0 to 60 min, period II: 160 to 240 min), using a face mask.
Computerized continuous gas analysis and volume measurements were performed (Oxycon
Champion, Jaeger, Breda, The Netherlands), as previously described (7). Gas and volume
calibrations were performed before each measurement. Standardization with alcohol burning was
performed regularly; the theoretical respiratory exchange ratio (0.67) was closely approached in all
measurements (mean 0.66; coefficient of variation 1.6 percent, n=10).
Blood sampling and urine collection. Blo d samples were drawn at regular intervals, placed on ice
and transferred into sodium fluoride tubes for plasma glucose, lactate and triglyceride measurements,
lithium-heparinized tubes for free fatty acids, glycerol, alanine, cortisol and insulin determinations,
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and whole blood was deproteinized for measurement of blood pyruvate, b-hydroxybutyrate and
acetoacetate. Samples for determination of deuterium enrichments were immediatly deproteinized
with Ba(OH)2 and ZnSO4, centrifuged at 4 °c and stored at - 70 °c. Subjects voided at time 0 and
240 min and urine was collected for determination of nitrogen excretion and deuterium enrichment.
Sample analysis
Plasma glucose, lactate and triglyceride concentrations were determined enzymatically using
autoanalyzers (Dimension AR and ACA SX, Dade USA). The concentrations of [6,6-2H2]glucose
used for the tracer infusions were measured with the autoanalyzer using calibration curves from
weighed, waterfree glucose (Merck, Darmstadt, Germany). Plasma insulin and cortisol
concentrations were determined using a microparticle enzyme immunoassay method (IMX analyzer,
Abbott, USA) and a fluorescence polarisation immunoassay (TDX analyzer, Abbott, USA),
respectively. Plasma alanine concentrations were determined gas chromatographically. Blood
pyruvate, b-hydroxybutyrate, acetoacetate, plasma free fatty acids and glycerol were measured using
automated enzymatic colorimetric methods (COBAS FARA II, Hoffmann-La Roche, UK). Urinary
nitrogen was assayed according to a micro Kjeldahl method (10). The deuterium enrichment of
hydrogen on carbon 5 (C-5) and carbon 6 (C-6) of glucose was measured as described previously
(11,12,13). Briefly, glucose was isolated from deproteinized plasma by successive ion-exchange
chromatography and high-performance liquid chromatography. For determination of deuterium
enrichment on C-5, glucose was first converted to xylose, and the C-5 of glucose with its hydrogens
was cleaved by periodate oxidation to formaldehyde, which was condensed with ammonium
hydroxide to form hexamethylenentetramine (HMT). C-6 of glucose was cleaved directly to
formaldehyde and then condensed with ammonia to form HMT, which was analyzed on a Hewlett
Packard mass spectrometry system (HP 5970 equipped with an HP 5890 gas chromatograph, Palo
Alto, USA). Electron impact ionization (70 eV) was used, and ions m/z 140 and 141 were
monitored using the selected-ion monitoring (SIM) software. [6,6-2H2]glucose enrichments were
also measured in HMT together with (m+0) and (m+1) enrichments in the same run (m+2 at carbon
6 of glucose: selected ion m/z 142). Standard solutions of glucose of known enrichment were run
along with unknowns to calibrate for instrument variations. Enrichment of deuterium in urine water
was determined in acetylene gas on a GCMS system, according to Previs et al. (14). Briefly, urine
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samples were reacted with calcium carbide to form acetylene gas, in which deuterium enrichment
was determined by gas chromatography electron impact ionization mass spectrometry.
All samples were reacted in triplicate and the measured deuterium enrichments showed a coefficient
of variation < 5%.
Calculations
Whole-body turnover of glucose. At r st, steady-state whole-body glucose rate of appearance was
calculated as follows (15):
Glucose Ra (µmol/kg/min) = I / TTR [1]
where glucose Ra is the rate of whole-body glucose turnover, I the infusion rate of the [6,6-
2H2]glucose tracer in µmol/kg/min, and TTR the tracer to tracee molar ratio in plasma (M+2 at
carbon 6). Isotopic enrichments were considered to be in steady-state when TTRs of four
consecutive samples had a coefficient of variation < 10%, and a slope not significantly different from
zero. During exercise, glucose turnover rates were calculated as described for the resting state when
isotopic enrichments were in steady-state. When the isotopic enrichments were not in steady-state,
turnover rate was calculated with Steele’s equations for non-steady-state conditions (16), as follows:
I - Vd ((Gi + Gj)/2)*(DTTR/DT)
Glucose Ra (µmol/kg/min) =_________________________ [2]
(TTRi + TTRj)/2
where Vd is the volume of distribution of glucose in ml/kg (200 ml/kg, Ref. 17), (Gi + Gj)/2 is the
mean plasma glucose concentration (in µmol/ml) measured at time points Ti and Tj, DTTR is the
change in TTR from Ti to Tj, DT is the time interval (Tj-Ti) in minutes, and (TTRi + TTRj)/2 is the
mean TTR measured at time points Ti and Tj.
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Gluconeogenesis (GNG). The contribution of GNG to the production of glucose was calculated as
described previously (11):
Fractional contribution of GNG to total glucose production (GNGTOT) (%)
= 100 x ( 2H enrichment of glucose C-5 / 2H enrichment in body water) [3]
Fractional contribution of GNG via pyruvate to total glucose production (GNGPYR) (%)
 = 100 x (0.5 x 2H enrichment of glucose C-6 / 2H enrichment in body water) [4]
The 2H enrichment on C-6 was divided by two because two hydrogens bound to C-6 of glucose are
enriched. The difference between equations [3] and [4] provides an estimate of the fractional
contribution of GNG from glycerol to total glucose production. The lack of complete equilibration
of the hydrogens in pyruvate with those of body water may lead to underestimation of GNG via
pyruvate. In normal subjects after prolonged fast, the equilibrium between the hydrogens in pyruvate
and body water has been estimated to be 80% complete (13); however no data are available during
exercise.
Rate of total GNG (µmol/kg/min) = Glucose Ra x GNGTOT [5]
Respiratory calorimetry. Rates of carbohydrate and fatty acid oxidation were calculated according
to standard equations (18). Protein oxidation was calculated from urinary nitrogen excretion,
assuming that 1 g nitrogen equals 6.25 g protein.
Correction of respiratory exchange ratio (RER) during sodium lactate infusion. Because infusion
of sodium lactate is associated with alkalosis in both the circulating and intracellular compartments
(3), the rates of carbon dioxide production during lactate infusion have to be corrected for the
retention of carbon dioxide in the whole-body bicarbonate pool. This correction was applied by
estimating the expansion of the readily exchangeable body bicarbonate pool according to Ferrannini
(19): for each 20-min time interval during lactate infusion, the change in whole blood bicarbonate
concentration was multiplied by the whole-body distribution volume of bicarbonate, i.e., 400 ml/kg
(20). To calculate the total carbohydrate and fatty acid oxidation rates, these three values were
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averaged and added to the mean carbon dioxide production rates measured by calorimetry over the
1-h infusion period.
Statistical analysis
The results are presented as means ± SE. Paired student’s t-tests were used for comparison between
lactate and control infusion studies. Statistical significance was set at P < 0.05.
Results
Plasma concentrations (Table 2)
Control studies. Basal period. Basal plasma glucose after an overnight fast was 5.0±0.2 mM.
Gluconeogenic precursor levels were 0.7±0.1 mM, 69±7 µM, 234±14 µM, 0.05±0.02 mM for
plasma lactate, pyruvate, alanine, and glycerol, respectively. Exercise. Plasma glucose levels
decreased continuously during exercise: from basal levels of 5.0±0.2 mM to 4.2±0.3 mM at the end
of 4 hours exercise (Figure 1A). Plasma lactate levels remained fairly constant during the first 3
hours of exercise (Figure 1B). During the final hour of exercise plasma lactate levels tended to
increase slightly. Blood pyruvate concentrations showed similar changes as plasma lactate. Plasma
alanine concentrations deceased from basal levels of 234±14 µM to 184±11 µM after 4 hours of
exercise, while plasma glycerol concentrations increased from 0.05±0.02 mM to 0.32±0.05 mM.
Plasma triglyceride and free fatty acid concentrations increased during exercise: from 0.73±0.05 mM
to 0.92±0.04 mM and from 0.61±0.08 mM to 2.35±0.06 mM, respectively. In addition, blood b-
hydroxybutyrate and acetoacetate levels increased significantly.
Plasma insulin levels remained < 5 mU/l at all times. Plasma cortisol levels rose from 0.54±0.05 mM
to 0.79±0.09 mM during the bicarbonate infusion.
Lactate studies. Basal period. Basal plasma glucose and gluconeogenic precursor levels did not
differ significantly between lactate and control experiments. Exercis . Plasma glucose levels were
not different from those in control experiments during the first three hours of exercise. Lactate
infusion resulted in an increase in plasma glucose level from 4.4±0.2 (pre infusion) to 4.9±0.3 mM
(end of infusion, P < 0.05). Plasma glucose levels were significantly higher after lactate infusion than
after bicarbonate infusion (P < 0.05, Figure 1A). There were no differences in plasma lactate levels
between lactate and control experiments during the first three hours of exercise. Lactate infusion
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during the final hour of cycle exercise significantly increased plasma lactate levels: from 0.8±0.2 mM
to 4.4±0.6 mM (P < 0.01). Already after 5 minutes of infusion plasma lactate levels during lactate
infusion were ~ 3.3 mM higher than during bicarbonate infusion experiments (Figure 1B).
Table 2. Plasma metabolite and hormone concentrations in sodium lactate infusion (lactate) or sodium
bicarbonate infusion (control) studies.
    Control (bicarbonate)    Lactate
____________________________ ____________________________
        Exercise     Exercise
__________________ __________________
    Basal    Pre-   End of    Basal      Pre-   End of
   infusion  infusion  infusion  infusion
  (180 min)(240 min) (180 min) (240 min)
____________________________________________________________________________________________
Plasma glucose (mM)       5.0±0.2    4.5±0.2  4.2±0.3   5.0±0.2   4.4±0.2   4.9±0.3§
Plasma lactate (mM)       0.7±0.1    0.7±0.1  1.0±0.2   0.6±0.1   0.8±0.2   4.4±0.6*
Blood pyruvate (µM) 69±7      60±4    75±7    65±7    68±9  148±23§
Lactate/Pyruvate Ratio       9.4±0.9  11.0±1.413.3±1.3 10.0±0.7 11.4±2.1 25.8±2.7‡
Plasma alanine (µM)      234±14   212±11  184±11   204±28  183±20  223±12§
Plasma glycerol (mM)     0.05±0.02  0.27±0.040.32±0.05 0.04±0.020.26±0.020.28±0.01
Plasma triglycerides (mM)    0.73±0.05  0.87±0.050.92±0.04 0.76±0.120.87±0.100.85±0.07
Plasma free fatty acids (mM)    0.61±0.08  1.84±0.272.35±0.36 0.52±0.081.79±0.191.86±0.17
Blood b-hydroxybutyrate (mM) 0.03±0.03  .47±0.090.77±0.12 0.03±0.030.73±0.13§ 0.74±0.15
Blood acetoacetate (mM)   0.06±0.01  0.24±0.030.40±0.05 0.10±0.030.34±0.06§ 0.36±0.07
Plasma insulin (mU/l)     < 5    < 5   < 5   < 5  < 5  < 5
Plasma cortisol (mM)    0.57±0.14  0.54±0.050.79±0.09 0.55±0.120.69±0.130.92±0.12
Values are means ± SE in 7 subjects. * P < 0.001, ‡ P < 0.01, § P < 0.05 lactate infusion versus control infusion.
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Figure 1A. Plasma glucose concentrations (mean±SE, n=7 subjects) in lactate (LAC; ) and control bicarbonate (BIC;
) infusion studies. Lactate, or bicarbonate (prime 675 µmol/kg in 5 min, constant-rate 60 µmol/kg/min thereafter)
was infused starting at 180 minutes until 240 minutes. § P < 0.05 lactate versus bicarbonate (control) infusion.
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Figure 1B. Plasma lactate concentrations (mean±SE, n=7 subjects) in lactate (LAC; ) and control bicarbonate (BIC;
) infusion studies.
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Lactate infusion resulted in a significant increase in blood pyruvate concentration as well as in
lactate-to-pyruvate ratio (P < 0.05 and P < 0.01, respectively). Plasma alanine concentrations were
not different from those in control experiments during the first three hours of exercise. Plasma
alanine concentrations increased from 183±20 µM to 232±12 µM during lactate infusion, values
significantly higher than during bicarbonate infusion (P < 0.05). Plasma glycerol, triglyceride, and
free fatty acid concentrations were not different from control experiments at any time. Blood b-
hydroxybutyrate and acetoacetate levels were both significantly higher just before infusion in the
lactate infusion studies, when compared with control studies (both P < 0.05), while there was no
difference at the end of infusion. Plasma insulin levels remained < 5 mU/l at all times. There was a
similar increase in plasma cortisol levels during lactate infusion, when compared with bicarbonate
infusion. Plasma cortisol levels were not different from control values at all times.
Plasma electrolyte concentrations and blood gas analysis (Table 3)
There were no differences in plasma sodium, potassium, blood pH, pCO2, bicarbonate or base
excess between lactate and control infusion experiments at any time.
Glucose kinetics
Glucose Ra was similar in lactate and control experiments in the basal state (Table 4).
In response to exercise there was an increase in glucose Ra in both groups that reached a
plateau during the final hour of cycle exercise. There were no significant differences in glucose Ra
rates between lactate and control infusion studies at all times.
Gluconeogenesis (GNG)
Fractional contribution to glucose Ra. Control studies. The fractional contribution of GNG via
pyruvate to total glucose production (GNGPYR) decreased from 36.3±2.0 % at rest to 27.9±1.9 %
after three hours of cycle exercise (P<0.05, Table 5). The fractional contribution of total GNG
(GNGTOT) was unchanged: 39.3±1.7 % at rest versus 39.3±0.2 % after three hours of cycle exercise
(Table 6). During the bicarbonate infusion in the final hour of cycle exercise GNGPYR increased
slightly from 27.9±1.9 % to 30.8±1.5 %, while GNGTOT increased from 39.3±0.2 % to 45.8±3.0 %
(both NS).
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Table 3. Plasma electrolyte concentrations and bloodgas analysis in sodium lactate infusion (lactate) or sodium
bicarbonate infusion (control) studies.
    Control (bicarbonate)    Lactate
____________________________ ____________________________
        Exercise     Exercise
__________________ __________________
    Basal          Pre-   End of    Basal      Pre-   End of
  infusion  infusion  infusion  infusion
 (180 min)(240 min) (180 min) (240 min)
____________________________________________________________________________________________
Plasma sodium (mM)    140±1   140±1  144±1  140±1  141±1  144±1
Plasma potassium (mM)     4.7±0.1   4.4±0.1   3.7±0.2   4.9±0.1   4.2±0.1   3.8±0.1
Blood pH   7.38±0.01 7.38±0.017.49±0.01 7.37±0.017.38±0.017.52±0.01
Blood pCO2 (mm Hg)      41±3     37±1    40±1    42±1    39±1    39±2
Blood bicarbonate (mM)      24±1     21±1    30±2    24±1    22±1    30±1
Blood base excess (mM)   -1.5 ±0.7  -3.1 ±0.3   6.3±2.3 -1.3 ±0.7 -2.8±0.5   7.1±0.6
Values are means ± SE in 7 subjects.
Table 4. Glucose production and gluconeogenesis via pyruvate in sodium lactate infusion (lactate) or sodium
bicarbonate infusion (control) studies.
   Exercise Exercise
Basal Pre infusion Infusion
_________ _________ ______________________________
180 min 200 min 220 min 240 min
____________________________________________________________________________________________
Control 10.60±0.23 18.04±0.54 16.41±0.8316.28±0.7416.14±0.84 Glucose Ra
Lactate 10.45±0.34 17.60±1.27 17.27±1.0517.63±1.018.75±1.05 (µmol/kg/min)
Control   36.3±2.0  27.9±1.9   29.8±1.7  30.9±1.5  30.8±1.5 GNGPYR
Lactate   39.1±2.6  29.2±3.6   38.6±3.2§   43.4±2.7‡   45.7±3.6‡ (%Glucose Ra)
Control  3.86±0.26  4.79±0.29   4.74±0.46  5.05±0.44  5.13±0.49 Absolute GNG
Lactate  4.15±0.31  5.05±0.35   6.56±0.44§   7.61±0.59‡   8.82±0.44* (µmol/kg/min)
Values are means ± SE in 7 subjects. * P<0.001, ‡ P<0.01, § P < 0.05 lactate infusion versus control infusion. GNGPYR
is the contribution of GNG via pyruvate to total glucose Ra.
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Table 5. Deuterium enrichment in hydrogens at C-6 of glucose and in body water and estimates of GNG via pyruvated
in lactate and control studies.
   Exercise  Exercise
Basal Pre infusion     End of infusion
  (180 min)   (240 min)
____________________________ _________________ ________________
 2H enrichment 2H enrichment 2H enrichment
___________________ _________ ________
Water 0.5 x C-6 1 GNGPYR 0.5 x C-6 
1 GNGPYR 0.5 x C-6
1   GNGPYR
  (%) (%) (%) (%) (%) (%) (%)
____________________________________________________________________________________________
Control 1. 0.50 0.20 40.0 0.175 35.0 0.145 29.0
(bicarbonate)
2. 0.50 0.19 38.0 0.12 24.0 0.135 27.0
3. 0.39 0.11 28.2 0.095 24.4 0.105 26.9
4. 0.56 0.185 33.0 0.18 32.1 0.19 33.9
5. 0.48 0.215    44.8 0.13 27.1 0.16 33.3
6. 0.46 0.16 34.8    -    - 0.16 34.8
7. 0.51 0.18 35.3 0.125 24.5    -    - 
____ ____ ____ ____ ____ ____ ____ 
Mean 0.49 0.18 36.3 0.14 27.9§ 0.15 30.8
SE 0.02 0.01   2.0 0.01   1.9 0.01   1.5
Lactate 1. 0.50 0.20 40.0 0.125 25.0 0.23 46.0
2. 0.50 0.18 36.0 0.10 20.0 0.165 33.0
3. 0.41 0.15 36.6 0.125    30.5 0.185 45.1
4. 0.60 0.27 45.0 0.285    47.5 0.33 55.0
5. 0.47 0.20 42.6 0.125    26.6 0.22 46.8
6. 0.47 0.125 26.6 0.095    20.2 0.165 35.1
7. 0.46 0.215 46.7 0.16 34.8 0.27 58.7
____ ____ ____ ____ ____ ____ ____ 
Mean 0.48 0.19 39.1 0.145    29.2§ 0.22 45.7‡
SE  0.02 0.02   2.6 0.025   3.6 0.02   3.6
Values are means ± SE in 7 subjects. § P<0.05 significantly different from basal values. ‡ P<0.01 significantly
different from pre infusion values. GNGPYR is the contribution of GNG via pyruvate to total glucose Ra.
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1 The deuterium enrichment at C-6 is multiplied by 0.5 because 2 hydrogens are bound to C-6.
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Table 6. Deuterium enrichment in hydrogens at C-5 of glucose and in body water and estimates of total GNG in
lactate and control studies.
Exercise Exercise
Basal     Pre infusion   End of infusion
      (180 min) (240 min)
________________________ ______________ ______________
    2H enrichment 2H enrichment 2H enrichment
______________ ______ ______
Water C-5 GNGTOT C-5 GNGTOT C-5 GNGTOT
(%) (%) (%) (%) (%) (%) (%)
____________________________________________________________________________________________
Control 2.  0.50    -    - 0.20 40.0 0.21 42.0
(bicarbonate)
3. 0.39 0.16 41.0 0.15 38.5 0.17 43.6
4. 0.56 0.21 37.5 0.22 39.3 0.29 51.8
 ____ ____ ____ ____ ____ ____ ____
Mean  0.48 0.19 39.3 0.19 39.3 0.22 45.8
SE   0.05 0.02   1.8 0.02   0.4 0.03   3.0
Lactate 2.  0.50 0.24 48.0 0.18 36.0 0.32 64.0
3.  0.41 0.20 48.4 0.17 41.5 0.26 63.4
4.  0.60 0.32 53.3 0.38 63.3 0.38 63.3
5.  0.47 0.21 44.7 0.19 40.4 0.30 63.8
 ____ ____ ____ ____ ____ ____ ____
Mean  0.50 0.24 48.7 0.23 45.3 0.315       63.6*,§
SE  0.04 0.03   1.8 0.05   6.1 0.025   0.2
* P<0.001 significantly different from basal and control study values. § P<0.05 significantly different from pre infusion
values. GNGTOT is contribution of total gluconeogenesis to glucose Ra.
Lactate studies. GNGPYR decreased from 39.1±2.6 % at rest to 29.2±3.6 % after three hours of
cycle exercise, a decrease similar to that in control experiments (P<0.05, Table 5). GNGTOT was
unchanged: 48.7±1.8 % at rest versus 45.3±6.1 % after three hours of cycle exercise (Table 6).
Lactate infusion during the final hour of cycle exercise significantly increased GNGPYR from
29.2±3.6 % to 45.7±3.6 % (P < 0.01). Also GNGTOT increased: from 45.3±6.1 % to 63.6±0.2 %
(P<0.05).
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Absolute gluconeogenic rates (Table 4). GNG via pyruvate remained unchanged during bicarbonate
infusion in control experiments. Lactate infusion increased GNG via pyruvate from pre infusion
values of 5.05±0.35 µmol/kg/min to 8.82±0.44 µmol/kg/min at the end of one hour infusion (P <
0.001). GNG rates during lactate infusion were significantly higher than those during control
(bicarbonate) infusion (P < 0.001).
Disposal of the lactate load via GNG (Figure 2)
Lactate infusion (at a continuous infusion rate of 60 µmol/kg/min) resulted in an increase of GNG
via pyruvate (expressed in lactate/pyruvate equivalents) over control values of 17.63 – 10.25 = 7.38
µmol/kg/min (calculated from 60 min infusion values, P<0.001)  i.e. ~12 % of the lactate load.
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Figure 2. Absolute contribution of GNG via pyruvate to glucose Ra (mean±SE, n=7 subjects) in lactate (filled bars)
and bicarbonate (control; open bars) infusion studies. * P < 0.001, ‡ P < 0.01, § P < 0.05 lactate versus bicarbonate
(control) infusion. Time 0 min: basal values. Time 180-240 min: lactate or bicarbonate (control) infusion.
Respiratory calorimetry (Table 7)
The rates of oxygen consumption and CO2 production were not different between control and
lactate infusion studies at all times. The RER decreased during exercise in both studies, indicating
enhanced fatty acid oxidation. RERs were not different between control and lactate infusion studies
at rest and during the first 3 hours of exercise. During the lactate infusion in the final hour of cycle
exercise the RER dropped from 0.77±0.01 to 0.74±0.01 (P < 0.0 ), while during bicarbonate
infusion it was unchanged. The uncorrected RER was significantly lower during lactate infusion,
when compared with bicarbonate infusion (P < 0.001). Correction of the RER during lactate
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infusion for retention of CO2 in the bicarbonate pool resulted in an increase in RER from 0.77±0.01
to 0.82±0.01 (P < 0.01).
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Table 7. Rates of oxygen consumption (VO2), CO2 production (VCO2), and RER.
Control (bicarbonate)
     Exercise
______________________________________
    basal 0-60 min 160-180 min 180-240 min
____________________________________________________________________________________________
VO2 (ml/kg/min) 3.34±0.14 12.85±0.63 14.22±0.62 14.44±0.69
VCO2 (ml/kg/min) 2.76±0.09 10.57±0.49 11.03±0.47 11.41±0.55
RER 0.83±0.01   0.82±0.01   0.78±0.01   0.79±0.01
Lactate
  Exercise
______________________________________
  basal 0-60 min 160-180 min 180-240 min
____________________________________________________________________________________________
VO2 (ml/kg/min) 3.29±0.14 13.59±0.84 14.08±1.02 15.05±1.20
VCO2 (ml/kg/min) 2.68±0.11 10.97±0.74 10.91±0.81 11.09±0.92
RER 0.82±0.01   0.81±0.01   0.77±0.01   0.74±0.01*
Corrected RER   0.82±0.01*
Values are means ± SE in 7 subjects. * P<0.001 significantly different from pre infusion and control study values. RER
is respiratory exchange ratio.
Discussion
Substrate regulation of gluconeogenesis during exercise. Data from the present study show that
during low-intensity exercise the rates of both lactate GNG and total GNG increased upon
intravenous administration of an external lactate load. Despite significantly higher plasma glucose
concentrations during lactate infusion, when compared with bicarbonate infusion, there were no
differences in glucose Ra between the two infusion conditions. Thus apparent autoregulation of
glucose output during exercise was demonstrated in that, even when gluconeogenesis is increased by
providing exogenous substrates, there is no increase in total glucose Ra. Several studies have shown
unchanged hepatic glucose output (HGO) rates during lactate infusion in both resting dogs (21) and
humans (1,3). Changes in HGO in resting healthy subjects could neither be demonstrated upon
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administration of other gluconeogenic substrates like alanine and glycerol (2) or fructose (4). Several
authors have speculated about the mechanism responsible for this apparent autoregulation of HGO.
Steele and Jahoor have suggested that increased supply of one gluconeogenic precursor in resting
healthy subjects may be associated with decreased incorporation of other precursors in blood
glucose (2,6).
Thus the unchanged rate of total GNG may be an explanation for the apparent failure to increase
HGO by lactate infusion. However, both Jenssen in humans (3) and Connolly in dogs (21) have
shown that lactate infusion not only increased the incorporation of carbons from lactate but also
from alanine into blood glucose. Therefore, at least as reflected by alanine, GNG from precursors
other than lactate was not reduced during infusion of lactate. The results of our studies during low-
intensity exercise support the data of Jenssen and Connolly because we have shown that not only
GNG from lactate but also the total gluconeogenic rate was increased during lactate infusion.
Calculation of the latter value from deuterium enrichment at C-5 of glucose is precise because
exchange of the hydrogens of glyceraldehyde-3-P with body water in the isomerization with
dihydroxyacetone-3-P is extensive and complete (22). Glucose Ra was measured with [6,6-
2H2]glucose, independently from the measurements of deuterium enrichment. Therefore, our finding
of apparent autoregulation of glucose output and the proposed mechanism responsible for it should
not be subject to major methodological critique.
Disposal of a lactate load during exercise via gluconeogenesis. The present study provides the first
data in humans on disposal of an exogenous lactate load during exercise via GNG. Our data show
that during prolonged low-intensity exercise GNG accounted for ~ 12% (range 8-20 %) of the
disposal of an external lactate infusion. These values probably represent a minimum estimation of the
incorporation of lactate into blood glucose, because measurements of GNG from C-6 of glucose
may underestimate GNG from lactate/pyruvate due to possible incomplete exchange of the
hydrogens of pyruvate with those of water. While in resting healthy subjects after an overnight fast
this exchange has been shown to be 80 % complete (13), the extent of this equilibrium during low-
intensity exercise has not been measured. In addition, the applied [2H2]O metho  cannot differentiate
between GNG from lactate, pyruvate, or alanine. Plasma alanine concentrations during lactate
infusion were not much different from pre-infusion values, suggesting alanine is not likely to
contribute significantly to the rise in GNG from pyruvate during lactate infusion. On the other hand,
pyruvate levels more than doubled during lactate infusion. Because of the rapid equilibrium between
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lactate and pyruvate in plasma (23) this is not a major concern: most of the carbons coming from
plasma pyruvate for incorporation into blood glucose are likely to originate from the external lactate
infusion. In our calculations of the contribution of gluconeogenesis to lactate disposal we have
assumed that exogenous lactate infusion does not affect endogenous lactate production during
exercise. The impact of exogenous lactate infusion on endogenous lactate production and lactate +
pyruvate production (glycolysis) has been addressed only in a few studies with conflicting results.
Although studies of Searle (24) had suggested suppression of endogenous lactate production as a
consequence of exogenous lactate infusion, these are in contrast to the data of Jenssen (25) who did
not show any similar effect. These differences may be related to study design because Searle et al.
used a bolus dose tracer administration while the study by Jenssen was a constant rate infusion
study.
In as much as we did not measure lactate turnover, our estimation of exogenous lactate disposal will
be affected by the contribution of the endogenous lactate production or lack of it.
The relative contribution of GNG to total plasma lactate disposal during exercise has been estimated
by several authors in several species using different techniques, and ranged from 7 to 25 %
(8,26,27,28,29). Our estimates of the relative contribution of GNG to total plasma lactate disposal
during exercise are in agreement with these previous estimates. The relatively new [2H2]O techniqu
represents an advantage over previous (tracer) approaches for quantifying gluconeogenesis in that it
involves only minor assumptions, whereas most previous approaches rely on a number of major
assumptions. Calculation of lactate GNG from measurements of hepatic blood flow and
arteriovenous lactate differences across the splanchnic bed is probably not quantitative because of
extrahepatic metabolism of lactate and glucose in the splanchnic compartment. In addition, these
calculations rely on accurate hepatic blood flow measurements and the assumption that glucose is
the only fate of the lactate taken up across the splanchnic bed, which is probably not a valid
assumption. Studies using isotopic tracer methods have provided estimates of lactate GNG
expressed as a percentage of isotopically determined total plasma lactate Rd. These estimates of
incorporation of labeled carbon of lactate into glucose upon administering of labeled lactate rely on
assumptions regarding the specific activity or enrichment of the hepatic pyruvate pool and on
assumptions with respect to dilution or loss of label at the level of oxaloacetate, an intermediate
common to the Krebs cycle and gluconeogenesis (30).
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In addition, determination of total plasma lactate Rd from dilution of labeled lactate in the plasma
compartment is likely to include not only lactate but also pyruvate Rd, due to rapid and almost
complete equilibration between lactate and pyruvate pools (23,31,32). The isotopic tracer method
applied in this study does not suffer from any of these limitations and at present provides the most
precise measurements of GNG from lactate during exercise.
Table 8. Contributions of gluconeogenesis and oxidation to disposal of a lactate load.
    Disposal
______________________________________________
Subject Lactate load GNG (%) Oxidation (%) Other (%)
Nr. (µmol/kg/min) (µmol/kg/min) (µmol/kg/min)       (µmol/kg/min)
____________________________________________________________________________________________
1. 60   7.9 (13%) 27.1 (45%) 25.0 (42%)
2. 60 12.1 (20%) 19.1 (32%) 28.8 (48%)
3. 60   4.6 (8%) 22.7 (38%) 32.7 (54%)
4. 60   6.1 (10%) 19.0 (32%) 34.9 (58%)
5. 60     8.7 (15%) 24.7 (41%) 26.6 (44%)
6. 60     7.5 (13%) 26.0 (43%) 26.5 (44%)
7. 60     6.3 (11%) 16.3 (27%) 37.4 (62%)
  _________ _________ _________
Mean   7.4 (12%) 22.1 (37%) 30.5 (51%)
SE     0.9 (1.5%)   1.5 (2.5%)   1.8 (2.8%)
Metabolic fates of the infused lactate load during exercise other than GNG. (Table 8).
Lactate oxidation is quantitatively the most important way of lactate removal during exercise in
humans (29,33). Total carbohydrate oxidation rates, which can be derived from respiratory
calorimetry, are the sum of glucose and lactate oxidation in unknown proportions. In the
present study lactate infusion during exercise caused a drop in respiratory exchange ratio
(RER), suggesting an apparent decrease in total carbohydrate oxidation and an increase in fatty
acid oxidation. However, because infusion of sodium lactate is associated with alkalosis the
rates of carbon dioxide production (as measured at the mouth by respiratory calorimetry) have
to be corrected for the retention of significant amounts of carbon dioxide in the bicarbonate
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pool. We have corrected the carbon dioxide production rates during lactate infusion according
to Ferrannini (19). The corresponding “corrected” RER value was significantly increased by
lactate infusion: from 0.77±0.01 to 0.82±0.01. Total carbohydrate oxidation rose with
11.1±0.8 µmol/kg/min during lactate infusion. Assuming unchanged glucose oxidation rates,
this increase in total carbohydrate oxidation would correspond to 22.1±1.5 µmol/kg/min
(range 16.3-27.1 µmol/kg/min) of lactate oxidation. Lactate oxidation then would account for
37% (range 27-45%) of the disposal of the lactate load, assuming total lactate disposal is 60
µmol/kg/min (= infusion rate of exogenous lactate load).
These calculated lactate oxidation rates probably are minimum estimates because competition
between lactate and glucose as substrate for oxidation is possible (34,35). To what extent this
substrate competition has occured during lactate infusion in our study cannot be inferred from
our data. Thus our calculations can explain 50% of the disposal of the lactate load, leaving the
other 50% unaccounted for. Possibly the remaining 50% of the lactate load was stored, for
glycogen and fat are established end points of nonoxidative lactate metabolism (36,37).
Conversion of lactate into muscle glycogen requires gluconeogenic enzymes, which have been
shown to be present in skeletal muscle, although at low concentration and activity. In rats
muscle glycogen synthesis from lactate did not appear to be a major pathway of lactate
removal after exhausting exercise (37). Lactate conversion into liver glycogen could possibly
account for the observed failure to increase HGO by lactate infusion. Our finding of elevated
total gluconeogenic rates during lactate infusion, while HGO was unaffected, suggest a
reduction of net liver glycogenolysis. Perfusion of rat liver with lactate not only increases
release of glucose derived from lactate but also increases glycogen formation from lactate (38).
This increase in liver glycogen formation is mediated by glucose-6-phosphate, a known
inhibitor of glycogen phosphorylase and activator of glycogen synthase (39). An increase in
intrahepatic glucose-6-phosphate could have led to inhibition of glycogen phosphorylase and
activation of glycogen synthase resulting in a net reduction of glycogenolysis.
In summary, the present study shows the following: (I) apparent autoregulation of glucose
output in normal healthy subjects during low-intensity exercise. (II) lactate infusion increases
GNG from lactate, while GNG from non-lactate precursors was unaffected. (III) GNG is only
a minor route and oxidation a major route for exogenous lactate disposal in normal healthy
subjects during low-intensity exercise.
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Abstract
This study evaluated lactate disposal via gluconeogenesis as well as effects of free fatty acid
availability on gluconeogenesis in patients with mitochondrial myopathy due to complex I
deficiency (CID). Gluconeogenic rates were measured in three CID patients and six healthy
controls at rest and during 90 min cycle exercise, using the deuterated water method. All
subjects served as their own control: on one occasion they received an infusion of
triacylglycerol plus heparin, in the control experiment they were studied in the fasting state. At
rest gluconeogenic rates from pyruvate (GNGPYR) tended to be higher in patients than in
controls in the fasting state, but not during triacylglycerol infusion. GNGPYR increased during
exercise in the CID patients (P<0.01), while they were unchanged in the controls, both while
fasting and during triacylglycerol administration. Circulating lactate and pyruvate levels were
threefold increased during exercise in the CID patients, when compared with controls.
Triacylglycerol infusion was associated with increased rates of GNGPYR at rest in controls
(P<0.05) but not in patients. During exercise triacylglycerol infusion was not associated with
increased rates of GNGPYR, both in patients and controls. These findings suggest (1)
gluconeogenesis via pyruvate is increased during exercise in CID patients. (2) increased
pyruvate availability contributes to the stimulated gluconeogenic rates in the CID patients. (3)
increased availability of free fatty acids is not associated with increased rates of
gluconeogenesis via pyruvate in CID patients, neither at rest nor during exercise.
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Introduction
Recently we proposed a potential role for high fat-low carbohydrate diets in the treatment of
patients with mitochondrial myopathy due to Complex I Deficiency (CID, ref. 1,2).
We hypothesized that these patients may benefit from fatty acid supplementation by supplying
FADH2 distal to complex I, with lower plasma lactate levels and production rates as a possible
consequence. Here we propose an additional rationale for the use of high fat diets in patients with
CID:
(I) Lactate conversion into blood glucose (gluconeogenesis) may be an important way of
lactate disposal in CID patients, especially during exercise.
(II) Increased free fatty acid availability (and oxidation) may stimulate lactate disposal via
gluconeogenesis in these patients.
Plasma lactate and pyruvate levels were significantly increased during low-intensity exercise in CID
patients, when compared with normal controls (2).  Lactate-to-pyruvate molar ratios were also
elevated, suggesting cellular redox state is more reduced in these patients. In vivo human studies
generally have shown inhibition of gluconeogenesis upon reduction of cellular redox state by
intravenous or oral administration of ethanol (3,4,5,6,7). An indirect mechanism has been suggested
to be responsible for the inhibition of gluconeogenesis by ethanol, via reduction of pyruvate
availability. If so, gluconeogenesis can be expected to be increased rather than decreased during
exercise in CID patients, because of increased pyruvate availability (as reflected by their circulating
pyruvate levels) during exercise in these patients.
Free fatty acids have long been known to be permissive for gluconeogenesis to proceed (8,9).
Recent studies in humans have reported significant effects of free fatty acid availability on
gluconeogenesis, suggesting that free fatty acids may play a more direct role in the regulation of
gluconeogenesis (10,11). Thus we hypothesized that gluconeogenesis may be increased in CID
patients and controls by increasing free fatty acid availability.
In the present study gluconeogenesis was studied at rest and during low-intensity cycle exercise in
three patients and six controls. In order to examine effects of free fatty acid availability on
gluconeogenesis, subjects served as their own control: on one occasion they received an infusion of
triacylglycerol (Intralipid) plus heparin, in the control experiment they were studied in the fasting
state. Gluconeogenesis was measured using the deuterated water method (12,13,14), because this
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method can discriminate between gluconeogenesis via pyruvate and gluconeogenesis from other
gluconeogenic precursors (glycerol).
Patients and methods
Subjects
Three CID patients (all females, age range 16 to 29 years) and six healthy control subjects (two
male and four female), age range 18 to 32 years, were studied. Their physical characteristics are
listed in Table 1. None of the control subjects had a family history of diabetes mellitus or were
taking any medications. Details of the three patients have been covered in a previous paper (1).
Written informed consent was obtained in each subject. The experimental protocol was approved by
the Medical Ethics Committee of our hospital.
Preexperiment testing (Table 1). All participants reported to the laboratory at least three days
before the experiments to perform an incremental maximal exercise test on an electrically braked
cycle ergometer (Lode Instruments, Groningen, The Netherlands). Maximal workload (Wmax) and
maximal oxygen uptake (VO2max) were assessed as previously described (15). Wmax in patients
ranged from 55 to 60 W, while in the controls it averaged 258 W. The results of this test were used
to calculate a workload equal to 15% of each subject’s Wmax, which was used in both studies.
Thus patients exercised at a workload of only 9 W on the same cycle ergometer that was used for
the incremental maximal exercise test. This cycle ergometer was designed to give reliable output at
very low workloads. Workload in control subjects ranged from 36 to 65 W.
Experimental protocol
Subjects reported at the laboratory at 7:30 AM on two occasions, separated by at least six weeks.
The triacylglycerol and fasting studies were assigned in random order. All subjects participated in
both studies. Four days before each study, subjects were placed on a diet containing at least 200
grams of carbohydrate daily. The subjects ate their last meals at 6:00 PM the evening before the day
of the study. For measurement of GNG, they were given oral [2H2]O (Isotec, Miamisburg, Ohio), 5
g/kg body water divided into four doses (at 9:00, 10:00, 11:00 P.M., and 12:00 midnight).
Table 1. Physical characteristics of the study population.
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Age BW FFM   Wmax     VO2max
Sex (yr) (kg) (kg) (W) (W/kg) 1  (ml/min/kg) 1
__________________________________________________________________________________________
CID patients
1. F 29 55.0 43.4     60 1.09     13.1
2. F 23 61.0 45.0   60 0.98     12.3
3. F 16 47.0 36.2     55 1.17     17.7
Mean 23 54.3 41.5   58 1.08     14.4
SD   6   7.0   4.7     3 0.10       2.9
Controls
1. F 24 59.0 46.3 210 3.56     41.9
2. F 18 54.0 41.6 260 4.81     54.3
3. F 24 55.0 44.0 240 4.36     46.1
4. F 27 65.1 50.1 200 3.07     33.9
5. M 22 70.3 66.3 340 4.84     65.7
6. M 32 83.0 73.0 300 3.61     42.0
Mean 25 64.4 53.6 258 4.04     47.3
SD   5 11.0 13.0   54 0.73     11.2
1 Wmax and VO2max are expressed per kg BW. BW is body weight. FFM is fat free mass.
Body water was assumed to be 73% of fat free mass, which was assessed by skinfold measurement.
At  8:00 AM on the day of the study two indwelling catheters were inserted, one into a cubital vein
for infusion and the other into a dorsal hand vein of the contralateral arm for blood sampling. The
hand was kept warm in a heated box to achieve arterialization of the venous blood (16). After
drawing blood sample, the catheter was flushed with heparinized saline (2.5 U/ml). Subjects were
acclimatized to room conditions (temperature 21-25 °c) on a bed in the supine position for 30
minutes before beginning the study.After a basal blood sample was obtained at 8:30 AM (time 0
min), a primed constant-rate infusion of [6,6-2H2]glucose (98% enriched, Mass Trace, Woburn,
USA) was started and continued for 4.5 hours (prime: 15 µmol/kg, continuous infusion rate
0.15µmol/kg/min). Subjects then rested in the supine position for three hours (time 0 to 180 min).
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After this resting period they stepped from the bed on the cycle ergometer after voiding for urine
collection. Then they performed stationary cycle exercise for 90 minutes (180 to 270 min).
Triacylglycerol infusion. In the triacylglycerol infusion studies an infusion of Intralipid 20% w/v
(1.85 mg/kg/min of triacylglycerol) + heparin (7.5 U/kg/hr, prime 14 U/kg) was initiated at time 0
and maintained throughout the 4.5 hour study (rest and exercise).
Respiratory calorimetry. Open circuit indirect calorimetry was performed at rest using a ventilated
hood system for 40 minutes (time 120 to 160 min). Stable values for oxygen consumption (VO2)
were reached within 5 min of recording. During exercise, respiratory calorimetry measurements
were performed continuously, using a face mask. Computerized continuous gas analysis and volume
measurements were performed (Oxycon Champion, Jaeger, Breda, The Netherlands), as previously
described (17). Gas and volume calibrations were performed before each measurement.
Standardization with alcohol burning was performed regularly; the theoretical respiratory exchange
ratio (0.67) was closely approached in all measurements (mean 0.66; coefficient of variation 1.6
percent, n=10).
Blood sampling and urine collection. Blo d samples were drawn at regular intervals at rest and
during exercise, and were handled as described previously (18). Subjects voided at time 180 and
270 min and urine was collected for determination of nitrogen excretion and deuterium enrichment.
Sample analysis
Plasma metabolite concentrations were determined routinely using autoanalyzers, as described
previously (18). Urinary nitrogen was assayed according to a micro Kjeldahl method (19).
The deuterium enrichment of hydrogen on carbon 6 (C-6) of glucose was measured as described
previously (12,13,14,18). Briefly, glucose was isolated from deproteinized plasma by successive
ion-exchange chromatography and high-performance liquid chromatography. C-6 of glucose was
converted into formaldehyde and then condensed with ammonium hydroxide to form
hexamethylenentetramine (HMT), which was analyzed on a Hewlett Packard mass spectrometry
system (HP 5970 equipped with an HP 5890 gas chromatograph, Palo Alto, USA). Electron impact
ionization (70 eV) was used, and ions m/z 140 and 141 were monitored using the selected-ion
monitoring (SIM) software. Plasma [6,6-2H2]glucose enrichments were measured in the penta-
acetate derivative, using electron impact ionization, selectively monitoring ions at mass-to-charge
ratio (m/z) 201 and 203. Glucose enrichments were corrected (by subtraction) for increased
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background enrichment due to the administration of [2H2]O. This increase in background
enrichment was studied in an additional control subject and was found to be stable over time at rest
and during exercise, both when fasting and during triacylglycerol administration (data not shown).
Standard solutions of glucose of known enrichment were run along with unknowns to calibrate for
instrument variations. Enrichment of deuterium in urine water was determined in acetylene gas on a
GCMS system, according to Previs et al. (20). Briefly, urine samples were reacted with calcium
carbide to form acetylene gas, in which deuterium enrichment was determined by gas
chromatography electron impact ionization mass spectrometry. All samples were reacted in
triplicate and the measured deuterium enrichments showed a coefficient of variation < 5%.
Calculations
Whole-body turnover of glucose. At r st, steady-state whole-body glucose rate of appearance was
calculated as follows (21):
Glucose Ra (µmol/kg/min) = I / TTR [1]
where glucose Ra is the rate of whole-body glucose turnover, I the infusion rate of the [6,6-
2H2]glucose tracer in µmol/kg/min, and TTR the tracer to tracee molar ratio in plasma, sampled at
15 min intervals during the final hour of rest (120 to 180 min). Isotopic enrichments were
considered to be in steady-state when TTRs of four consecutive samples had a coefficient of
variation < 10%, and a slope not significantly different from zero. During exercise, glucose turnover
rates were calculated as described for the resting state when isotopic enrichments in plasma,
sampled at 15 min intervals during the final hour of exercise (210 to 270 min), were in steady-state
(as defined for the resting state). When isotopic enrichments were not in steady-state, turnover rate
was calculated with Steele’s equations for non-steady-state conditions (22), as follows:
 I - Vd ((Gi + Gj)/2)*(DTTR/DT)
Glucose Ra (µmol/kg/min) =_________________________ [2]
(TTRi + TTRj)/2
where Vd is the volume of distribution of glucose in ml/kg (200 ml/kg, ref. 23), (Gi + Gj)/2 is the
mean plasma glucose concentration (in µmol/ml) measured at time points Ti and Tj, DTTR is the
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change in TTR from Ti to Tj, DT is the time interval (Tj-Ti) in minutes, and (TTRi + TTRj)/2 is the
mean TTR measured at time points Ti and Tj.
Gluconeogenesis (GNG). The contribution of gluconeogenesis to the production of glucose in
patients and controls was calculated as described previously (18):
Fractional contribution of GNG via pyruvate to total glucose production (gngpyr) (%)
 = 100 x (0.5 x 2H enrichment of glucose C-6 / 2H enrichment in body water) [3]
The 2H enrichment on C-6 was divided by two because two hydrogens bound to C-6 of glucose are
enriched. The lack of complete equilibration of the hydrogens in pyruvate with those of body water
may lead to underestimation of gluconeogenesis via pyruvate. In normal subjects after prolonged
fast, the equilibrium between the hydrogens in pyruvate and body water has been estimated to be
80% complete (14); however no data are available during exercise or in CID patients.
Rate of GNG via pyruvate (GNGPYR, µmol/kg/min) = Glucose Ra x gngpyr [4]
Respiratory calorimetry. Rates of carbohydrate and fatty acid oxidation were calculated according
to standard equations (24). Protein oxidation was calculated from urinary nitrogen excretion,
assuming that 1 g nitrogen equals 6.25 g protein.
Statistical analysis
The results are presented as means ± SD. Because control data were normally distributed
whereas patient data were not, parametric and non-parametric statistical methods were used
for comparison within both groups: Student’s t-tests and Wilcoxon ranked sum tests for paired
data in controls and patients, respectively. Between group comparisons were made using non-
parametric Mann-Whitney tests. Statistical significance was set at p < 0.05.
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Results
Plasma concentrations (Table 2)
Fasting studies. There were no significant differences in plasma glucose concentrations between
patients and controls at all times.  Plasma lactate and blood pyruvate levels as well as lactate-to-
pyruvate molar ratios decreased slightly from rest to exercise in controls, whereas concentrations of
lactate and pyruvate and their molar ratios increased two- to threefold during exercise in patients to
values significantly different from those in controls (all P < 0.001).
Plasma free fatty acid concentrations in controls increased nearly threefold during exercise, when
compared with rest. The increase in free fatty acid levels during exercise was much less attenuated
in patients than in controls, with significantly lower levels during exercise in patients as a
consequence (P < 0.05).
Table 2. Plasma metabolite concentrations in fasting and triacylglycerol infusion studies.
Rest  Exercise          
______________________ ______________________
CID patients   Controls CID patients   Controls
__________________________________________________________________________________________
Fasting studies
Plasma glucose [mmol/L]    5.0±0.3    4.9±0.2    5.5±0.4    4.8±0.1
Plasma lactate [mmol/L]    1.2±0.2§    0.8±0.1    4.1±0.8*    0.6±0.1
Blood pyruvate [µmol/L]     93±21     74±7   176±17 *     64±5
Lactate/pyruvate ratio  13.5±1.0§  10.7±0.6  22.5±2.2*    9.4±1.0
Plasma FFA [µmol/L]   700±79   572±110   877±126§ 1469±165
Triacylglycerol infusion studies
Plasma glucose [mmol/L]    4.9±0.3    4.7±0.1    5.1±0.2    4.5±0.1
Plasma lactate[mmol/L]    1.1±0.1‡    0.6±0.1    4.0±1.0‡    0.7±0.1
Blood pyruvate [µmol/L]     78±10     58±8   161±20 ‡     69±20
Lactate/pyruvate ratio  14.0±1.2  11.3±1.6  24.3±4.3‡  11.5±1.6
Plasma FFA [µmol/L] 1258±272 § 1236±88 ‡ 1370±243 § 1510±74
Values are means ± SD in 3 patients and 6 controls. * P < 0.001, ‡ P < 0.01, § P < 0.05 patients versus controls
(Mann-Whitney test). ‡ P < 0.01, § P < 0.05 triacylglycerol infusion versus fasting state (Wilcoxon ranked sum
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test and t-test in patients and controls, respectively) Rest: mean value from final hour of rest (120 to 180 min),
exercise: mean value from final hour of exercise (210 to 270 min). FFA: free fatty acids.
Triacylglycerol infusion studies. There were no significant differences in plasma glucose
concentrations between patients and controls at all times. Plasma lactate and  blood pyruvate levels
as well as lactate-to-pyruvate ratios remained unchanged from rest to exercise in controls. In
patients exercise elicited similar increases in lactate and pyruvate concentrations and their molar
ratios, when compared with the fasting studies. Lactate and pyruvate levels and their molar ratios
during exercise were significantly higher in patients than in controls (all P < 0.01). Pl sma free fatty
acid concentrations did not increase from rest to exercise in patients, whereas they did increase
mildly in controls. There were no differences in free fatty acid concentrations between patients and
controls, neither at rest nor during exercise.
Plasma free fatty acid concentrations at rest were significantly higher during the triacylglycerol
infusion studies in patients and controls, when compared with the fasting studies (P < 0.05 and P <
0.01, in patients and controls, respectively). Whereas plasma free fatty acid levels during exercise
were significantly higher during the triacylglycerol infusion studies in patients, when compared with
the fasting studies (P < 0.05), free fatty acid levels in both studies were not different in controls.
Gluconeogenesis (Table 3, 4)
Fractional contribution to glucose Ra. Fasting  studies. The fractional contribution of
gluconeogenesis via pyruvate to total glucose production (gngpyr) increased only slightly during the
final hour of the resting period (from 120 to 180 min) in patients and controls (Table 3). gngpyr
remained unchanged in response to exercise in control subjects, whereas gngpyr incr ased in
response to exercise in all three patients, and r ached maximum values after 30 min of exercise in
patient #2, and after 60 min of exercise in the other two patients. gngpyr w s significantly increased
in patients when compared with controls, both at rest and during exercise (both P < 0.05, Ta le 4).
Triacylglycerol infusion studies. gngpyr remained unchanged in response to exercise in controls,
whereas it increased in all three patients (Table 3). gngpyr was significantly increased in patients
when compared with controls during exercise but not at rest (P < 0.05, Table 4). gngpyr was
significantly increased upon infusion of triacylglycerol in resting controls only (P < 0.05,
triacylglycerol infusion versus fasting).
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Table 3. Fractional contribution of gluconeogenesis via pyruvate to glucose Ra (% of glucose Ra) in fasting and
triacylglycerol infusion studies.
Fasting  Triacylglycerol
_________________________________ _________________________________
Rest    Exercise Rest    Exercise
__________ ________________ __________ ________________
Time [min] 120 180 210 240 270 120 180 210 240 270
__________________________________________________________________________________________
Patient   1. 41.3 46.2 46.8 57.4 48.9 51.4 52.7 55.4 56.8 60.8
   2. 50.0 48.8 55.6 52.8 38.6 40.9 55.3 51.3
   3. 49.0 53.1 63.1 69.0 60.7 52.3 56.8 61.1 58.9 58.9
___ ___ ___ ___ ___ ___ ___ ___ ___ ___
  Mean46.8 49.4 55.2 59.7 54.8 47.4 50.1 57.3 55.7 59.9
  SD   4.8   3.5   8.2   8.3   5.9   7.7   8.3   3.3   3.9   1.0
Controls  Mean38.5 38.9 40.6 41.4 38.3 49.7 44.5 48.0 46.0 41.4
   SD   5.3   5.5   6.4   5.6   9.0   3.3   1.0   5.0   4.0   4.4
Glucose kinetics (Table 4). Changes in glucose Ra in response to exercise were generally small
and not statistically significant. Glucose Ra in patients tended to be higher during exercise than
at rest. There were no significant differences in glucose Ra between patients and controls at
rest and during exercise, both in fasting and Intralipid studies.
Absolute rates of gluconeogenesis via pyruvate (Table 4). Fasting studies. At rest absolute
gluconeogenic rates via pyruvate (GNGPYR) in patients were not significantly different from
those in controls. In response to exercise GNGPYR remained unchanged in controls: 3.8±0.6
µmol/kg/min at rest versus 4.0±0.7 µmol/kg/min during exercise. In patients GNGPYR
increased from 4.5±1.4 µmol/kg/min at rest to 7.4±1.9 µmol/kg/min during exercise. GNGPYR
was significantly increased during exercise in patients, when compared with controls (P <
0.01). Triacylglycerol infusion studies. In response to exercise GNGPYR remained unchanged
in controls, whereas it increased from 5.1±1.8 µmol/kg/min at rest to 7.9±1.2 µmol/kg/min
during exercise. Again GNGPYR was significantly increased during exercise in patients, when
compared with controls (P < 0.01). In resting controls gluconeogenic rates during
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triacylglycerol infusion were significantly increased, when compared with fasting rates (P <
0.05).
Table 4. Glucose Ra and gluconeogenesis via pyruvate in fasting and triacylglycerol studies.
Fasting    Triacylglycerol
______________________ ______________________
Rest Exercise Rest Exercise
__________________________________________________________________________________________
[2H2]O  measurement of fractionalgluconeogenesis via pyruvate (% of glucose Ra)
CID patients 48.1±3.8 § 56.5±6.9 § 48.8±7.9 56.9±3.2 §
Controls 38.7±5.4 37.9±8.0 47.1±2.1 § 43.9±4.9
[6,6-2H2]glucose measurement of Ra  (µmol/kg/min)
CID patients   9.3±2.5 13.0±3.1 10.2±2.5 13.9±2.6
Controls   9.8±0.8 10.7±1.3   9.9±0.7 10.4±0.5
Calculated rate of absolute GNG via pyruvate (µmol/kg/min)
CID patients   4.5±1.4   7.4±1.9 ‡   5.1±1.8   7.9±1.2 ‡
Controls     3.8±0.6   4.0±0.7   4.6±0.4 §   4.6±0.6
Values are means ± SD in 3 CID patients and 6 controls. ‡ P < 0.01, § P < 0.05 patients versus controls (Mann-
Whitney test), or triacylglycerol infusion versus fasting in resting control study (paired t-test). Rest: mean value
measured/calculated during final hour of rest (120 to 180 min), exercise: mean value measured/calculated
during final hour of exercise (210 to 270 min).
Discussion
Data from the present study show that gluconeogenesis via pyruvate (GNGPYR) is increased in CID
patients (when compared with normal controls) during exercise, despite reduced cellular redox
state. Also resting rates of GNGPYR tended to be increased in patients, but only in the fasting state.
Circulating pyruvate levels were always higher in patients than in controls, both at rest and during
exercise. Triacylglycerol infusion was not associated with  increased resting rates of GNGPYR in th
patient group, whereas increased rates were observed in the control group. Triacylglycerol infusion
was not associated with increased GNGPYR during exercise either, both in patients and in controls.
Effects of cellular redox state changes on gluconeogenesis. Our findings in CID patients
during exercise are in apparent contrast to the results reported from ethanol studies in healthy
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subjects (4,5,7): whereas cellular redox state is reduced in both situations (as reflected by
increased lactate-to-pyruvate molar ratios), gluconeogenic rates were found to be increased in
our CID patients during exercise, whereas they were decreased during ethanol infusion.
Several explanations can be provided for this apparent contrast. First, differences in
gluconeogenic substrate supply should be considered, as availability of gluconeogenic
substrates is known to affect gluconeogenic rates in a dose-responsive manner (25,26,27).
Second, intrinsic regulation of gluconeogenesis by cellular redox state in CID patients (during
exercise) may be different from that in normal subjects.
Gluconeogenic substrate availability. As far as reflected by circulating pyruvate levels,
intracellular pyruvate availability for gluconeogenesis was decreased during ethanol
administration in normals and in NIDDM patients (6,28), whereas it was threefold increased in
our patients during exercise. At rest, when pyruvate levels were also higher in patients than in
controls, rates of GNGPYR tended to be higher in patients than in controls, accordingly. These
findings suggest that differences in pyruvate availability are likely to contribute to the
contrasting findings with respect to the gluconeogenic rates in our study and the studies in
which ethanol was administered. Our finding of increased rates of GNGPYR in CID patients
during exercise then bears not only pathophysiological but also physiological relevance.
The contrast with the ethanol studies suggests that changes in cellular redox state do not
directly affect gluconeogenic rates, but rather affect gluconeogenesis indirectly via intracellular
pyruvate availability.
Intrinsic regulation of gluconeogenesis in CID patients.In a recent study on hepatic
autoregulation of glucose production during low-intensity exercise in normal healthy
volunteers, we examined effects of an exogenous lactate load on gluconeogenesis and
glycogenolysis (18). The administered lactate load was aimed to elevate plasma lactate
concentrations in controls to levels comparable to those in patients during exercise.
In addition to the plasma lactate levels, pyruvate levels and lactate-to-pyruvate molar ratios
were also very similar. The fractional contribution of gluconeogenesis via pyruvate to glucose
Ra increased with ~ 17% upon administration of the lactate load during exercise in the
volunteer study, whereas the difference in fractional contribution between patients and controls
during exercise in the present study was ~ 19%. The similarity of these two values suggests
that lactate disposal via gluconeogenesis in CID patients is not different from normal subjects.
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Furthermore, we have no indication that gluconeogenic tissues (i.e. liver and kidney) are
affected in our patients. Fractional rates of gluconeogenesis via pyruvate were stimulated
rather than impaired in these patients, when compared with resting controls.
Effects of free fatty acid availability on gluconeogenesis. Resti g state. Data from the present
study show increased rates of GNGPYR during triacylglycerol infusion, when compared with the
fasting state, in resting controls but not in resting patients. Our findings in controls confirm
recent observations in humans by Chen et al. (10). Whereas these authors suggested a direct
hepatic relationship between acute changes in gluconeogenesis and endogenous free fatty acids
(by administration of nicotinic acid), our data are suggestive for a similar relationship between
gluconeogenesis and free fatty acids of exogenous origin. In an another recent study on
metabolic effects of nicotinic acid, similar changes in free fatty acid levels and fractional
gluconeogenesis were reported by Wang et al. (29). Instead of a direct hepatic relationship,
Wang et al. postulated an indirect relation between free fatty acid levels and gluconeogenic
rates, secondary to effects of nicotinic acid on glucose utilization by peripheral tissues. These
authors justified their contention by showing increased rates of whole-body carbohydrate
(glucose) oxidation upon acute administration of nicotinic acid, matched by increased rates of
glucose Ra (due to increased rates of glycogenolysis). Our finding of increased rates of
GNGPYR during triacylglycerol administration, when compared with fasting rates in resting
controls (Table 4), while rates of whole-body carbohydrate (glucose) oxidation (data not
shown) and glucose Ra (Table 4) were not different, are not in favor of the hypothesis of
Wang et al. however.
There were no differences in GNGPYR between triacylglycerol infusion and fasting studies in
resting CID patients. Some remarks need to be made regarding this observed lack of effect of
triacylglycerol infusion in CID patients. First, free fatty acid availability may be lower in
patients than in controls. However, the difference in free fatty acid levels between
triacylglycerol infusion and fasting studies was comparable in resting patients and controls
(Table 2). Second, GNGPYR in resting patients may have been optimized in the fasting state
already. Rates of GNGPYR were increased in fasting patients at rest, possibly because of
increased pyruvate availability. Increasing free fatty acid availability by triacylglycerol infusion
then did not seem to further increase fractional gluconeogenic rates in these patients. However,
gluconeogenic rates were not yet maximal as these patients were able to further increase their
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fractional gluconeogenic rates during exercise. Exercise. Rates of GNGPYR during
triacylglycerol infusion were not significantly different from fasting rates during exercise in
CID patients or controls. In the control studies, there were no differences in free fatty acid
levels between triacylglycerol infusion and fasting experiments. In fasting control experiments,
GNGPYR did not change in the transition from rest to exercise, despite a nearly threefold
increase of free fatty acid levels, making a significant relationship between free fatty acid
concentrations and gluconeogenic rates during exercise unlikely. In addition, our finding of a
significantly increased rate of GNGPYR in patients despite their nearly twofold lower free fatty
acid levels, suggests that effects of substrate (pyruvate) availability may overrule effects of free
fatty acid availability on gluconeogenesis. Together the findings of the triacylglycerol infusion
studies in patients and controls indicate that effects of free fatty acid availability on
gluconeogenesis are complex and depend on physiological state (i.e. rest or exercise).
In summary, results of the present study in CID patients and controls suggest the following:
(I) Gluconeogenesis via pyruvate is increased during exercise in CID patients, despite reduced
cellular redox state. (II) Increased pyruvate availability likely contributes to the stimulated
gluconeogenic rates in the CID patients. (III) Increased availability of free fatty acids is not
associated with increased rates of gluconeogenesis via pyruvate in CID patients, neither at rest
nor during exercise. The results of the present study do not support the use of high fat diets in
CID patients.
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The studies presented in this thesis describe a macronutrient approach in the nutritional
management of four patients with a mitochondrial myopathy due to Complex I deficiency, a
respiratory chain disorder characterized by impaired mitochondrial oxidation of NADH.
In chapter 2 the results are reported of respiratory calorimetry and 31P-MRS studies in three
of these patients. Whole-body oxygen consumption was found to be substantially increased in
the patients at rest, when compared with healthy controls. This in vivo finding is in apparent
contrast with the in vitro finding of impaired mitochondrial oxidation of NADH-linked
substrates. It is suggested that this paradox can be explained by an increased rate of electron
transport through the respiratory chain distal to CoQ, driven by a decreased phosphorylation
potential measured with 31P-MRS. The increased electron transport rate at rest can be regarded
as an in vivo mechanism compensating for the respiratory chain deficit present in the
mitochondria of these patients. With resting oxygen consumption rates increased up to 37% at
the whole-body level in the four patients, it is likely that this compensating mechanism is also
present in other than clinically affected tissues since muscle contributes only 20 - 30% to total
resting oxygen uptake (1). The patients studied have a very similar clinical picture dominated
by exercise intolerance and with no signs or symptoms at rest. Because we have found
enhanced resting whole-body oxygen consumption rates in all four patients (suggesting an
increased electron transport rate distal to CoQ), it is tempting to speculate that the clinical
picture (phenotype) may correlate with the presence or absence of this compensating
mechanism. Thus the phenotype would correlate with secondary compensation mechanisms
rather than the primary respiratory chain deficit. Although we have not been able to
characterize the respiratory chain deficit at the DNA level (genotype) in our patients, it is well
known that correlation between phenotype and genotype in these type of patients is poor (2).
When compensation is absent, patients may present with a different clinical picture, for
example a neonatal presentation with lactacidemia/ lactic acidosis. In these patients oxygen
consumption rates at the whole-body level may not be increased or even decreased. However,
resting oxygen consumption was reported to be 150% of normal controls in an incidental case
of such a patient (3). Because we have not studied patients with a clinical picture other than
that of a myopathy, the study presented in chapter 2 does not allow for a conclusion regarding
the issue.
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Strategies for treatment of Complex I deficiency (CID) have focussed on restoring electron
flow through the defective complex by suppletion of micronutrients (Coenzyme Q, riboflavin,
thiamine, nicotinamide) in pharmacological doses. Despite reported improvements of
symptoms in a few patients (4,5,6,7), disappointing results were observed in the treatment of
the majority of cases reviewed by Walker and Byrne (8). As an alternative to suppletion of
micronutrients, a macronutrient approach may be of interest for the therapy of these patients.
In recent years there has been a resurgence of interest in the ketogenic (high fat) diet, used in
the treatment of refractory childhood epilepsy and metabolic disease (e.g. phosphofructokinase
and pyruvate dehydrogenase deficiency, Ref. 9,10). A high fat-low carbohydrate diet has been
recommended in patients with Complex I deficiency (11), because it was recognized that high
glucose diets may impose a metabolic challenge in these patients. In chapter 3 a hypothesis is
presented regarding beneficial effects of fatty acid supplementation in CID by supplying
FADH2 distal to complex I. Effects of intravenous administration of a lipid emulsion
(Intralipid) or glucose were studied in four CID patients at rest and during low-intensity
exercise. At rest Intralipid infusion, compared with glucose infusion, did not improve oxidation
of substrates or skeletal muscle energy state and did not lower plasma lactate concentration
and its rate of turnover to normal values in these patients. Thus a lack of effect was observed
at rest. Several explanations can be provided. First, free fatty acid availability for oxidation may
be lower in patients than in controls. However, our finding of lower RERs during Intralipid
infusion in patients compared with controls, suggests that free fatty acid oxidation is
unimpaired or even stimulated. The lower plasma free fatty acid concentrations during
Intralipid infusion in patients, compared with controls, may also be the consequence of their
preferential oxidation in CID patients. Second, the type of fatty acids administered may be of
importance. Because we have only studied effects of Intralipid administration in a limited
number of patients, the results of our study do not allow for a conclusion regarding the issue.
Third, the lack of effect may be related to the type of patients that were selected to participate
in the study. Whole-body oxygen consumption rates were increased during infusion of both
Intralipid and glucose, to rates comparable to those reported in the fasting state (c apter 2). In
analogy to the fasting studies, this suggests an increased rate of electron transport through the
respiratory chain (distal to CoQ), and stimulated rather than impaired oxidation of infused
substrates at rest. Fatty acid supplementation then may be of little benefit, because it may not
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be able to improve already stimulated (mitochondrial) oxidation of substrates. In those patients
that do suffer from impaired oxidation of substrates (possibly neonatal cases presenting with
lactacidemia/ lactic acidosis) fatty acid supplementation may be of benefit, however. In
addition, triacylglycerol administration may be useful in myopathic CID patients during
exercise, when energy demands are increased.
Indeed, Intralipid infusion allowed all four patients to sustain low-intensity cycle exercise for at
least 90 minutes, whereas three of them were unable to do so during infusion of glucose in
isocaloric amounts. Furthermore, our studies during low-intensity cycle exercise showed
improved whole-body oxygen consumption rates during triglyceride infusion in all four
patients, when compared with glucose infusion. In comparison with healthy control subjects
exercising at a similar workload (7W), absolute rates of oxygen uptake were lower in two of
the patients, while they were higher in the other two. The finding of lower absolute oxygen
consumption rates during exercise suggests that the in vivo mechanism that compensates for
the respiratory chain deficit at rest (chapter 2) is insufficient to compensate for the increased
demands during exercise in these two patients. Here triglyceride administration can be
expected to be beneficial, resulting in increased oxygen uptake and lower plasma lactate
concentration and turnover, when compared with glucose administration. In one of these two
patients however, triglyceride infusion was associated with higher instead of lower plasma
lactate concentration and turnover. This finding was even more remarkable since exercise
endurance time during triglyceride administration was significantly better despite higher lactate
concentration and turnover. We have no explanation for these contrasting findings.
In two patients absolute oxygen consumption rates during exercise were increased suggesting
that the in vivo mechanism that compensates for the respiratory chain deficit at rest (chapter
2), may also compensate during exercise in these two patients, or at least in part. This is
supported by our finding that in one of these two patients exercise endurance time was not
different whether triglyceride or glucose was being administered. This patient also had the
lowest plasma lactate concentration and turnover rate of the patient group, during exercise
with either substrate. It may be that this patient will benefit from triglyceride administration
when exercising at higher workloads. The other patient shows the paradoxical situation of
increased absolute oxygen consumption rates togeth r with the highest plasma lactate
concentrations and turnover rates of the patient group. Differences in whole-body oxygen
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consumption, plasma lactate concentration and turnover rate, between the two infusion
conditions are considerable and seem to be even more important when the difference in
exercise endurance time is taken into account. Together the studies described in chapt r 3
suggest that beneficial effects can be expected from triglyceride administration in CID patients
during exercise (only), when compared with glucose administration. It should be noted
however that these findings can also be interpreted as glucose being harmful in these patients
during exercise, a notion that should not surprise since glucose is a substrate which is mainly
oxidized via NADH. In the design of our study effects of isocaloric infusion of two substrates
on mitochondrial substrate oxidation and lactate metabolism have been compared.
Control experiments without infusion of substrates have been done as part of diet intervention
studies in the same patients (see diet intervention studies). The results of these fasting studies
were not much different from the results of the triglyceride infusion experiments. This would
suggest that the patients had only little benefit from triglyceride administration during their
low-intensity exercise. However, since exercise was always terminated after 90 min by design,
it may be that we have missed an effect of triglyceride infusion beyond 90 min of exercise.
Diet intervention studies. In addition to the substrate infusion studies, the patients also took
part in diet intervention studies. They have been prescribed two different diets (of approx.
2,000 kcal) containing different amounts of carbohydrate and fat. The high fat diet contained
55 energy% (~ 1100 kcal) fat, while the low fat diet contained only 25 energy% (~ 500 kcal)
of fat. Each of the diets have been consumed for three weeks, and ingestion was recorded in
dietary diaries. The two three week diet periods were assigned in random order with at least
one week in between, when the patients were on their own diet. Two of the patients have also
been studied while they were on their own diet for three weeks. After completion of each
dietary period, testing followed that focussed on the chief complaint of these patients: their
exercise intolerance. Dietary effects on exercise intolerance were studied using both exercise
endurance and maximal exercise tests. Exercise endurance time was tested using a protocol
similar to that of the substrate infusion studies, with patients exercising on a cycle ergometer
for 90 minutes (nominal). Maximal performance (Wmax) was tested in an incremental maximal
exercise test (incremental steps of 10W/min) on the same ergometer.
Exercise endurance and maximal exercise tests were performed after an overnight fast, on
separate days. The results of the dietary intervention studies are presented in Table 1.
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Table 1. Diet intervention studies: exercise endurance and maximal exercise tests.
   Exercise endurance testing  Maximal exercise testing
  ________________________________________ _____________________
Subject     Diet E%  WorkEnduranceVO2  RER Lactate: Wmax VO2max   Lactate
  Load      Time rest exercise
       (Watts)     (min) (ml/ (mmol/L) (Watts)(ml/
(mmol/L)
 kg/min) kg/min)
__________________________________________________________________________________________
CB Own diet 40 7 90 2.5   6.6 60 13.6 14.3
High fat 55 7 90 2.5   6.3 70 16.0 24.0
Low fat 25 7 90 1.7   5.8 60 13.4 11.0
EK Own diet 35 9 90 2.9   6.9 60 12.5 13.2
High fat 55 9 90  8.0 0.90 1.7   6.2 55 14.1   8.7
Low fat 25 9 90  7.5 1.00 1.8   5.4 50 10.7   7.3
CV High fat 55 5 90  8.8 0.85 5.7 14.5 50 10.5 13.5
Low fat 25 5 73  8.1 0.90 11.5 45 11.6 13.8
CS High fat 55 8 90  8.5 0.85 4.6   4.3 55 17.9 10.8
Low fat 25 8 90   7.5 0.85 2.2   4.7
E % fat: energy % from fat. RER: respiratory exchange ratio.
There were no significant differences between any of the diets with respect to endurance time,
oxygen consumption, RER, or plasma lactate levels measured during prolonged low-intensity
cycle exercise (Table 1). The results of the maximal exercise tests were also not in favor of any
particular diet (Table 1). These results suggest that the exercise intolerance in myopathic CID
patients is not likely to improve from consumption of high fat diets. The results of the diet
intervention studies are in line with those of the substrate infusion studies: neither three w eks
of high fat diet consumption nor intravenous administration of triglycerides did significantly
improve exercise intolerance in patients during 90 minutes of cycle exercise after an overnight
fast.
Lactate metabolism in myopathic CID patients. Elevated plasma lactate concentrations are a
common laboratory finding in human CID (3,12,13,14). The elevated lactate concentrations
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are thought to reflect increased oxidation of NADH (coupled to reduction of pyruvate) in the
cytosol, resulting from the impaired oxidation of NADH inside the mitochondria of CID
patients. However, the elevated lactate concentrations at rest in our myopathic patients cannot
be explained by this mechanism, because mitochondrial oxidation of NADH likely was
increased rather than impaired (chapter 2), as reflected by their increased rates of whole-body
oxygen consumption at rest. We speculate that the elevated plasma lactate levels and lactate-
to-pyruvate ratios (reflecting increased reduction of cellular redox state) at rest can be
explained by an inverse relationship between the (increased) redox state and the (decreased)
phosphorylation potential in these patients. Cellular redox state and phosphorylation potential
are inversely coupled at the level of glycolysis by the simultaneous action of glyceraldehyde-3-
phosphate dehydrogenase and phosphoglycerate kinase, and at the level of transport of
cytosolic reducing equivalents into the mitochondria by the energy-dependent malate-aspartate
shuttle (15,16). During exercise, when mitochondrial oxidation of NADH is likely to be
impaired in at least two patients (as reflected by their decreased whole-body oxygen uptake),
escape oxidation of NADH in the cytosol may be important. On the other hand, the associated
increased glycolytic ATP production in the cytosol seems quantitatively not important for
sustaining the increased ATP demand during exercise in these patients.
Circulating lactate levels are generally thought to be determined by two simultaneous
processes: production of lactate into the circulation and disposal of lactate from the circulation.
In chapter 4 emphasis is put on lactate disposal via gluconeogenesis in CID patients (and
controls) at rest and during exercise. In an exercise study in normal healthy volunteers sodium
lactate was infused to raise plasma lactate concentration to levels similar to those measured in
the CID patients during low-intensity exercise (chapter 3). Sodium lactate infusion increased
gluconeogenesis from lactate, while gluconeogenesis from non-lactate precursors (glycerol)
was unaffected. Thus total gluconeogenic rates increased upon lactate infusion. The results of
this study indicate that gluconeogenesis is involved in the disposal of an exogenous lactate load
during low-intensity exercise in normal healthy volunteers. Furthermore we hypothesized
stimulating effects of increased fatty acid availability on lactate disposal via gluconeogenesis,
providing another potential rationale for fatty acid supplementation in these patients.
Gluconeogenesis was measured in three of our CID patients and in six healthy controls, both at
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rest and during 90 minutes of low-intensity cycle exercise. All subjects served as their own
control: on one occasion they received an infusion of
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Intralipid (+heparin), in the control experiment they were studied in the fasting state.
When compared with resting values, gluconeogenic rates from lactate were elevated during
exercise in patients but not in controls. In our patients there were no differences in
gluconeogenic rates from lactate between the Intralipid infusion and fasting studies, both at
rest and during low-intensity exercise. These findings suggest that gluconeogenesis contributes
to the disposal of endogenous lactate accumulating during exercise in our myopathic CID
patients. Beneficial effects of fatty acid supplementation could not be shown however.
Overall, the results of the studies presented in this thesis suggest that when these myopathic
CID patients want to exercise, a metabolic environment in favor of fatty acid oxidation should
be accomplished. This can be achieved by (prolonged) fasting or by oral intake of fat prior to
or during exercise. Oral intake of excess carbohydrates should be avoided. Our studies do not
provide much support for prescription of high fat diets in these myopathic CID patients.
Results from the studies presented in chapter 2 and 3 suggest that when these patients have
(partly) compensated their respiratory chain deficit in vivo, at y acid supplementation has little
to add in these already ‘compensated’ patients. It is tempting to speculate however, that fatty
acid supplementation may be of benefit to patients that lack this compensation.
In neonatal cases presenting with overwhelming lactic acidosis (probably lacking
compensation) intravenous Intralipid administration may be preferable over intravenous
glucose infusion. When these patients can tolerate enteral feedings, institution of high fat diets
may be considered. Respiratory calorimetry may be a helpful tool in decision making with
respect to initiation of fatty acid supplementation. When the resting oxygen consumption rate
is found to be elevated, fatty acid supplementation may be less warranted. The results of the
substrate infusion studies suggest harmful effects of intravenous glucose infusion during
exercise in our myopathic patients. Since all our patients were females, this finding may have
special implications, e.g. if they want to give birth to offspring. When they are in need of an
intravenous infusion during obstetrical help intravenous Intralipid infusion is likely to be
preferable over intravenous glucose infusion in these patients.
Future perspectives. Gene therapy possibly represents the ultimate therapy for these patients.
The fact that the subunits of complex I are in part mitochondrially and in part nuclearly
encoded, may impose problems in gene targeting. Whereas the genes involved in the
processing of the seven mitochondrially encoded subunits are known, the location the nuclear
General discussion and summary
____________________________________________________________________________
- 165 -
genes involved remains largely unknown. However, the number of human nuclear genes
encoding for complex I subunits that have been chromosomally localized in the past few years,
is encouraging (17,18,19). In addition, the first nuclear encoded gene mutations in complex I
are being recognized (20). The first steps towards gene therapy have been made by the group
of Yagi. With their ultimate goal to use the yeast NDI1 gene to restore the NADH-oxidase
activity in human mitochondria with complex I deficiency, they were able to introduce the
NDI1 gene into proliferating and non-proliferating cells and to functionally express it (21,22).
The NDI1 gene was introduced using a recombinant adeno-associated virus vector as the gene
delivery method. The expressed Ndi1 protein accounted almost entirely for the i  vitro
electron transfer from NADH to ubiquinone in the mitochondria of these cells. However,
whether expression of the single polypeptide enzyme Ndi1 upon insertion of this yeast gene
can restore function of the defective protein complex i  vivo remains to be established, because
the Ndi1 protein has no proton-translocating properties (21).
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Dit hoofdstuk bevat een Nederlandse samenvatting van het proefschrift, getiteld:
“Voedingsinterventie bij patiënten met Complex I Deficiëntie: een rol voor macronutriënten?”.
In deze samenvatting heb ik getracht op eenvoudige wijze antwoord te geven op de vraag die
in de titel ligt opgesloten.
De energiecentrale van de cel
Mitochondriën zijn bolvormig tot langgerekte celorganellen die zich in cytoplasma van een cel
bevinden. Mitochondriën hebben een eenvoudig buitenmembraan en een sterk geplooid
binnenmembraan, dat zeer selectief is in het doorlaten van stoffen. In de mitochondriën vinden
veel belangrijke biochemische processen plaats, zoals de citroenzuurcyclus en de oxydatieve
fosforylering. Via dit laatste proces wordt in het mitochondrion energie aangemaakt in de vorm
van ATP. Mitochondriën kunnen daarom als de energiecentrales van de cel worden
beschouwd. De belangrijkste energieleveranciers, suikers (glucose) en vetten, worden met de
voeding opgenomen. De suikers en de vetten worden in een samenspel tussen cytoplasma en
mitochondriën afgebroken tot Acetyl CoA. Acetyl CoA wordt in de citroenzuurcyclus volledig
geoxydeerd, waarbij de energierijke producten NADH en FADH2 vrijkomen. NADH en
FADH2 worden op hun beurt in de ademhalingsketen van het mitochondrion geoxydeerd.
Hierbij worden door NADH en FADH2 electronen afgegeven aan de ademhalingsketen. De
mitochondriële ademhalingsketen bestaat uit vijf eiwitcomplexen gelegen in de mitochondriële
binnenmembraan: complex I t/m V. Electronentransport in de ademhalingsketen (van complex
I richting complex IV) is gekoppeld aan protonentransport over het mitochondriële
binnenmembraan ter hoogte van complex I, III, en IV, waardoor een protonengradiënt
ontstaat. Complex V gebruikt deze protonengradiënt weer om in het mitochondrion ADP om
te zetten in ATP (zie hoofdstuk 1, figuur 1). Het eerste complex van de ademhalingsketen
(complex I) is specifiek betrokken bij de oxydatie van NADH.
Complex I Deficiëntie
De patiënten die in dit promotieonderzoek zijn onderzocht, hebben allen een zeer zeldzame
spierziekte (myopathie) op basis van een defect in complex I van de ademhalingsketen
(Complex I Deficiëntie, CID). Er wordt verondersteld dat de mitochondriële oxydatie van
NADH gestoord is bij deze patiënten. Dit leidt vervolgens tot stoornissen in de oxydatie van
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suikers en vetten en daarmee in de energievoorziening. De gestoorde energievoorziening in de
spieren lijkt ten grondslag te liggen aan de klachten van inspanningsintolerantie en spierzwakte
bij deze patiënten. Behalve in de mitochondriën kan NADH ook nog in het cytoplasma worden
geoxydeerd, wat gepaard gaat met vorming van melkzuur in de spieren. Dit leidt bij CID
patiënten tot verhoogde melkzuurspiegels in het bloed.
De hypothesen
Voor patiënten met CID is vooralsnog geen effectieve therapie voor handen. In dit proefschrift
is een mogelijke oplossing gezocht in de voeding van deze patiënten:
(I) Door FADH2 te benutten als electronendrager kan mogelijk het enzymdefect ter hoogte
van complex I worden omzeild, omdat FADH2 electronen grotendeels afgeeft aan
complex II dat stroomafwaarts gelegen is van complex I in de ademhalingsketen.
(II) FADH2 en NADH ontstaan in verschillende verhoudingen bij de oxydatie van suikers of
vetten. Relatief meer FADH2 ontstaat bij de oxydatie van vetten.
Dit leidde tot de hypothese dat verhoging van het vetgehalte in de voeding gunstige effecten
zou kunnen hebben op de (inspanningsgebonden) klachten van de patiënten door het
enzymdefect te omzeilen. Dit zou onder andere kunnen leiden tot minder melkzuurvorming en
daarmee tot minder hoge melkzuurspiegels in het bloed, wat gunstig is voor deze patiënten.
Minder hoge melkzuurspiegels in het bloed kunnen ook het gevolg zijn van een verhoogde
afbraak van melkzuur. Verhoging van het vetgehalte in de voeding van deze patiënten zou ook
een gunstig effect kunnen hebben op de afbraak van melkzuur:
(III) Omzetting van melkzuur in bloedglucose (glucosenieuwvorming) kan van belang zijn
voor de afbraak van melkzuur, met name tijdens inspanning.
(IV) Verhoogde beschikbaarheid (en oxydatie) van vetzuren stimuleert mogelijk de afbraak
van melkzuur via glucosenieuwvorming bij deze patiënten.
De studies
Om de bovenstaande hypothesen nader te onderzoeken zijn voedingsinterventiestudies
uitgevoerd bij in totaal vier patiënten met een myopathie op basis van Complex I Deficiëntie,
en een goed vergelijkbare controlegroep van gezonde proefpersonen.
In de studies naar hypothesen (I) en (II) heeft interventie plaatsgevonden door middel van
intraveneuze infusie van een vetemulsie (Intralipid), of van glucose (een eenvoudige suiker), en
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zijn beide vergeleken. In de studies naar hypothesen (III) en (IV) zijn patiënten en controles
bestudeerd zowel onder intraveneuze infusie van Intralipid als ook in nuchtere toestand en zijn
beide wederom vergeleken. Tenslotte zijn bij de patiënten ook dieetinterventiestudies
uitgevoerd: gedurende perioden van telkens drie weken kregen zij een vetrijk en een suikerrijk
dieet voorgeschreven. In de bovengenoemde studies zijn mogelijke effecten van
voedingsinterventie zowel in rust als ook tijdens inspanning (fietsen) bestudeerd, wanneer deze
patiënten juist klachten hebben.
Resultaten
In de studies naar hypothesen (I) en (II) zijn voor de rustsituatie geen verschillen in (onder
andere) de melkzuurspiegels in het bloed gevonden tussen vet- en glucoseinfusie, die afwijken
van de verschillen die ook in de controlegroep zijn gevonden. In rust lijken deze patiënten geen
baat te hebben van vetinfusie. Tijdens fietsen worden wel voordelen van vetinfusie gezien ten
opzichte van glucose infusie: lagere melkzuurspiegels in het bloed en een duidelijk beter
uithoudingsvermogen bij drie van de vier onderzochte patiënten. In de controlegroep zijn er
geen of slechts geringe verschillen tussen vet- en glucoseinfusie tijdens fietsen.
In de studies naar hypothesen (III) en (IV) zijn voor de rustsituatie geen verschillen in afbraak
van melkzuur via glucosenieuwvorming gevonden tussen patiënten en de controlegroep.
Tijdens fietsen is de afbraak van melkzuur via glucosenieuwvorming bij de drie onderzochte
patiënten duidelijk hoger dan in de controlegroep.
Noch in rust, noch tijdens fietsen worden er positieve effecten gezien van vetinfusie op de
afbraak van melkzuur bij de drie onderzochte patiënten. Ook de dieetinterventiestudies laten
geen duidelijke verschillen zien tussen vet- en suikerrijke diëten.
Wat leert dit proefschrift ons?
De resultaten van dit proefschrift pleiten niet voor het voorschrijven van een vetrijk dieet in
myopathische CID patiënten. Wel wijzen de bevindingen tijdens fietsen erop dat deze patiënten
het beste inspanning kunnen verrichten door relatief veel vet te verbranden. Dit kan worden
bewerkstelligd door inspanning te verrichten in nuchtere toestand (na een aantal uren vasten
wordt al relatief veel vet verbrand). Als inspanning op de nuchtere maag als onprettig wordt
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ervaren kan worden overwogen vooraf of tijdens de inspanning relatief vetrijke voeding tot
zich te nemen. Voeding rijk aan suikers lijkt daarentegen juist uit den boze te zijn.
Dat het voorschrijven van een vetrijk dieet niet zinvol lijkt te zijn voor myopatische CID
patiënten, wil nog niet zeggen dat dit geldt voor alle CID patiënten. Uit het onderzoek
beschreven in dit proefschrift zijn aanwijzingen naar voren gekomen dat intraveneuze infusie
van vet of het voorschrijven van een vetrijk dieet misschien wel degelijk zinvol kan zijn voor
bepaalde patiënten. Hierbij wordt dan met name gedacht aan patiëntjes die door de Complex I
Deficiëntie tijdens of kort na de geboorte al in de problemen komen. Nader onderzoek zal uit
moeten wijzen of intraveneuze infusie van vet of (wanneer voeding langs de normale weg
wordt verdragen) het voorschrijven van een vetrijk dieet geïndiceerd is bij deze patiëntjes.
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Dankwoord
Toen ik vier en een half jaar geleden werd benaderd voor het promotieonderzoek waarvan het
eindresultaat thans voor U ligt, had ik in meerdere opzichten geen flauw idee aan welk
avontuur ik zou beginnen. Allereerst het onderwerp: daar had ik nog nooit van gehoord.
Complex I Deficiëntie was voor mij een duistere diagnose en ook na een eerste greep in mijn
eigen boekenkast bleef dat zo. Pas in de bibliotheek van het WKZ kwam de diagnose voor mij
tot leven. Dan: wetenschappelijk onderzoek. Hoewel ik als geneeskunde student wel eens een
statusonderzoekje had gedaan, is het mij gebleken dat de geneeskunde c.q. artsopleiding
weinig tools aanreikt waar je wat aan hebt bij het bedrijven van wetenschappelijk onderzoek.
Maar ja, wat mag je ook verwachten van een dergelijke beroepsopleiding? Mede hierdoor
vertoonde mijn ontwikkelingscurve de eerste anderhalf à twee jaar een zeer vlak stuk met
hobbels alvorens de opgaande lijn werd gevonden (dit is voor promovendi een normale curve,
zo weet ik nu). Die opgaande lijn was echter zeker niet gevonden zonder de hulp van allen die
ik nu bij naam zal noemen. Daar gaat hij dan:
Prof. Dr. Berger, beste Ruud,
De afgelopen vier en een half jaar heb ik me door jou altijd gesteund geweten. Ook in de
moeilijke beginjaren heb je me steeds weer moed weten in te praten om door te gaan. Ik ben je
daar zeer erkentelijk voor. Ik ben blij dat ik jouw vertrouwen heb mogen genieten en hoop dat
je tevreden kunt zijn over het eindresultaat.
Prof. Kalhan, dear Satish,
My first stay in your lab turned out to be the turning point in my ‘career’ as a researcher. When
I returned to Holland I felt a lot more confident about what I was doing. During my second
stay you learned me how to write manuscripts and getting them published. I appreciate your
help with all of this very much: it wasn’t just OK (you may remember my comment on a bottle
of wine you ordered in that restaurant close to your home). I am honoured that you will act as
one of my thesis promotors on D(efense)-day.
Dr. de Meer, beste Kees,
Door jou ben ik in de wetenschap gerold en gepokt en gemazeld. Tot jouw vertrek uit het
WKZ in februari 1999 heb je menig uurtje in mij geïnvesteerd en ook daarna ben je actief bij
het project betrokken gebleven, ook al was de afstand noodgedwongen wat groter. Ik ben je
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voor dit alles zeer dankbaar en ik hoop dat je jouw investeringen beloond ziet in dit
proefschrift.
Dr. Reijngoud, beste Dirk-Jan,
Hoewel ik weet dat je ook betrokken bent geweest bij de initiatie van dit promotieproject, is de
afgelopen twee jaar de meest intensieve periode van onze samenwerking geweest.
Jouw hulp bij het schrijven van de manuscripten die ten grondslag liggen aan dit proefschrift, is
van onschatbare waarde geweest. Ik heb het zeer gewaardeerd dat ondanks het feit dat onze
meningen soms een heel eind uit elkaar lagen, we elkaar altijd (en relatief snel) ergens in het
midden konden ontmoeten om een compromis te sluiten. En daar gaat het in het leven om,
nietwaar?
Auke Renard en Rob Roef, beste paranymfen,
Ik ben blij dat jullie mij op 12 januari a.s. als paranymfen willen bijstaan. Auke: ik heb op jouw
promotie in augustus jl. de kunst van het verdedigen van het proefschrift al even af kunnen
kijken. Rob: deze keer is er wel een belangrijke taak voor jou weggelegd.
Dr. Houwen, beste Roderick,
Al ben je misschien niet steeds inhoudelijk betrokken geweest bij het promotieproject, toch wil
ik je bedanken voor het in mij gestelde vertrouwen als afdelingshoofd de afgelopen jaren.
Prof. Dr. Okken, beste Albert,
Jouw betrokkenheid was het grootst in de beginjaren en meer recent als rapporteur van de
beoordelingscommissie. Ik wil je hierbij hartelijk danken voor het vertrouwen en de mij
geboden kansen, ook na deze promotie.
Dr. Jacobs, beste Carel, Dr. Kulik, beste Wim,
Bedankt voor de laboratoriumstage die ik eind 1997 in jullie lab mocht lopen ter voorbereiding
van mijn eerste verblijf in Cleveland.
Dr. de Sain-van der Velden, beste Monique,
Bedankt voor jouw betrokkenheid bij de gluconeogenese metingen van mijn laatste studie.
Dankzij jouw hulp hoefde ik hiervoor niet opnieuw naar Cleveland. Wie weet kunnen we deze
goede samenwerking in de toekomst voortzetten.
H. Straver, beste Helma,
Jij moet wel haast helemaal gek zijn geworden van alle te meten lactaat- en carbietmonsters
(vooral als het weer eens over moest). Het is nu gelukkig allemaal voorbij.
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Mijn dank voor jouw tomeloze inzet.
M. de Barse, beste Martina,
Bedankt voor alle pentacetaatmonsters die je de afgelopen jaren voor mij hebt gemeten,
voorwaar een hele klus.
P. Allers, beste Paul,
Mijn dank voor jouw ondersteuning van Helma en Martina bij al hun meetwerk.
L. Gruca, E. Burkett, A. O’Brien, J. Nolan, dear Lourdes & Ed & Alicia & Joyce,
Thank you for your moral (and technical) support when I was doing my countless analyses in
Prof. Kalhan’s lab.
M. Krom, beste Mieke,
Altijd kon ik bij je binnenlopen met mijn bloedmonsters voor bepaling in lab F van het oude
WKZ. Ik ben je hier zeer dankbaar voor.
D. van Heumen, J. Lavell, W. van de Hoeven, beste Diana & Jolenta & Winny,
Ook al wisten jullie niet altijd even goed waar ik nou eigenlijk mee bezig was, wel mocht ik
altijd tegen jullie aanpraten en samen met jullie de lunch gebruiken. Bedankt!
(Functie) assistenten pulmo, apotheek: bedankt voor de goede samenwerking en jullie geduld.
Dr. Gulmans, beste Vincent, en andere kinderfysiotherapeuten,
Bedankt voor jullie soepele opstelling bij het beschikbaar stellen van de inspanningsruimte.
Drs. Wolters, beste Victorien,
Jij hebt de eer gehad de laatste maanden een kamer met mij te mogen delen. Ik hoop dat ik niet
teveel in mezelf heb gepraat. Mijn excuses voor de eventuele overlast.
C. Reynen-Buys, E. Kalkman, C. de Vries, C. Schutter, beste Claudia & Esther & Claudia &
Carolien,
Het komt niet vaak voor dat alle patiënten die aan het onderzoek hebben meegedaan, met
naam genoemd kunnen worden. Jullie zijn hierop een uitzondering. Bedankt voor jullie
medewerking, zonder welke dit onderzoek niet mogelijk was geweest.
Mijn dank gaat ook uit naar alle gezonde vrijwilligers die controlepersoon zijn geweest voor de
studies beschreven in dit proefschrift.
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Nu ik ben aangeland bij de laatste regels van dit dankwoord, gaan mijn gedachten uit naar mijn
familie. Lieve ma, met liefde en trots draag ik dit proefschrift (mede) op aan jou, omdat je altijd
vertrouwen hebt gehad in een goede afloop. Lieve pa, helaas heb je nooit geweten van mijn
keuze voor promotieonderzoek, maar ik weet zeker dat je heel trots zou zijn op het
eindresultaat. Dit proefschrift is dan ook ter nagedachtenis aan jou.
Lieve Ynsche, dankzij jouw liefde, geduld en trouw bleef mijn innerlijk kompas de afgelopen
jaren steeds de juiste richting uit wijzen. Ook aan jou draag ik dit proefschrift op.
Allerliefste Bas, jij als laatste, we kennen elkaar nog maar vijf maanden als ik dit proefschrift
ook aan jou opdraag. Ik vraag je later nog wel eens wat je er van vindt.
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Curriculum Vitae
De schrijver van dit proefschrift werd geboren op 1 augustus 1968 te Nijmegen. Na het
behalen van het VWO-diploma aan het R.K. Lyceum Dominicus College te Nijmegen in 1986
werd er in hetzelfde jaar begonnen met de studie Geneeskunde aan de Katholieke Universiteit
Nijmegen. Het propaedeutisch examen werd in 1987 behaald. In 1990 liep hij gedurende een
maand stage op de afdeling kindergeneeskunde van het Kaplan Hospital te Rohovot, Israël.
Een wetenschappelijke stage van drie maanden werd in 1991 doorgebracht op de afdeling
kindercardiologie van het Academisch Ziekenhuis St. Radboud te Nijmegen (Drs. R.B. Tanke,
hoofd: Dr. O. Daniëls). Van 1987 tot 1990 was hij lid van de Nijmeegse Studenten Vereniging
Carolus Magnus en sinds 1988 is hij lid van het Medisch Genootschap SO.DA.NO.GO. te
Nijmegen. Ook is hij actief geweest in het bestuur van de Medische Faculteits Vereniging,
waar hij zich bezig heeft gehouden met het organiseren van studiereizen naar onder andere de
toenmalige Sovjet-Unie. Het doctoraal examen Geneeskunde werd in 1991 behaald.
Aansluitend aan het doctoraalexamen werd de artsopleiding gevolgd aan dezelfde universiteit.
Het keuze-coschap werd gelopen op de afdeling neonatologie van het Academisch Ziekenhuis
St. Radboud te Nijmegen (Dr. L.A.A. Kollée). Het artsexamen werd behaald in december
1993. In maart 1994 moest hij als één van de laatsten der Mohicanen opkomen voor vervulling
van zijn militaire dienstplicht. Deze werd gedurende 13 maanden met veel plezier doorgebracht
als arts-officier bij de Koninklijke Luchtmacht op onder andere de vliegbases Volkel in ons
Brabantse Nederland, Villafranca in Italië en Goose Bay in Canada.
Daarna werd gedurende een periode van 13 maanden gewerkt als assistent geneeskundige niet
in opleiding (AGNIO) op de afdeling Intensive Care van het Academisch Ziekenhuis St.
Radboud te Nijmegen (hoofd: Drs. S.J. van Leeuwen). In mei 1996 kon hij beginnen aan dit
promotieonderzoek. Gedurende de afgelopen vier en een half jaar is hij daartoe als arts-
onderzoeker verbonden geweest aan de afdeling Kindergastroenterologie (Dr. K. de Meer,
hoofd: Dr. R.H.J. Houwen) en het Laboratorium Metabole Ziekten (Prof. Dr. R. Berger) van
het Wilhelmina Kinderziekenhuis te Utrecht. In 1998 en 1999 werden gedurende in totaal acht
maanden onderzoekswerkzaamheden verricht binnen het Robert Schwartz M.D., Center for
Metabolism and Nutrition, MetroHealth Medical Center te Cleveland, V.S. (Prof. S.C.
Kalhan). Vanaf april 2001 zal de schrijver van dit proefschrift de opleiding tot kinderarts gaan
volgen in het Wilhelmina Kinderziekenhuis te Utrecht (hoofd: Prof. Dr. J.L. Kimpen).
